( 12 ) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY ( PCT ) . . ( 19 ) W0rld Intellectual Pr0perty Organizati0n Internati0nal Bureau. / . ( 43 ) Internati0nal Publicati0n Date 17 December 2009 ( 17.12.2009 ) . , , , \\ p 4 N ' .!. . v. . |||||||||||||||||||||||||||||||||||||||||||| ||| ||||||||||||||| ||||||||||||||||||||||||| |||||||| ( 10 ) Internati0nal Publicati0n Number. WO 2009 / 150144 A1. . . ( 51 ) Internati0nal Patent Classiﬁcati0n : A61K 3I / 453 ( 2006.01 ) A61K 31 / 538 ( 2006.01 ) A61K 3I / 454 ( 2006.01 ) C07D 405 / 04 ( 2006.01 ) A61K31 / 4545 ( 2006.01 ) C07D 405 / I4 ( 2006.01 ) C07D 4I3 / 04 ( 2006.01 ) A6IP 3 / 00 ( 2006.01 ) . A6IK3I / 496 ( 2006.01 ) A6IK3I / 497 ( 2006.01 ) A61K3I / 53 77 ( 2006.01 ) . ( 21 ) . Internati0nal Applicati0n Number : PCT / EP2009 / 057074. ( 22 ) Internati0nal Filing Date : 9 June 2009 ( 09.06.2009 ) ( 25 ) Filing Language : Enghsh ( 26 ) Publicati0n Language : Enghsh ( 30 ) Pri0rity Data : 0801371 - 6 10 June 2008 ( 10.06.2008 ) SE 61 / 076 , 457 27 June 2008 ( 27.06.2008 ) US ( 71 ) Applicant 00r all designated States except US ) : INOVACIA AB [ SE / SE ] ; Lindhagensgatan 133 , 112 51 St0ck - h0lm ( SE ) . ( 72 ) Invent0rs ; and ( 75 ) Invent0rs / Applicants €0r US 0nIy ) : KO0LMEISTER , . T0bias [ SE / SE ] ; Wittst0cksgatan 28 , S - 115 27 St0ck - h01m ( SE ) . JOHANSSON , Gary [ SE / SE ] ; LeVertinsgatan 8 bV , S - 754 30 St0ck1101111 ( SE ) . HARTIKKA , Antti [ SE / SE ] ; S : t J0hannesgatan 30 D , S - 752 33 Upp - sa1a ( SE ) . BERTS , Wei [ SE / SE ] ; B1aVingeVagen 22 , S - 749 45 Enk6ping ( SE ) . NILSSON , Bjiirn M. [ SE / SE ] ; Ige1dammsgatan 20 , S - 112 49 St0ckh01m ( SE ) . J0 - HANSSON , Lars [ SE / SE ] ; B6rjes011sVagen 8 , S - 168 50 Br0mma ( SE ) . EMOND , Rikard [ SE / SE ] ; M6rtgatan 5 , . s—133 43 Sa1tsj6baden ( SE ) . BRANDT , Peter [ SE / SE ] ; G1‘ane1idsVagen 18 B , S - 756 55 Uppsa1a ( SE ) . NILSSON , Junas [ SE / SE ] ; Past0r Odmans Vag 35 , S - 134 60 IngaI6 ( SE ) . LINDQVIST , Bengt [ SE / SE ] ; Myskda1en 44 , s - 755 97 Uppsa1a ( SE ) . Agent : CHRISTENSEN , Ida ; Brann AB , P. O. BOX 17192 , 104 62 St0ckh01m ( SE ) . ( 74 ) . ( 81 ) Designated States ( unless 0therwise indicated , f0r eveijy kind 0f nati0nal pr0tecti0n available ) : AE , AG , AL , AM , AO , AT , AU , AZ , BA , BB , BG , BH , BR , BW , BY , BZ , CA , CH , CL , CN , CO , CR , CU , CZ , DE , DK , DM , DO , DZ , EC , EE , EG , ES , FI , GB , GD , GE , GH , GM , GT , HN , HR , HU , 1D , IL , IN , IS , JP , KE , KG , KM , KN , KP , KR , KZ , LA , LC , LK , LR , LS , LT , LU , LY , MA , MD , ME , MG , MK , MN , MW , MX , MY , MZ , NA , NG , NI , NO , NZ , OM , PE , PG , PH , PL , PT , RO , RS , RU , SC , SD , SE , SG , SK , SL , SM , ST , SV , SY , TJ , TM , TN , TR , TT , TZ , UA , UG , US , UZ , VC , VN , ZA , ZM , ZW. ( 84 ) Designated States ( unless 0therwise indicated , f0r eveijy kind 0f regi0nal pr0tecti0n available ) : ARIPO ( BW , GH , GM , KE , LS , MW , MZ , NA , SD , SL , SZ , TZ , UG , ZM , ZW ) , EuIasian ( AM , AZ , BY , KG , KZ , MD , RU , TJ , TM ) , Eur0pean ( AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , [ E , IS , 1T , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , SE , SI , SK , TR ) , OAPI ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NE , SN , TD , TG ) . Published : . — with internati0nal search rep0rt ( Art. 2l ( 3 ) ) . . ( 54 ) Title : NEW GPR119MODULATORS. Ar1 W. m ( 1a ) . 2009 / 150144 A1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. o B. ( 57 ) Abstract : The app1ieation re1ates to eomp0unds of Formu1a ( Ia ) : and pharmaeeutieaﬂy aeeeptab1e salts , s01vates , hydrates , ge0metrica1 is0mers , taut0mers , 0ptica1 is0mers0r N - 0Xides there0f. The app1icati0n als0 re1ates t0 pharmaceutica1 00mp0siti0ns 00mprising these 00mp0unds and t0 the use 0f these 00mp0unds f0r the pr0phy1aXis and treatment of medica1 00nditi0ns re1ating t0 dis0rders 0f the G - pr0tei11 - 00up1ed recept0r GPR119 , such as diabetes , 0besity and 0ste0p0r0sis. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. NEW GPRl19MODULATORS. FIELD OF INVENTION. The present inVention re1ates to certain noVe1 compounds , to pharmaceutica1 compositions comprising these noVe1 compounds , and to the use of these compounds for the prophy1axis and treatment of medica1 conditions re1ating to disorders of the G - protein - coup1ed receptor. GPR119 such as diabetes , obesity and osteoporosis. BACKGROUND ART. Diabetes me11itus is a group of disorders characterized by abnorma1 g1ucose homeostasis resu1ting in high 1eVe1s of b1ood g1ucose. The most common cases of diabetes me11itus are Type 1 ( a1so referred to as insu1in - dependent diabetes me11itus or IDDM ) and Type 2 diabetes ( a1so referred to as non - insu1in - dependent diabetes me11itus or NIDDM ) . Type 2 diabetes accounts for approXimate1y 90% of a11 diabetic cases. Type 2 diabetes is a serious progressiVe disease that resu1ts in the deVe1opment of microVascu1ar comp1ications ( e. g. retinopathy , neuropathy , nephropathy ) as We11 as macroVascu1ar complications ( e. g. acce1erated atherosc1erosis , coronary heart disease , stroke ) . More than 75% of peop1e With Type 2 diabetes die of cardioVascu1ar diseases. The increasing preVa1ence of obesity together with an ageing popu1ation is contributing to the predicted eXp1osion in diabetes across the globe. Current projections suggest that 300 mi11ion peop1e Wor1dWide Wi11haVe diabetes by 2025. The pathogenesis of Type 2 diabetes inVo1Ves insu1in resistance , insulin secretory dysfunction ( i. e. pancreatic beta ce11 dysfunction ) and hepatic g1ucose oVerproduction. Insu1in rcsistancc is highly corrclatcd With obcsity. Accumulating rcports suggcst insulin resistance to be central to a cluster of metabo1ic abnorma1ities - including dyslipidemia , hypertension , endothe1ia1 dysfunction , reduced f1brino1ysis , and chronic systemic inﬂammation - that together are responsib1e for the increased cardioVascular risk. Current antidiabetic therapy is targeting the defects mentioned aboVe. For instance , su1phony1ureas increase production of endogenous insu1in. HoWeVer , this enhanced insu1in production is not g1ucose dependent and there is risk for deVe1oping hypog1ycaemia. Metformin 10Wers hepatic g1ucose output. Thiazo1idindiones ( TZDs ) reduce insu1in. resistance in musc1e and 1iVer and suppress inﬂammatory responses. A major side effect of. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. TZDs is Weight gain due to ﬂuid retention and increase in total body fat. An ear1ier drug in this c1ass , trog1itazone , Was WithdraWn due to rare but serious cases of hepatotoXicity. Current therapies haVe 1imited durabi1ity and / or signiﬁcant side effects. The Widespread aVailability and increased consumption of Western diet combined With the adoption of a sedentary 1ife - sty1e has increased the number of obese peop1e. Obesity is 1inked to a Wide range of medica1 comp1ications , such as diabetes , cardioVascu1ar disease and cancer. In addition , being oVerWeight can exacerbate the deVe1opment of osteoporosis and asthma. Obesity is a1so proVen to doub1e the risk of hypertension. Obesity has on1y recent1y been regarded as a disease in the sense of being a specific target for medica1 therapy. Current therapies for obesity are based on diet and eXercise and stomach surgery for eXtreme1y obese patients. On1y a feW Weight 10ss medications are today aVai1ab1e for 10ng - term use. Sibutramine , a serotonin - and noradrenaline - reuptake inhibitor , controls appetite by producing a fee1ing of satiety. HoWeVer , a prominent side effect is hypertension. Or1istat inhibits the 1ipase - mediated breakdoWn of fat in the gastrointestina1 tract , thereby limiting ca1oric intake resu1ting in Weight 10ss. HoWeVer , approXimate1y 20% of the patients using Orlistat deVelop faeca1 incontinence and urgency. Thus , there is an. unmet medica1 need for neW and noVe1 antidiabetic and antiobesity therapies. Osteoporosis , or porus bone , is a disab1ing disease characterized by 10W bone mass and structural deterioration of bone tissue , 1eading to compromised bone strength and an increased risk of fractures of the hip , spine and Wrist. Anyone can deVe1op osteoporosis , but it is common in older Women. As many as ha1f of all Women and a quarter of men older than 50 Wi11 haVe an osteopeorosis - re1ated fracture in their 1ife - time. Risk factors include getting older , gender , fami1y history , body size , ethnicity ( higher risk for Caucasians and Asians ) , inactiVe lifesty1e , smoking and oVerconsumption of a1cohol. It has recently been shoWn that one of the incretins , G1ucose - dependent Insu1inotropic Po1ypeptide ( GIP , a1so knoWn as gastric inhibitory po1ypeptide ) , promotes bone mass ( Zhong et a1. , AM J Physio1 Endocrinol Metab , 292 , E543 - E548 , 2007 ) . GPR119 is a G - protein coup1ed receptor identiﬁed as SNORF25 in WO 00 / 50562. In humans , GPR119 is selectiVe1y eXpressed in pancreas and gastrointestinal tract. ActiVation of GPR1 19 by 1ysophosphatidy1cho1ine ( LPC ) induces g1ucose - dependent insu1in secretion from pancreatic beta - ce11s ( Soga et a1. , Biochem. Biophys. Res. Commun. 326 , 744 - 751 , . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. 2005 ) . GPR119 agonists stimu1ate insu1in secretion in rat is1ets and reduce b1ood g1ucose in diabetic Leprdb / db mice ( WO 2004 / 065380 and Chu et a1. , Endocrino1ogy 148 , 2601 - 2609 , 2007 ) . GPR119 agonists enhances the re1ease of the incretins , GLP - 1 and GIP in mice models and in GLUTag cel1s , Which is a model used to inVestigate the function of. intestinal L - ce1ls ( Chu et al. , Endocrino1ogy 149 , 2038 - 2047 , 2008 ) . Another endogenous ligand for GPR119 , oleoylethanolamide ( OEA ) , and a sma1lmolecu1e GPR119 agonist , PSN632408 , both suppress food intake and reduce body Weight gain in rat ( OVerton et a1. , Ce1l Metabo1ism 3 , 167 - 175 , 2006 ) . Taken together , these data suggest that GPR119 is an interesting target for treating diabetes and / or obesity. WO 2004 / 065380 , WO 2004 / 076413 , WO 2005 / 007647 , WO 2005 / 007658 and WO 2005 / 121121 disc1oses compounds that are modu1ators of the Rup3 receptor , a1so referred to as SNORF25 ( WO 00 / 50562 ) or as GPR119 ( Fredriksson et a1. , FEBS Lett , 554 , 381— 388 , 2003 ) , and Which inter alia may be used for the treatment of metabo1ic disorders and comp1ications thereof , such as , diabetes and obesity. WO 2005 / 061489 , WO 2006 / 067531 , WO 2006 / 067532 and WO 2006 / 070208 disc1ose compounds that are agonists of GPR116 , a1so referred to as SNORF25 or as GPR119 ( see OVerton et a1 , Ce11 Metabo1ism 3 , 167 - 175 , 2006 ) , and which inter a1ia may be used for the treatment of metabo1ic disorders and comp1ications thereof , such as diabetes and obesity. WO 2008 / 025798 , WO 2008 / 025799 and WO 2008 / 025800 disc1ose pyridine , pyridazine and pyrimidine compounds , respectiVe1y , as agonists of GPR119 , Which can be used for the treatment of metabo1ic disorders and comp1ications thereof , such as diabetes and obesity. WO 2006 / 076231 disc1oses a synergistic effect of a GPR119 agonist in combination With a DPP - 1V inhibitor , in 10Wering e1eVated g1ucose 1eVe1s in mice. Further , a synergistic effect With the said combination is shoWn in increasing b1ood GLP - 1 1eVe1s after g1ucose cha11cngc in micc. WO 2007 / 120689 disc1oses a method of using GPR119 receptor to identify compounds useful for increasing bone mass in an indiVidual. GPR119 agonists are shoWn to enhance. G1P in Wi1d type mice. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. DISCLOSURE OF THE INVENTION. It has surprisingly been found that compounds of the genera1 Formula ( Ia ) to ( Id ) are actiVe as agonists of GPR119 and are potential1y usefu1 in the treatment or prophy1aXis of disorders re1ating to GPR119. EXamp1es of such disorders inc1ude Type 1 diabetes , Type 2 diabetes , inadequate g1ucose to1erance , insu1in resistance , hyperg1ycemia , hyper1ipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosc1erosis , reduced ﬂbrino1ysis , . endothe1ia1 dysfunction and osteoporosis. In a ﬂrst aspect , the present inVention proVides a compound of Formu1a ( Ia ) , . AH vv\ U X Y ) \©1m N m \R1. or a pharmaceutical1y acceptab1e salt , solVate , hydrate , geometrical isomer , tautomer , . ( 1a ) . optica1 isomer or N - oXide thereof , Wherein : . W , X and Y are each independent1y CH2 , O , NH or N ( CH3 ) , proVided that at 1east one of W and X is CH2 ; . m is each independently 0 or 1 ; . R1 is —C ( O ) OR2 , —C ( O ) R2 , —C ( O ) NR2R3 , —C ( O ) CH2NR2R3 , —CH2C ( O ) NR2R3 , —S ( O ) 2R2 , —C ( O ) C ( O ) R9 or a 5 - or 6 - membered heteroary1 group 1inked Via a ring carbon atom , Wherein said heteroary1 group is optiona11y substituted With C1 - 4 - a1kyl ; . Ar1 is pheny1 or heteroary1 , each of Which is optiona11y independent1y substituted in one or more positions With a substituent se1ected from : . ( a ) CF3SO3 , . ( b ) ha1ogen se1ected from bromine , ch1orine and ﬂuorine , . ( c ) C1 - 4 - a1kylsu1foximine , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( d ) ( e ) ( f ) ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) . ( s ) ( t ) 00 ( V ) ( W ) ( X ) ( y ) ( z ) ( aa ) ( bb ) ( cc ) ( dd ) ( ee ) ( ff ) ( gg ) ( hh ) ( ii ) ( jj ) . —S ( O ) R“ , —S ( O ) 2R4 , —S ( O ) 2NR5R5 , —NR6S ( O ) 2R4 , —CH2 - NR6C ( O ) R4 , —NR6C ( O ) R4 , —C ( O ) NR5R5 , —CH2 - C ( O ) NR5R5 , —C ( O ) R4 , H2N - C ( O ) O— , CH3 - NH - C ( O ) O— , ( CH3 ) 2NC ( O ) O— , CH3OC ( O ) NH - , . C - heterocyc1y1 , optiona11y substituted with C1_4 - a1ky1 , N - heterocyclylcarbony1Viny1 , wherein N - heterocycly1 is optional1y substituted. with C1 - 4 - alkyl , —CN , . —OR8 , . —SCF3 , . —NO2 , . PCT / EP2009 / 057074. C - heterocyc1y1su1fony1 , optiona11y substituted with C1_4 - a1ky1 , . —NR5R5 , —C ( OH ) CH3CF3 , [ CF3CH3 ( OH ) C ] —C1_6—a1ky1 , cyano - C1_6 - a1ky1 , guanidino , . amidino , . C1_6 - a1ky1 , C1_6 - a1ky1thio , C1_4 - a1koXy - C1_4 - a1kyl , ﬂuoro - C1_4 - a1ky1 , C2 - 6 - a1kenyl , ﬂuoro - C2_4 - a1keny1 , hydroxy - C1_6 - a1ky1 , . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( kk ) ( 11 ) . C1_4 - a1kylsu1fonyl - C1_4 - a1kyl , hydroxy - C2_4 - alkoxy - C1_4 - a1ky1 , . ( mm ) C2_3 - acy1 - C1_3 - a1kyl , . ( nn ) ( 00 ) ( pp ) ( qq ) ( rr ) ( ss ) . 00 ( uu ) ( W ) ( W ) ( XX ) ( yy ) . C2_6 - a1kyny1 , . C3_6 - cyc1oa1ky1 , . hydroXy - C3_6 - cyc1oa1ky1 , . ﬂuoro - C3_6 - cyc1oa1ky1 , . methy1 - C3_6 - cyc1oa1ky1 , . C3_6 - cyc1oa1ky1 - C1_4 - alky1 , wherein C3 - 6 - cyc1oa1ky1 is optiona1ly substituted with methyl , . C - heterocyc1y1carbony1 , optiona11y substituted with C1_4 - a1ky1 , C3_6 - cyc1oalky1thio , . R5R5N—C1_2—a1ky1 , . — ( CH2 ) nC ( O ) OR7 , wherein n is 0 , 1 , 2 or 3 , . phenyl , and. heteroaryl , . wherein pheny1 or heteroaryl as substituent on Ar1 is optional1y substituted in one or more. positions with a substituent independent1y se1ected from the group Zl consisting of : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) . halogen se1ected from bromine , ch1orine and ﬂuorine , C1_4 - alkyl , . hydroxy , C1_4 - a1koXy , —OCF3 , . —SCF3 , . —CN , —C ( OH ) CH3CF3 , hydroXy - C 1_4 - alky1 , —CF3 , . —S ( O ) 2CH3 , —S ( O ) 2NH2 , —S ( O ) 2NHCH3 , —S ( O ) 2N ( CH3 ) 2 , —N ( CH3 ) S ( O ) 2CH3 , —N ( CH3 ) C ( O ) CH3 , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( q ) ( r ) ( S ) ( t ) ( 11 ) ( V ) ( W ) ( X ) ( y ) ( z ) ( aa ) . —C ( O ) NH2 , . —C ( O ) NHCH3 , . —C ( O ) N ( CH3 ) 2 , . —C ( O ) CH3 , . N - heterocyc1y1methy1 , . N - heterocyc1y1 , optiona11y substituted with methy1 , phenoxy , . —NH2 , . —NHCH3 , . —N ( CH3 ) 2 , and. methoXycarbony1 ; . R2 is se1ected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) ( s ) ( t ) . C1_6 - a1ky1 , . C1_6 - a1koxy - C1 _6 - a1ky1 , hydroXy - C2_6 - alkyl , ﬂuoro - C2_6 - a1ky1 , amino - C2_6 - a1ky1 , C1_3 - a1kylamino - C2_6 - a1kyl , di ( C13 - a1kyl ) amino - C2_6 - a1kyl , cyano - C1_6 - a1ky1 , C1_6 - a1ky1su1fony1 - C2_6 - a1ky1 , C2_3 - acy1amino - C2_4 - a1ky1 , C1_4—a1kylthio - C2_4—a1kyl , C2_4 - acyl - C1_4 - alkyl , C3_6 - a1kyny1 , . C3_6 - a1kcny1 , . C3_7 - cyc1oa1ky1 , C5_g - cyc1oa1keny1 , . C - heterocyc1y1 , optiona11y substituted with C1_4 - a1ky1 , . C7_g - bicyc1y1 , optionally substituted with hydroxy , C7 - g - bicyclylmethyl , azabicyc1y1 , optional1y substituted with hydroxy , . PCT / EP2009 / 057074. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( u ) . ( V ) ( V0 ( X ) ( y ) ( z ) ( aa ) ( bb ) . ( CC ) . ( dd ) ( ee ) ( fD ( gg ) ( hh ) ( h ) ( U ) ( kk ) 00. ( nn ) ( o0 ) ( pp ) ( qq ) . C3_7 - cyc1oa1ky1 - C1_4 - a1ky1 , wherein cycloa1ky1 is optionally substituted with methyl or hydroXy , . C1_6 - a1ky1sulfony1 - C2_6 - a1ky1 , . C2_3 - acyl - C1_4 - alkyl , . diphenylmethyl , . ary1carbonyl - C1_4 - alky1 , . heteroary1carbonyl - C1_4 - alky1 , . [ CF3CH3 ( OH ) C ] - C1_6 - a1ky1 , . N - heterocyc1y1carbonyl - C2_4 - a1ky1 , wherein heterocyclyl is optionally substituted with methy1 , . C - heterocyc1y1carbony1 - C2_4 - a1ky1 , wherein heterocyc1y1 is optiona11y substituted with methy1 , . aminocarbonyl—C2_6 - a1kyl , . C1_3 - a1ky1aminocarbony1 - C2_6 - a1ky1 , . di ( C1 3 - a1kyl ) aminocarbony1 - C2_6 - a1ky1 , hydroXy - C2_4 - alkoXy - C2_4 - a1kyl , . hydroXy - C4_6 - cyc1oalky1 , . oxo - C4_6 - cycloa1ky1 , . ﬂuoro - C4_6 - cyc1oa1ky1 , . C1_3 - a1koXy - C4_6 - cyc1oa1ky1 , . methyl - C3_6 - cycloalky1 , . oxo - N - heterocyc1y1 - C2_4 - a1ky1 , . ﬂuoro - N - heterocyc1y1 - C2_4 - a1ky1 , . amino—N—heterocycly1 - C2_4—alkyl , . hydroXy - N - heterocyc1y1 - C2_4 - a1ky1 , . N - heterocycly1 - C2_4 - a1ky1 , wherein heterocyc1y1 is optionally substituted with mcthyl , . C - heterocyc1yl - C1_4 - a1kyl , wherein heterocyc1y1 is optiona11y substituted with methy1 , . ary1 , . ary1 - C1_4 - alky1 , . ary1 - C3 , 6 - alkenyl , . ary1 - C3_6 - a1kyny1 , . ary1oXymethy1 , . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( XX ) heteroary1 , . ( yy ) heteroary1 - C1_4 - alky1 , . ( zz ) heteroary1 - C3_6 - a1kenyl , and. ( aaa ) heteroary1 - C3_6 - alkynyl , wherein any aryl or heteroary1 residue , alone or as part of another group , is optional1y independent1y substituted in one or more position with a substituent se1ected from the. group Zl as defmed aboVe ; . R3 is se1ected from : ( a ) hydrogen , ( b ) C1_6 - a1ky1 , ( c ) ﬂuoro - C2_6 - a1ky1 , ( d ) hydroXy—C2_6—alky1 , ( e ) C1_6 - a1koxy - C2_6 - a1ky1 , ( f ) amino - C2_5 - a1ky1 , ( g ) C1_3 - alkylamino - C2_6 - a1kyl , ( h ) di ( C1_3 - a1ky1 ) amino - C2_6 - a1kyl , ( i ) cyano - C1_6 - alky1 , ( j ) C1_6 - alkylsu1fonyl - C2_6 - a1kyl , ( k ) C2_3 - acy1amino - C2_4 - alky1 , ( 1 ) C1_4 - alkylthio - C2_4 - a1kyl , and ( m ) C2_4 - acy1 - C1_4 - a1ky1 ; or R2 and R3 together with the nitrogen to which they are attached form a heterocyc1ic ring , wherein said heterocyclic ring may be optional1y substituted with : i ) a substituent se1ected from : ( aa ) hydroxy , ( bb ) C1 - 3 - a1ky1 , ( cc ) amino , ( dd ) methy1amino , ( ee ) dimethylamino , ( ff ) hydroxy - C1 - 2 - a1ky1 , and ( gg ) aminomethyl ; ii ) one or two OXO groups ; or. iii ) one or two ﬂuorine atoms , . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _10_. proVided that when the substituent is se1ected from ﬂuorine , hydroXy , amino , methylamino. and dimethylamino , said substituent is attached to the heterocyc1ic ring at a position other. than a1pha to a heteroatom ; . R4 is independent1y se1ected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) . ( H1 ) . ( 0 ) ( p ) ( q ) ( r ) ( s ) ( t ) ( 11 ) ( V ) ( W ) . ( X ) . ( y ) . C1_6 - a1ky1 , . ﬂuoro - C1_6 - a1ky1 , . hydroxy - C2_6 - a1ky1 , . C1_4 - a1koXy - C2_4 - a1kyl , . C2_4 - acy1 - C1_4 - a1ky1 , . carboxy - C1_3 - a1ky1 , . C3_6 - cyc1oa1ky1 , . oXo—C4_6—cyc1oa1ky1 , . hydroXy - C4_6 - cyc1oa1ky1 , . ﬂuoro - C4_5 - cyc1oa1ky1 , . methyl - C3_6 - cyc1oalky1 , . N - heterocyclylcarbonyl - C2_4 - a1ky1 , wherein heterocyc1y1 is optional1y substituted with methy1 , . N - heterocycly1 - C2_4 - a1kyl , wherein heterocyc1yl is optional1y substituted with methy1 , . oXo - N - heterocyc1y1 - C2_4 - a1ky1 , . ﬂuoro - N - heterocyc1y1 - C2_4 - a1ky1 , . hydroXy - N - heterocyc1yl - C2_4 - a1ky1 , . amino—N—heterocyclyl—C2_4 - a1kyl , . aminocarbony1 - C2_4 - a1ky1 , . C1_3 - a1ky1aminocarbonyl - C2_4 - a1ky1 , di ( C1_5 - a1ky1 ) aminocarbonyl - C2_4 - a1kyl , . C2_3 - acy1amino - C2_4 - alky1 , . hydroxy - C2_4 - a1koxy - C2_4 - a1ky1 , . C - heterocyclylcarbonyl - C2_4 - a1kyl , wherein heterocyc1y1 is optionally substituted with methy1 , . C3 , 6 - cycloalkyl - C1 , 2 - alkyl , wherein cycloa ] kyl is optionally substituted with methy1 , . amino - C2_4 - a1ky1 , . 5. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( Z ) . ( aa ) ( bb ) ( CC ) . _11_. C1_2 - a1kylamino - C2_4 - alkyl , di ( C1_2 - alkyl ) amino - C2_4 - alkyl , phenyl , and. heteroaryl , . wherein any pheny1 or heteroary1 residue is optiona11y substituted in one or more positions. with a substituent independently selected from the group Z2 consisting of : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D ( g ) ( h ) . halogen selected from chlorine and ﬂuorine , C1_4 - a1koxy , . hydroxymethyl , . —CN , . - CF3 , . C1_4 - alkyl , . - OCF3 , and. —C ( O ) CH3 ; . R5 is each independent1y selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( 0. ( g ) . ( h ) . ( i ) ( j ) ( k ) ( 1 ) ( m ) ( h ) ( 0 ) . hydrogen , . C1_6 - a1kyl , . C3 - 6 - alkenyl , . C3_6 - cyc1oa1ky1 , . methyl - C3_6 - cycloalkyl , . C3_6 - cycloa1kyl - C1 - 4 - a1ky1 , wherein cyc1oa1ky1 is optiona11y substituted with hydroxy or methyl , . N—heterocyclyl—C2 - 4 - alkyl , wherein heterocyclyl is optionally substituted with methy1 , . heteroaryl - C1 - 4 - alky1 , wherein heteroaryl is optionally substituted with mcthyl , . carboxy - C1 - 3 - a1ky1 , . ﬂuoro - C2_4 - a1kyl , . amino - C2_6 - alky1 , . cyano - C1_6 - a1ky1 , . hydroXy - CM - alkyl , . dihydroxy - C2_6 - a1kyl , . C1_4 - a1koXy - C2_4 - a1kyl , . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 12 _ PCT / EP2009 / 057074. ( p ) C1_4 - a1kylamino - C2_4 - alkyl , . ( q ) di ( C1_4 - alkyl ) amino - C2_4 - alkyl , . ( r ) aminocarbonyl - C1_4 - alkyl , . ( s ) C2_3 - acylamino - C2_4 - alkyl , . ( t ) C1_4 - a1ky1thio - C2_4 - a1ky1 , . ( u ) C2_4 - acyl - C1_4 - alkyl , and. ( V ) C1_4 - alkylsu1fonyl - C1_4 - a1kyl , or two R5 groups together with the nitrogen to which they are attached form a heterocyc1ic ring , wherein said heterocyclic ring may be optionally substituted with : i ) a substituent selected from : . ( aa ) hydroxy , . ( bb ) C1 - 3 - alky1 , . ( cc ) amino , . ( dd ) methylamino , . ( ee ) dimethylamino , . ( ff ) hydroXy - C1 - 2 - alkyl , and. ( gg ) aminomethyl ; ii ) one or two oxo groups ; or iii ) one or two ﬂuorine atoms , proVided that when the substituent is selected from ﬂuorine , hydroXy , amino , methylamino and dimethylamino , said substituent is attached to the heterocyclic ring at a position other than a1pha to a heteroatom ; or two R5 groups together with the nitrogen to which they are attached form the group. 4— ( pyrimidin—2—yl ) piperazin— 1 —yl ; . R6 is independently selected from : ( a ) hydrogcn , ( b ) C1_4 - a1kyl , and ( c ) hydroxy - C2_4 - alky1 ; . R7 is independently selected from : ( a ) hydrogen , and ( b ) C1_4 - a1ky1 ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _13_. R8 is independently selected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) ( i ) . ( i ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) . ( p ) ( q ) . hydrogen , . C1_6 - a1kyl , . ﬂuoro - C1_6 - a1kyl , . hydroXy - C2_6 - alky1 , . amino - C2_6 - alky1 , . C1_3 - alkylamino - C2_4 - alkyl , . di ( C1_3 - a1kyl ) amino - C2_4 - a1kyl , . C1_4 - a1kylsu1fonyl - C2_4 - a1kyl , . N - heterocycly1 - C2_4 - alkyl , wherein heterocycly1 is optionally substituted with methy1 , . C - heterocyclyl , optiona1ly substituted with methy1 , . C2_3—acylamino—C2_4—alkyl , . [ CF3CH3 ( OH ) C ] - C1_6 - alkyl , . C3_6 - cyc1oa1ky1 , . methyl - C3_6 - cycloalkyl , . C3_6 - cycloalkyl - C1_2 - alkyl , wherein cycloalkyl is optionally substituted with methyl , . aryl , and. heteroaryl , . wherein any aryl or heteroaryl residue is optionally independently substituted in one or two. positions with a substituent se1ected from the group Z2 as defined aboVe ; and. R9 is aryl or heteroaryl , each of which is optionally substituted in one or more positions. with a substituent independent1y se1ected from the group Z2 as defined aboVe. In a prcfcrrcd cmbodimcnt of compounds of formula ( Ia ) , W , X and Y arc cach independently CH2 , 0 or NH , proVided that ( i ) at least one of W and X is CH2 , and ( ii ) no more than one of W , X and Y is NH. In another preferred embodiment of compounds of formula ( Ia ) , m is each 1. 10. l5. 20. 25. WO 2009 / 150144 _ 14 _ PCT / EP2009 / 057074. A preferred group of compounds of the inVention are compounds of Formu1a ( Ib ) : . ( 1b ) . and pharmaceutically acceptab1e salts , solVates , hydrates , geometrical isomers , tautomers , . optica1 isomers or N—oxides thereof ; wherein : . W and X are each independently CH2 or O , proVided that at 1east one of W and X is CH2 ; Y is CH2 , 0 or NH ; and Ar1 , Z1 , Z2 , R1 to R9 are as deﬂned in Formula ( Ia ) . A further preferred group of compounds of the inVention are compounds of Formula ( Ic ) : . ( 1C ) . and pharmaceutically acceptab1e salts , solVates , hydrates , geometrical isomers , tautomers , . optica1 isomers or N - oXides thereof ; wherein : . Z1 , Z2 , R1 to R6 are as deﬂned in Forrnula ( Ia ) ; Ar1 is phenyl or heteroaryl , each of which is optiona1ly substituted in one or two positions with a substituent independently selected from the group Z3 consisting of : . ( a ) CF3SO3 , . ( b ) halogen selected from bromine , chlorine and ﬂuorine , . ( c ) C1 - 4 - alkylsulfoXimine , . ( d ) - S ( 0 ) R4 , . ( C ) - S ( 0 ) 2R4 , . ( r ) —S ( O ) 2NR5R5 , . 10. l5. 20. 25. 30. WO 2009 / 150144. ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) ( m ) ( n ) . ( p ) ( q ) ( r ) . ( S ) ( t ) ( 11 ) ( V ) ( W ) ( X ) ( y ) ( z ) ( aa ) ( bb ) ( CC ) ( dd ) ( CC ) ( ff ) ( gg ) ( hh ) ( ii ) 00 ( kk ) ( 11 ) . _15_. —NR6S ( O ) 2R4 , —NR6C ( O ) R4 , —CH2 - NR6C ( O ) R4 , —C ( o ) NR5R5 , —CH2 - C ( O ) NR5R5 , —C ( O ) R4 , H2N - C ( O ) O— , CH3 - NH - C ( O ) O— , ( CH3 ) 2NC ( O ) O— , —NHC ( O ) OCH3 , . C - heterocyc1y1 , optiona11y substituted with methy1 , N - heterocyclylcarbonylVinyl , wherein N - heterocyclyl is optionally substituted. with methyl , . —OR8 , —SCF3 , . nitro , . PCT / EP2009 / 057074. C - heterocyclylsulfony1 , optionally substituted with methy1 , . —NR5R5 , —C ( OH ) CH3CF3 , cyano - C1_6 - alky1 , guanidino , . C1_6 - a1kyl , C1_3—alkylthio , C1_4 - a1koXy - C1_4 - a1ky1 , ﬂuoro - C1_4 - a1kyl , C2_6 - alkcnyl , ﬂuoro - C2_4 - a1keny1 , hydroxy - C1_5 - alky1 , C1_4 - alkylsu1fonyl - C1_4 - a1kyl , . hydroxy - C2_4 - alkoxy - C1_4 - alkyl , . C2 - 3 - acyl - C1 , 3 - alkyl , C2_6 - a1kyny1 , . ( mm ) C3_6 - cycloalkyl , . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( nn ) ( 00 ) ( pp ) ( qq ) ( rr ) . ( ss ) ( tt ) . ( uu ) . —16—. hydroXy - C3_6 - cycloa1kyl , . ﬂuoro - C3_6 - cyc1oa1ky1 , . methyl - C3_6 - cycloalkyl , . C - heterocyc1ylcarbony1 , optional1y substituted with methy1 , C3_6 - cycloa1ky1 - C1_4 - alky1 , . R5R5N - C1_2 - a1ky1 , . — ( CH2 ) nC ( O ) OH , wherein n is 1 , 2 or 3 , and. heteroaryl , . wherein any heteroaryl residue as substituent on Ar1 is optionally substituted in one or. more positions with a substituent independently selected from the group Z2 as deﬁned. herein for Formu1a ( Ia ) ; . R8 is independently selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D ( g ) . hydrogen , . C1_4 - a1ky1 , . CF3 , . C3_5 - cyc1oa1ky1 , . methyl - C3_5 - cycloalkyl , di ( C1_3 - alkyl ) amino - C2_3 - alkyl , and C - heterocyclyl , optiona1ly substituted with methy1 ; . R9 is pheny1 which is optionally substituted in one or two positions with a substituent. independently selected from the group Z2 as deﬁned herein for Formula ( Ia ) . A preferred subgroup of compounds of Formu1a ( Ic ) consists of compounds wherein : . Ar1 is phcny1 , quinolinyl , pyridinyl , thiazolyl , thicnyl , ﬁlryl or iszazolyl , cach of which is. optional1y substituted in one or two positions with a substituent independently selected. from the group Z4 consisting of : . ( a ) ( b ) ( C ) ( d ) ( C ) . halogen selected from chlorine and ﬂuorine , C1 - 4 - alkylsulfoximine , . C1 , 4 - alkylsu1fonyl , . C1_4 - a1ky1su1ﬁny1 , hydroxy - C2_4 - alky1sulfonyl , . 10. l5. 20. 25. 30. WO 2009 / 150144. ( f ) ( g ) ( h ) ( i ) ( i ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) ( S ) ( t ) ( u ) ( V ) ( W ) ( X ) . ( y ) ( Z ) ( aa ) ( bb ) ( CC ) ( dd ) ( CC ) ( ff ) ( gg ) ( hh ) ( ii ) ( jj ) ( kk ) ( 11 ) . _17_. amino - C2_4 - alky1sulfonyl , . C 3_5 - cycloa1ky1su1fony1 , methyl - C3_5 - cycloalkylsulfonyl , triﬂuoromethylsulfonyl , methylthio , . —S ( O ) 2NR5AR5A , C1_4 - alkylsu1fonamido , C2_4 - acy1amino , C2_4 - acylaminomethyl , carboxy - C1_3 - alkylcarbony1amino , —C ( O ) NR5AR5A , —CH2 - C ( O ) NR5AR5A , - NHC ( O ) OCH3 , . C2_4 - acyl , C3_5 - cycloa1ky1carbony1 , . C1 _4 - alkoXy , C3_5 - cycloalkyloxy , C - heterocyclyl , . N - heterocyclylcarbonylVinyl , wherein N - heterocyclyl is optionally substituted. with methyl , . —CN , . —OH , . —OCF3 , . nitro , . —CF3 , . _NR5AR5A di ( C1_2 - alkyl ) amino - C2 - 3 - a1koXy , —C ( OH ) CH3CF3 , cyano - C1_2 - a1ky1 , guanidino , . C1_4 - a1kyl , C3 - 5 - cycloalkyl , C1_2 - a1koXy - C1_2 - a1ky1 , . Vinyl , . PCT / EP2009 / 057074. 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( mm ) ( nn ) ( 00 ) ( pp ) ( qq ) ( H ) . —18—. ethynyl , . 5 - membered heteroary1 , . hydroxy - C1_2 - alky1 , . C - heterocyclyloXy , optional1y substituted with methy1 , R5AR5AN - C1_2 - alkyl , and. — ( CH2 ) nC ( O ) OH , wherein n is 1 , 2 or 3 ; . R1 is a group R1A , which is se1ected from —C ( O ) OR2A , —C ( O ) R2A , —C ( O ) NR2AR3A , —CH2C ( O ) NR2AR3A , —C ( O ) C ( O ) - phenyl or a 6 - membered heteroary1 group linked Via a. ring carbon atom , wherein the said heteroaryl group is optionally substituted with methyl ; . R2A is selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) ( m ) . ( n ) ( 0 ) ( p ) ( q ) ( r ) ( S ) . ( t ) . C1_6—a1ky1 , . C1_6 - a1koXy - C1_6 - a1kyl , . hydroxy - C2_5 - alky1 , hydroXy - C2_4 - alkoxy - C2_4 - alkyl , . ﬂuoro - C2_6 - a1kyl , . C3_6 - a1kynyl , . C3_7 - cyC1oa1ky1 , . C5_g - cycloa1kenyl , . C - heterocyclyl , optiona1ly substituted with methyl , C7_g - bicyclyl , . 2 - norbornylmethy1 , . azabicyclyl , . C3_6 - cyc1oa1ky1 - C1_4 - a1ky1 , wherein cyc1oa1ky1 is optiona11y substituted with methyl , . C2_3 - acy1 - C 1 _4 - a1ky1 , . diphenylmethyl , . arylcarbony1 - C1_4 - alkyl , heteroarylcarbony1 - C1_4 - alkyl , [ CF3CH3 ( OH ) C ] - C1_6 - a1kyl , N - heterocyclylcarbonyl - C2 , 4 - alkyl , wherein heterocyclyl is optional1y substituted with methy1 , . hydroXy - C4_6 - cycloa1kyl , . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( u ) ( V ) ( V0 ( X ) ( y ) ( Z ) ( aa ) ( bb ) ( dd ) . ( CC ) . ( fD ( gg ) ( hh ) ( ﬁ ) ( U ) . _19_. oXo - C4_6 - cycloa1ky1 , . ﬂuoro - C4_6 - cyc1oa1ky1 , . methoXy - C4_6 - cycloalkyl , . methyl - C3_6 - cycloalkyl , . oXo - N - heterocyc1yl - C2_4 - a1ky1 , . hydroXy - N - heterocyclyl - C2_4 - a1kyl , . ﬂuoro - N - heterocyc1yl - C2_4 - alky1 , . amino - N - heterocycly1 - C2_4 - a1kyl , . N - heterocyclyl - C2 - 4 - alkyl , wherein heterocyclyl is optionally substituted with methyl , . C - heterocyc1y1 - C1_4 - a1ky1 , wherein heterocycly1 is optionally substituted with methyl , . aryl , . aryl - C1_4 - alkyl , . aryloxymethyl , . heteroaryl , and. heteroaryl - C1_4 - alkyl , . wherein any aryl or heteroary1 residue , alone or as a part of another group , is optional1y. substituted in one or more positions with a substituent independent1y se1ected from the. group Z5 consisting of : . ( a ) ( b ) ( C ) ( d ) ( C ) ( ﬂ ( g ) ( h ) ( D 0 ) ( k ) ( D ( nD 00. halogen selected from bromine , chlorine and ﬂuorine , methy1 , . ethyl , . methoXy , . ethoxy , . isopropoXy , . phcnoXy , morpho1in - 4 - ylmethyl , 4 - methylpiperazin - 1 - yl , hydroXy , . —OCF3 , . —CF3 , . —CN , . —C ( OH ) CH3CF3 , . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. ( 0 ) ( p ) ( q ) ( r ) ( S ) . _20_. —N ( CH3 ) 2 , hydroxymethyl , —S ( O ) 2CH3 , —C ( O ) CH3 , and —C ( O ) NH2 ; . R3A is selected from : . ( a ) ( b ) ( C ) ( d ) . hydrogen , . C1 _4 - a1ky1 , hydroXy - C2_4 - alky1 , and methoXy - C2_4 - a1ky1 ; . or R2A and R3A together with the nitrogen to which they are attached form a heterocyclic. ring , wherein said heterocyclic ring may be optionally substituted with : . i ) one hydroXy , amino or methyl group , . ii ) one or two ﬂuorine atoms , or. iii ) one or two oxo groups , . proVided that when the substituent is selected from ﬂuorine , hydroXy and amino , said. substituent is attached to the heterocyclic ring at a position other than a1pha to a. heteroatom ; . R5A is each independently selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( 0. ( g ) ( h ) ( i ) ( j ) ( k ) ( 1 ) . hydrogen , . C1_3 - a1kyl , . C3—4—alkenyl , C1_2 - a1koXy - C2_4 - a1ky1 , C3_4 - cyc1oa1ky1 , C5_4 - cycloalkyl - C1 - 2 - alkyl , whcrcin cycloa1kyl is optionally substitutcd with hydroxy , hydroxy - C2_4 - alky1 , cyano - C1_3 - alky1 , N - heterocyc1yl - C2 - 4 - a1kyl , heteroaryl - C1 - 2 - alky1 , carboxy - C1 - 2 - a1ky1 , dihydroxy - C2_4 - alkyl , . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 21 _ PCT / EP2009 / 057074. ( m ) aminocarbonyl - C1_2 - alkyl , . ( n ) C1_3 - alkylamino - C2_3 - alkyl , and. ( o ) di ( C1_3 - alkyl ) amino - C2_3 - alkyl ; or two R5A groups together with the nitrogen to which they are attached form a heterocyclic ring , wherein said heterocyclic ring may be optionally substituted with : i ) a substituent selected from : . ( aa ) hydroxy , . ( bb ) methy1 , . ( cc ) amino , . ( dd ) methylamino , . ( ee ) dimethy1amino , . ( ff ) hydroxy - C1 - 2 - alkyl , and. ( gg ) aminomethyl ; ii ) one or two OXO groups ; or iii ) one or two ﬂuorine atoms , proVided that when the substituent is selected from ﬂuorine , hydroXy , amino , methylamino and dimethylamino , said substituent is attached to the heterocyclic ring at a position other than a1pha to a heteroatom ; or two R5 groups together with the nitrogen to which they are attached form the group. 4 - ( pyrimidin - 2 - yl ) piperazin - 1 - yl. In another more preferred subgroup of compounds of Formu1a ( Ic ) , Ar1 is se1ected from [ ( dimethylamino ) carbonyl ] pheny1 , ( methylsulfonyl ) phenyl , quinolinyl , [ ( diethylamino ) - carbonyl ] phenyl , [ ( 4—methylpiperidin— 1 - yl ) carbonyl ] phenyl , [ ( 4—oXopiperidin— 1 —yl ) — carbony1 ] pheny1 , ( methy1su1fony1 ) pyridiny1 , [ ( methy1su1fony1 ) amino ] pheny1 , { [ ( 2 - morpholin - 4 - y1ethyl ) amino ] sulfonyl } pheny1 , ( methylsulfonyl ) nitropheny1 , ( methyl - su1fonyl ) aminophcnyl , { [ 2 - ( dimcthylamino ) cthyl ] amino } ( mcthylsulfonyl ) phcnyl , { [ 2 - ( isopropylamino ) ethyl ] amino } ( methylsulfonyl ) phenyl , ( methylsulfonyl ) [ ( 2 - morpholin - 4 - ylethyl ) amino ] phenyl , [ 2 - ( dimethylamino ) ethoxy ] ( methy1sulfony1 ) phenyl , [ ( methylamino ) - carbonyl ] phenyl , [ ( ethy1amino ) carbonyl ] phenyl , [ ( allylamino ) carbony1 ] phenyl , [ ( cyclopropylamino ) carbonyl ] phenyl , [ ( 2 - hydroxyethylamino ) carbonyl ] phenyl , [ ( 3 - hydroXypropylamino ) carbonyl ] phenyl , [ ( 2 - methoxyethylamino ) carbonyl ] phenyl , { [ ( 2 - hydroXy - l , l - dimethy1ethy1 ) amino ] carbony1 } pheny1 , [ ( 3 - hydroXyazetidin - 1 - y1 ) carbonyl ] - pheny1 , [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] phenyl , { [ 2 - ( furyl ) ethyl ] amino } carbonyl ) - phenyl , ( amino - . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 22 _ PCT / EP2009 / 057074. carbonyl ) phenyl , ( morpho lin - 4 - ylcarbonyl ) pheny1 , [ ( 2 - hydroXyethy1 ) sulfonyl ] pheny1 , [ ( 2 - aminoethyl ) sulfonyl ] phenyl , { [ ( 2 - methylprop - 2 - en - 1 - y1 ) amino ] carbonyl } phenyl , [ ( but - 3 - en - 1 - ylamino ) carbonyl ] - phenyl , ( { [ ( 1 - hydroXycyclopropyl ) methyl ] amino } carbonyl ) - pheny1 , { [ 2 - ( hydroXymethyl ) morpho lin - 4 - yl ] carbonyl } pheny1 , ( 2 - carboXyethyl ) - iszazo lyl , { [ ( carboXymethyl ) amino ] carbonyl } furyl , ( 1H - tetrazol - 5 - yl ) pheny1 , { [ amino - ( imino ) methyl ] amino } - methyl - 1 , 3 - thiazolyl , pyridinyl , [ ( 4 - methy1piperazin - 1 - yl ) - carbonyl ] ﬁ1ryl , [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridiny1 , [ ( 1E ) - 3 - ( 4 - methylpiperazin - 1 - y1 ) - 3 - oXoprop - 1 - en - 1 - y1 ] thieny1 , [ ( 1E ) - 3 - morpho1in - 4 - y1 - 3 - oXoprop - 1 - en - 1 - y1 ] thienyl , [ ( 4 - pyrimidin - 2 - ylpiperazin - 1 - yl ) carbonyl ] pyridinyl , { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) - amino ] carbonyl } pyridinyl , ( morpholin - 4 - y1carbonyl ) pyridiny1 and { [ 4 - ( 2 - hydroXyethyl ) - piperazin - 1 - y1 ] carbony1 } - pyridinyl. More preferably , Ar1 is se1ected from 4 - [ ( dimethylamino ) carbonyl ] phenyl , 4— ( methyl— su1fonyl ) phenyl , quinolin - 5 - yl , 4 - [ ( diethylamino ) carbonyl ] phenyl , 4 - [ ( 4 - methylpiperidin - 1 - yl ) carbonyl ] phenyl , 4 - [ ( 4 - oXopiperidin - 1 - yl ) carbonyl ] pheny1 , 5 - ( methylsulfonyl ) pyridin - 2 - yl , 4 - [ ( methylsu1fonyl ) amino ] phenyl , ( 4 - { [ ( 2 - morpholin - 4 - ylethyl ) amino ] sulfonyl } - pheny1 , 4 - ( methylsulfonyl ) - 2 - nitrophenyl , 2 - amino - 4 - ( methylsulfonyl ) pheny1 , 2 - { [ 2 - ( dimethylamino ) ethyl ] amino } - 4 - ( methylsulfonyl ) phenyl , 2 - { [ 2 - ( isopropy1amino ) ethyl ] - amino } - 4 - ( methylsulfonyl ) pheny1 , 4 - ( methylsulfonyl ) - 2 - [ ( 2 - morpholin - 4 - y1ethyl ) amino ] - pheny1 , 2 - [ 2 - ( dimethylamino ) ethoXy ] - 4 - ( methylsu1fonyl ) phenyl , 4 - [ ( methylamino ) - carbonyl ] phenyl , 4 - [ ( ethylamino ) carbonyl ] phenyl , 4 - [ ( allylamino ) carbonyl ] phenyl , 4 - [ ( cyc10propy1amino ) carbony1 ] pheny1 , 4 - { [ ( 2 - hydroXyethy1 ) amino ] carbonyl } pheny1 , 4 - { [ ( 3 - hydroXypropyl ) amino ] carbonyl } phenyl , 4 - { [ ( 2 - methoXyethyl ) amino ] carbonyl } - pheny1 , 4— { [ ( 2 - hydroXy— 1 , 1 —dimethylethy1 ) amino ] carbony1 } phenyl , 4— [ ( 3 —hydroXyazetidin— 1 - y1 ) carbony1 ] pheny1 , 4 - [ ( 4 - methy1piperazin - 1 - y1 ) carbony1 ] pheny1 , 4 - ( { [ 2 - ( 2 - ﬁ1ry1 ) ethy1 ] - amino } carbonyl ) phenyl , 4 - ( amino carbonyl ) phenyl , 4 - ( morpholin - 4 - ylcarbony1 ) phenyl , 4 - [ ( 2 - hydroXycthyl ) sulfonyl ] phcnyl , 4 - [ ( 2 - aminocthyl ) sulfony1 ] phcnyl , 4 - { [ ( 2 - mcthy1prop - 2 - en - 1 - yl ) amino ] carbonyl } pheny1 , 4 - [ ( but - 3 - en - 1 - ylamino ) carbonyl ] phenyl , 4 - ( { [ ( 1 - hydroXycyclopropyl ) methyl ] amino } carbonyl ) pheny1 , 4 - { [ 2 - ( hydroXymethyl ) morpholin - 4 - yl ] carbonyl } phenyl , 5 - ( 2 - carboXyethyl ) iso Xazol - 3 - yl , 5 - { [ ( carboXymethyl ) amino ] - carbonyl } - 2 - furyl , 6 - ( methylsu1fonyl ) pyridin - 3 - yl , 4 - ( 1H - tetrazol - 5 - yl ) phenyl , 2 - { [ amino - ( imino ) methyl ] amino } - 4 - methyl - l , 3 - thiazol - 5 - yl , 4 - pyridinyl , 3 - pyridinyl , 5 - [ ( 4 - methylpiperazin - 1 - y1 ) carbony1 ] pyridin - 2 - y1 , 6 - ( morpho1in - 4 - ylcarbony1 ) pyridin - 3 - y1 , 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl , 5 - ( morpholin - 4 - ylcarbonyl ) pyridin - 2 - yl , . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 23 _ PCT / EP2009 / 057074. 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] - 2 - furyl , 5 - [ ( 1E ) - 3 - ( 4 - methy1piperazin - 1 - yl ) - 3 - oXoprop - 1 - en - 1 - yl ] - 2 - thienyl , 5 - [ ( 1E ) - 3 - morpho lin - 4 - yl - 3 - oXoprop - 1 - en - 1 - yl ] - 2 - thienyl , 5 - [ ( 4 - pyrimidin - 2 - ylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl , 5 - { [ [ 2 - ( dimethy1amino ) ethyl ] - ( methyl ) amino ] carbonyl } pyridin - 2 - yl , 5 - { [ 4 - ( 2 - hydroXyethyl ) piperazin - 1 - y1 ] carbonyl } - pyridin - 2 - yl and 6 - { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) amino ] carbonyl } pyridin - 3 - yl. In another more preferred subgroup of compounds of Formula ( Ic ) , R1A is selected from C ( O ) OR2A , C ( O ) R2A , - CH2 - C ( O ) NR2AR3A , —C ( O ) C ( O ) - phenyl or a 6 - membered heteroaryl. group linked Via a ring carbon atom. In one embodiment , R1A is C ( O ) OR2A , wherein R2A is se1ected from benzy1 , tert - buty1 , . ethyl , ( 1 - methylcyclopropyl ) methyl and isopropyl. In another embodiment , R1A is C ( O ) R2A , wherein R2A is selected from 4 - cyanobenzyl , 3 , 4 - dichloropheny1 , 2 , 4 - diﬂuorobenzyl , 3 - ( triﬂuoromethy1 ) benzyl , 4 - methoxybenzyl , ( 1H - indol - 3 - yl ) methyl , ( 1 - methyl - 1H - indol - 3 - yl ) methyl , cycloheXylmethyl , 2 - methyl - 2 - phenyl - n - propyl , 2 - ( 4 - methoxyphenyl ) ethy1 , 2 - ( 3 - chloro - 4 - methoxyphenyl ) ethyl , 2 - ( 4 - hydroXypheny1 ) ethyl , 2 - ( 1H - indol - 3 - yl ) ethyl , 2 - cycloheXylethyl , 3 - ( 4 - ﬂuorophenyl ) propyl , 3 - oXo - butyl , 3 - oXo - 3 - ( pyrrolidin - 1 - yl ) propy1 , 2 - fury1 , ( 4 - ﬂuorophenoXy ) methy1 , 1H - pyrrol - 2 - y1 , ( 1H - tetrazol - 1 - yl ) methyl , 2 - pyridinyl , 4 - pyridinyl , 2 - pyrazinyl , 6 - quinoXalinyl , 4 - isopropoXyphenyl , 2 - naphthyl , phenyl , 2 - hydroxy - 4 - methylphenyl , 2 - phenoXypyridin - 5 - y1 , dipheny1methyl , 5 - isopropoxypyridin - 2 - yl , 2 , 2 , 2 - triﬂuoroethy1 , 3 - hydroXypyridin - 2 - y1 , ethyl , 7 - methoxy - 1 - benzofuran - 2 - yl , 3 - ( N , N - dimethy1amino ) phenyl , 2 - hydroxyphenyl , benzoyl , 2— ( 1 - methylpiperazin—4—yl ) ethy1 , 4 - ( 1 —methylpiperazin—4—yl ) phenyl , methoxymethy1 , 3 , 5 - diﬂuoropyridin - 2 - y1 , 4 - [ ( morpho1in - 4 - y1 ) methy1 ] pheny1 , 6 - bromo - 3 - hydroXypyridin - 2 - yl and 1 - ethylpropyl. In yet another embodiment , R1A is —CH2 - C ( O ) NR2AR3A , wherein R2A and R3A are both ethyl. In a further embodiment R1A is —C ( O ) C ( O ) - phenyl. In yet a further embodiment , R ] A is 2 - pyrimidinyl. WO 2009 / 150144 _ 24 _ PCT / EP2009 / 057074. Particular1y preferred compounds of Formula ( Ic ) are the compounds selected from the. group consisting of : . 10. l5. 20. 25. 30. - benzyl 4 - ( 6 - { 4 - [ ( dimethylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - . 1 - carboxylate ; . - benzyl 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - benzyl 4 - ( 6 - quinolin - 5 - yl - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboXylate ; - 4 - { 2 - [ 1 - ( 3 , 4 - dich1orobenzoy1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } - N , N - dimethy1 - . benzamide ; . - 4 - ( 2 - { 1 - [ ( 2 , 4 - diﬂuorophenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - N , N - . dimethy1benzamide ; . - N , N - dimethyl - 4 - [ 2 - ( 1 - { [ 3 - ( triﬂuoromethyl ) phenyl ] acetyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzo - . dioxin—6—yl ] benzamide ; . - 4 - ( 2 - { 1 - [ ( 4 - methoxyphenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - N , N - . dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ ( 4 - cyanopheny1 ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - N , N - . dimethylbenzamide ; . - 4 - { 2 - [ 1 - ( 1H - indol - 3 - ylacety1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } - N , N - dimethyl - . benzamide ; . - N , N - dimethyl - 4 - ( 2 - { 1 - [ ( 1 - methyl - 1H - indol - 3 - yl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzo - . dioxin - 6 - yl ) benzamide ; . - 4 - { 2 - [ 1 - ( cycloheXy1acety1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - y1 } - N , N - dimethy1 - . benzamide ; . - N , N— dimethyl - 4 - { 2— [ 1 - ( 3 —methyl - 3 - phenylbutano yl ) pip eridin—4—yl ] —4H— 1 , 3 —benzo dioXin—. 6 - y1 } benzamide ; . - 4 - ( 2 - { 1 - [ 3 - ( 4 - methoXyphenyl ) propanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - . N , N - dimcthylbcnzamidc ; . - 4 - ( 2 - { 1 - [ 3 - ( 3 - chloro - 4 - methoXyphenyl ) propanoy1 ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - . 6 - yl ) - N , N - dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ 3 - ( 4 - hydroXyphenyl ) propanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - N , N - . dimethylbenzamide ; . - 4 - ( 2 - { l - [ 3 - ( l H - indol - 3 - yl ) propanoyl ] piperidin - 4 - yl } - 4H - l , 3 - benzodioXin - 6 - yl ) - N , N - . dimethy1benzamide ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _25_. 0 4 - { 2 - [ 1 - ( 3 - cyclohexylpropanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - N , N - . dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ 4 - ( 4 - ﬂuoropheny1 ) butanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioXin - 6 - yl ) - N , N - . dimethylbenzamide ; . - N , N - dimethyl - 4 - { 2 - [ 1 - ( 4 - oXopentanoy1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } - . benzamide ; . - N , N - dimethyl - 4 - { 2 - [ 1 - ( 4 - oxo - 4 - pyrrolidin - 1 - ylbutanoy1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzo - . dioxin - 6 - y1 } benzamide ; . - benzyl 4 - ( 6 - { 4 - [ ( diethylamino ) carbonyl ] pheny1 } - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - . 1 - carboxylate ; . - benzy1 4 - ( 6 - { 4 - [ ( 4 - methy1piperidin - 1 - y1 ) carbony1 ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - . piperidine - 1 - carboXylate ; . - benzyl 4— ( 6 - { 4— [ ( 4—oxopiperidin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 —benzodioxin - 2 - yl ) —. piperidine - 1 - carboXylate ; . - benzyl 4 - { 6 - [ 5 - ( methylsulfonyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - 1 - ( 2 - furoyl ) - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ; - 1 - [ ( 4 - ﬂuorophenoxy ) acetyl ] - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - . y1 } piperidine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - 1 - ( 1H - pyrro l - 2 - yl - . carbonyl ) piperidine ; . - 4 - { 6 - [ 4 - ( methy1su1fony1 ) pheny1 ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } - 1 - ( 1H - tetrazo1 - 1 - y1acety1 ) - . piperidine ; . - 2 - [ ( 4 - { 6— [ 4 - ( methylsu1fonyl ) phenyl ] - 4H—1 , 3 —benzodioXin - 2 - y1 } piperidin—1—yl ) - . carbony1 ] pyridine ; . - 4 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] pyridinc ; . - 2 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] pyrazine ; . - 6 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] quinoxaline ; . - l - ( 4 - isopropoXybenzoyl ) - 4 - { 6 - [ 4 - ( methyl sul fonyl ) phenyl ] - 4H - l , 3 - benzodioXin - 2 - yl } - . piperidine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - 1 - ( 2 - naphthoyl ) piperidine ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —26—. - 1 - benzoyl - 4 - { 6 - [ 4 - ( methy1sulfony1 ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine ; - 5 - methyl - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidin - 1 - . yl ) carbonyl ] phenol ; . - 5 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] - 2 - phenoXypyridine ; . - 1 - ( diphenylacetyl ) - 4 - { 6 - [ 4 - ( methy1sulfony1 ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - . piperidine ; . - 5 - isopropoxy - 2 - [ ( 4 - { 6 - [ 4 - ( methy1su1fony1 ) pheny1 ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - . 1 - yl ) carbonyl ] pyridine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - 1 - ( 3 , 3 , 3 - triﬂuoro - . propanoy1 ) piperidine ; . - 2 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] pyridin—3—ol ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - 1 - propionylpiperidine ; - 1 - [ ( 7 - methoXy - 1 - benzo furan - 2 - yl ) carbonyl ] - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - . benzodioXin - 2 - yl } piperidine ; . - dimethyl { 3 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) pheny1 ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidin - 1 - . yl ) carbonyl ] phenyl } amine ; . 0 2 - [ ( 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidin - 1 - yl ) - . carbonyl ] pheno 1 ; . - 2 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - 2 - oXo - 1 - . pheny1ethanone ; . - 1 - methyl - 4 - [ 3 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidin - 1 - . yl ) —3 —oxopropyl ] pip erazine ; . - 1 - methy1 - 4 - { 4 - [ ( 4 - { 6 - [ 4 - ( methy1su1fony1 ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidin - . 1 - yl ) carbonyl ] phenyl } piperazine ; . - 1 - ( mcthoXyacctyl ) - 4 - { 6 - [ 4 - ( mcthylsulfony1 ) phcnyl ] - 4H - 1 , 3 - bcnzodioXin - 2 - yl } - . piperidine ; . - 3 , 5 - diﬂuoro - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidin - 1 - . y1 ) carbonyl ] pyridine ; . - 4 - { 4 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] benzyl } morpholine ; . - 6 - bromo - 2 - [ ( 4 - { 6 - [ 4 - ( methy1su1fony1 ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidin - 1 - y1 ) - . carbonyl ] pyridin - 3 - ol ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _27_. - benzyl 4 - ( 6 - { 4 - [ ( methylsulfonyl ) amino ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) piperidine - 1 - . carboxy1ate ; . - benzyl 4 - [ 6 - ( 4 - { [ ( 2 - morpholin - 4 - ylethyl ) amino ] sulfonyl } pheny1 ) - 4H - 1 , 3 - benzodioXin - . 2 - yl ] piperidine - 1 - carboxylate ; . - benzyl 4 - { 6 - [ 4 - ( methylsulfonyl ) - 2 - nitrophenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - benzyl 4 - { 6 - [ 2 - amino - 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - . 1 - carboxy1ate ; . - benzyl 4 - { 6 - [ 2 - { [ 2 - ( dimethylamino ) ethy1 ] amino } - 4 - ( methylsulfony1 ) phenyl ] - 4H - 1 , 3 - . benzodioXin - 2 - yl } piperidine - 1 - carboXylate ; . - benzy1 4 - { 6 - [ 2 - { [ 2 - ( isopropy1amino ) ethy1 ] amino } - 4 - ( methy1su1fony1 ) phenyl ] - 4H - 1 , 3 - . benzodioXin - 2 - yl } piperidine - 1 - carboXylate ; . - benzyl 4— ( 6 - { 4— ( methylsulfonyl ) - 2 - [ ( 2—morpholin—4—ylethyl ) amino ] phenyl } —4H— 1 , 3—. benzodioXin - 2 - yl ) piperidine - 1 - carboxylate ; . - benzyl 4 - { 6 - [ 2 - [ 2 - ( dimethylamino ) ethoXy ] - 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzo - . dioxin - 2 - yl } piperidine - 1 - carboXylate ; . - N , N - diethyl - 2 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - . yl ) acetamide ; . 0 1 - benzoyl - 4 - { ( 2R * ) - 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine ; - 1 - benzoyl - 4 - { ( 2S * ) - 6 - [ 4 - ( methy1sulfony1 ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine ; - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( methylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxy1ate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( ethylamino ) carbonyl ] pheny1 } - 4H - 1 , 3 - benzo - . dioxin—2—yl ) pip eridine - 1 - carboXylate ; . - ( 1 - methy1cyc10propy1 ) methy1 4 - ( 6 - { 4 - [ ( a11y1amino ) carbony1 ] pheny1 } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1 - mcthylcyclopropyl ) mcthyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbonyl ] phcnyl } - 4H - 1 , 3 - . benzodioXin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroXyethyl ) amino ] carbonyl } pheny1 ) - 4H - . 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboXylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroXypropyl ) amino ] carbonyl } phenyl ) - 4H - . l , 3 - benzodioXin - 2 - yl ] piperidine - l - carboXyl ate ; . 0 ( 1 - methylcyc10propyl ) methy1 4 - [ 6 - ( 4 - { [ ( 2 - methoxyethy1 ) amino ] carbonyl } pheny1 ) - 4H - . 1 , 3 - benzodioXin - 2 - yl ] piperidine - 1 - carboXylate ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —28—. 0 ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroXy - 1 , 1 - dimethylethyl ) amino ] - . carbonyl } phenyl ) - 4H - 1 , 3 - benzodioXin - 2 - y1 ] piperidine - 1 - carboXylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( 3 - hydroXyazetidin - 1 - yl ) carbony1 ] phenyl } - 4H - . 1 , 3 - benzodioXin - 2 - yl ) piperidine - 1 - carboXylate ; . - ( 1 - methylcyclo pro pyl ) methyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carbony1 ] phenyl } - 4H - . 1 , 3 - benzodioXin - 2 - yl ) piperidine - 1 - carboXylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amino } carbonyl ) phenyl ] - 4H - . 1 , 3 - benzodioXin - 2 - y1 } piperidine - 1 - carboxy1ate ; . - tert - butyl 4 - { 6 - [ 4 - ( methylsu1fonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - tert - buty1 4 - { 6 - [ 4 - ( aminocarbonyl ) pheny1 ] - 4H - 1 , 3 - benzodioXin - 2 - y1 } piperidine - 1 - . carboxy1ate ; . - tert—butyl 4 - ( 6— { 4 - [ ( dimethy1amino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin—2—yl ) - . piperidine - 1 - carboXylate ; . - tert - butyl 4 - { 6 - [ 4 - ( morpholin - 4 - ylcarbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine - 1 - carboXylate ; . - 2 - ( { 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodio Xin - 6 - yl ] phenyl } sulfonyl ) ethanol ; - 2 - ( { 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodio Xin - 6 - yl ] phenyl } sulfonyl ) - . ethanamine ; . - tert - butyl 4 - ( 6 - { 4 - [ ( methy1amino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - . piperidine - 1 - carboXylate ; . - tert - buty1 4 - ( 6 - { 4 - [ ( ethy1amino ) carbony1 ] pheny1 } - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - . 1 - carboxylate ; . - tert—butyl 4 - ( 6— { 4 - [ ( allylamino ) carbonyl ] pheny1 } - 4H - 1 , 3 —benzodioXin - 2 - yl ) piperidine—. 1 - carboxy1ate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbony1 ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - . pipcridinc - 1 - carboXylatc ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxyethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzodioXin - 2 - . y1 ] piperidine - 1 - carboXylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - methylprop - 2 - en - 1 - yl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ] piperidine - 1 - carboxylate ; . 0 tert - butyl 4 - ( 6 - { 4 - [ ( but - 3 - en - l - ylamino ) carbonyl ] phenyl } - 4l - l - l , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboXy1ate ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _29_. - tert - butyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroXypropyl ) amino ] carbonyl } pheny1 ) - 4H - 1 , 3 - benzodioXin - 2 - . y1 ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - methoXyethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzodioxin - 2 - . y1 ] piperidine - 1 - carboXylate ; . - tert - butyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydroXycyclo pro pyl ) methyl ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - . benzodioXin - 2 - yl } piperidine - 1 - carboXylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroXy - 1 , 1 - dimethylethyl ) amino ] carbony1 } phenyl ) - 4H - 1 , 3 - . benzodioXin - 2 - yl ] piperidine - 1 - carboxy1ate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( 3 - hydroXyazetidin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - . y1 ) piperidine - 1 - carboXylate ; . - tert - buty1 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - y1 ) carbony1 ] pheny1 } - 4H - 1 , 3 - benzodioXin - 2 - . y1 ) piperidine - 1 - carboXylate ; . - tert—butyl 4 - { 6— [ 4 - ( { [ 2— ( 2—ﬁ1ry1 ) ethyl ] amino } carbony1 ) phenyl ] —4H—1 , 3—benzodioXin—2—. yl } piperidine - 1 - carboXylate ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzodioXin - 6 - yl ] - N - methylb enzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzodioXin - 6 - yl ] - N - ethylb enzamide ; . - N - allyl - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - b enzo dioXin - 6 - yl ] benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzodioXin - 6 - yl ] - N - cyclopropylb enzamide ; 0 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzodioXin - 6 - yl ] - N - ( 2 - hydroXyethyl ) - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - ( 2 - methylprop - 2 - en - 1 - yl ) - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - but - 3 - en - 1 - ylbenzamide ; - 4 - [ 2— ( 1 - benzoylpiperidin—4—yl ) - 4H - 1 , 3 - benzodioXin—6—yl ] - N - ( 3 —hydroxypropyl ) —. benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - ( 2 - methoXyethyl ) - . bcnzamidc ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - [ ( 1 - hydroxycyclopropyl ) - . methyl ] benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - ( 2 - hydroxy - 1 , 1 - dimethyl - . ethyl ) benzamide ; . - l - { 4 - [ 2 - ( l - benzoylpiperidin - 4 - yl ) - 4H - l , 3 - benzodioXin - 6 - yl ] benzoy1 } azetidin - 3 - ol ; - 1 - { 4 - [ 2 - ( 1 - benzoy1piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - y1 ] benzoyl } - 4 - methy1 - . piperazine ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _30_. - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] - N - [ 2 - ( 2 - furyl ) ethy1 ] - . benzamide ; . - ethyl 4 - ( 6 - { 4 - [ ( methylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) piperidine - 1 - . carboxy1ate ; . - ethyl 4 - ( 6 - { 4 - [ ( ethy1amino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) piperidine - 1 - . carboxy1ate ; . - ethyl 4 - ( 6 - { 4 - [ ( allylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - y1 ) piperidine - 1 - . carboxy1ate ; . - ethyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - . piperidine - 1 - carboXylate ; . - ethy1 4 - [ 6 - ( 4 - { [ ( 2 - hydroXyethy1 ) amino ] carbony1 } pheny1 ) - 4H - 1 , 3 - benzodioxin - 2 - y1 ] - . piperidine - 1 - carboXylate ; . - ethyl 4— [ 6— ( 4— { [ ( 2 - methylprop - 2 - en—1—yl ) amino ] carbonyl } phenyl ) - 4H—1 , 3 —benzodioxin - . 2 - yl ] piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 4 - [ ( but - 3 - en - 1 - y1amino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - . piperidine - 1 - carboXylate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroXypropyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] - . piperidine - 1 - carboXylate ; . 0 ethyl 4 - [ 6 - ( 4 - { [ ( 2 - methoXyethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzodioXin - 2 - yl ] - . piperidine - 1 - carboXylate ; . - ethyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydroxycyclopropyl ) methy1 ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - . benzodioXin - 2 - y1 } piperidine - 1 - carboXy1ate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroXy - 1 , 1 - dimethylethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzo - . dioxin—2—yl ] piperidine - 1 - carboXylate ; . - ethy1 4 - ( 6 - { 4 - [ ( 3 - hydroxyazetidin - 1 - y1 ) carbony1 ] pheny1 } - 4H - 1 , 3 - benzodioXin - 2 - y1 ) - . piperidine - 1 - carboXylate ; . - cthyl 4 - ( 6 - { 4 - [ ( 4 - mcthylpipcrazin - 1 - yl ) carbonyl ] phcnyl } - 4H - 1 , 3 - bcnzodioXin - 2 - yl ) - . piperidine - 1 - carboXylate ; . - ethyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - . piperidine - 1 - carboXylate ; . - ethyl 4 - [ 6 - ( 4 - { [ 2 - ( hydroxymethyl ) morpho lin - 4 - y1 ] carbonyl } phenyl ) - 4H - 1 , 3 - benzo - . dioXin - 2 - yl ] piperidine - l - carboXylate ; . - 3 - ( 3 - { 2 - [ 1 - ( tert - butoXycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioxin - 6 - y1 } iszazo l - 5 - . yl ) propanoic acid ; . 10. l5. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. _31_. 0 [ ( 5 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } - 2 - ﬁ1royl ) - . amino ] acetic acid ; . - tert - butyl 4 - { 6 - [ 6 - ( methylsu1fonyl ) pyridin - 3 - yl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - tert - butyl 4 - { 6 - [ 5 - ( methylsu1fonyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benzodioXin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - tert - butyl 4 - { 6 - [ 4 - ( 1H - tetrazol - 5 - yl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - 1 - . carboxy1ate ; . - tert - butyl 4 - [ 6 - ( 2 - { [ amino ( imino ) methyl ] amino } - 4 - methyl - 1 , 3 - thiazo l - 5 - yl ) - 4H - 1 , 3 - . benzodioXin - 2 - yl ] piperidine - 1 - carboXylate ; . - tert - buty1 4 - ( 6 - pyridin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 2 - y1 ) pip eridine - 1 - carboXy1ate ; - tert - butyl 4 - ( 6 - pyridin - 3 - yl - 4H - 1 , 3 - benzodioxin - 2 - yl ) pip eridine - 1 - carboXylate ; - tert—butyl 4 - ( 6— { 5 - [ ( 4—methylpiperazin—1 - yl ) carbonyl ] pyridin—2—yl } —4H— 1 , 3 —benzo—. dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - { 6 - [ 6 - ( morpholin - 4 - ylcarbonyl ) pyridin - 3 - y1 ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - . piperidine - 1 - carboXylate ; . - tert - butyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboXylate ; . 0 tert - butyl 4 - { 6 - [ 5 - ( morpholin - 4 - ylcarbonyl ) pyridin - 2 - y1 ] - 4H - 1 , 3 - benzodioXin - 2 - yl } - . piperidine - 1 - carboXylate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] - 2 - ﬁ1ryl } - 4H - 1 , 3 - benzodioxin - 2 - . y1 ) piperidine - 1 - carboXylate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 1E ) - 3 - ( 4 - methylpiperazin - 1 - yl ) - 3 - oxoprop - 1 - en - 1 - y1 ] - 2 - thienyl } - . 4H - 1 , 3 - benzodioXin—2—yl ) piperidine— 1 —carboXy1ate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 1E ) - 3 - morpho1in - 4 - y1 - 3 - oXoprop - 1 - en - 1 - y1 ] - 2 - thieny1 } - 4H - 1 , 3 - . benzodioXin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 4 - pyrimidin - 2 - ylpipcrazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - 1 , 3 - . benzodioXin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 5 - { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) amino ] carbonyl } pyridin - 2 - y1 ) - . 4H - 1 , 3 - benzodioXin - 2 - yl ] piperidine - 1 - carboXy1ate ; . - tert - butyl 4 - [ 6 - ( 5 - { [ 4 - ( 2 - hydroXyethyl ) piperazin - 1 - yl ] carbonyl } pyridin - 2 - yl ) - 4H - 1 , 3 - . benzodioXin - 2 - yl ] piperidine - l - carboXyl ate ; . - tert - buty1 4 - [ 6 - ( 6 - { [ [ 2 - ( dimethy1amino ) ethy1 ] ( methyl ) amino ] carbony1 } pyridin - 3 - y1 ) - . 4H - 1 , 3 - benzodioXin - 2 - yl ] piperidine - 1 - carboxy1ate ; . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 32 _ PCT / EP2009 / 057074. - ethyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzodioXin - 2 - y1 ) piperidine - 1 - carboxylate ; . - isopropyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benzodioXin - 2 - y1 ) piperidine - 1 - carboXylate ; . - 1 - ( { 5 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodio Xin - 6 - yl ] pyridin - 2 - yl } carbony1 ) - 4 - methy1piperazine ; . - 1 - [ ( 5 - { 2 - [ 1 - ( 2 - ethylbutanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } pyridin - 2 - yl ) - carbonyl ] - 4 - methylpiperazine ; and. 0 2 - [ 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbony1 ] pyridin - 2 - y1 } - 4H - 1 , 3 - benzodioXin - 2 - yl ) - pip eridin - 1 - yl ] pyrimidine. A further preferred group of compounds of the inVention are compounds of Formula ( Id ) : . ( 1d ) . and pharmaceutica11y acceptab1e sa1ts , so1Vates , hydrates , geometrical isomers , tautomers , . optica1 isomers or N - oXides thereof ; wherein : . Z1 , Z2 , R1 to R6 are as deﬁned in Formula ( Ia ) ; R8 and R9 are as deﬁned in Formula ( Ic ) ; Ar1 is phenyl which is optionally substituted in one or two positions with a substituent. independently selected from the group Z3 as deﬁned in Formula ( Ic ) . A preferred subgroup of compounds of the general Formula ( Id ) consists of compounds wherein : . Ar1 is phenyl , which is optional1y substituted in one or two positions with a substituent independently se1ected from the group Z4 as deﬁned in Formu1a ( Ic ) ; . R1 is a group R1A , wherein R ] A is as deﬁned in Formula ( Ic ) ; . 10. l5. 20. 25. 30. WO 2009 / 150144 3 3 PCT / EP2009 / 057074. R2A , R3A , and R5A are as deﬁned in Formula ( lc ) . In a more preferred subgroup of compounds of Formu1a ( Id ) , Ar1 is methylsu1fony1phenyl. In another more preferred subgroup of compounds of Formula ( Id ) , R1A is selected from. C ( o ) oR2A and C ( O ) R2A. In one embodiment , R1A is C ( O ) OR2A , wherein R2A is C1 - 5 a1kyl. Preferab1y R2A is tert - . butyl. In another embodiment , R1A is C ( O ) R2A , wherein R2A is selected from C3 - 6 - cycloalkyl - . C1 - 3 - a1kyl and phenyl. Preferably R2A is selected from cyclohexylmethyl and phenyl. Particu1ar1y preferred compounds of Formula ( Id ) are the compounds selected from the. group consisting of : . 0 tert - butyl 4 - { 7 - [ 4 - ( methylsu1fonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoXazin - 3 - yl } - piperidine - 1 - carboXylate ; . - 3 - [ 1 - ( cyclohexylacetyl ) piperidin - 4 - yl ] - 7 - [ 4 - ( methy1sulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoXazine ; and. 0 3 - ( 1 - benzoylpiperidin - 4 - y1 ) - 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - . benzoXazine. Another object of the inVention is a compound of Formu1a ( Ia ) to ( Id ) for use in therapy. The compounds can be used in the treatment or prophy1axis of disorders re1ating to GPR119. Examp1es of such disorders are Type 1 and Type 2 diabetes , inadequate g1ucose to1erance , insulin resistance , hyperglycemia , hyperlipidemia , hypercholestero1emia , dyslipidcmia , syndromc X , obcsity , hypcrtcnsion , chronic systcmic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , reduced ﬁbrinolysis , endothelial. dysfunction and osteoporosis. Another object of the inVention is the use of a compound of Formula ( Ia ) to ( Id ) in the manufacture of a medicament for use in the treatment or prophylaXis of disorders related to GPR119. The GPR119 - related disorder is any disorder or symptom wherein GPR119 is. inVolVed in the process or presentation of the disorder or the symptom. The GPR119 - . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 34 _ PCT / EP2009 / 057074. re1ated disorders inc1ude , but are not limited to , Type 1 and Type 2 diabetes , inadequate glucose tolerance , insu1in resistance , hyperglycemia , hyper1ipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , reduced ﬁbrinolysis , . endothelia1 dysfunction and osteoporosis. In one aspect , the method for preparation of a pharmaceutical composition comprises combining a compound according to any of the formulae herein with a pharmaceutica11y acceptab1e carrier. In another aspect , the method further comprises combining a compound according to any of the formu1ae herein , an additional therapeutic agent , and a pharmaceutical1y acceptable carrier. The additional therapeutic agent can be , for eXamp1e , . a DPP - IV inhibitor. Another object of the inVention is a method for modulating the GPR119 receptor actiVity ( e. g. , agonizing human GPR119 ) , comprising administering to a subject ( e. g. , mammal , human , or animal ) in need thereof an effectiVe amount of a compound of Formula ( Ia ) to ( Id ) or a composition comprising such a compound. Yet another object of the inVention is a method for the treatment or prophy1aXis of disorders re1ated to GPR119 , said method comprising administeIing to a subject ( e. g. , mammal , human , or animal ) in need of such treatment an effectiVe amount of a compound of Formula ( Ia ) to ( Id ) . The GPR119 - related disorder is any disorder or symptom wherein GPR119 is inVo1Ved in the process or presentation of the disorder or the symptom. The GPR119 - related disorders include , but are not limited to Type 1 and Type 2 diabetes , inadequate g1ucose tolerance , insulin resistance , hyperglycemia , hyperlipidemia , hypercho1estero1emia , dys1ipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , reduced ﬁbrinolysis , . cndothclia1 dysfunction and ostcoporosis. Methods delineated herein include those wherein the subject is identiﬁed as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjectiVe ( e. g. opinion ) or objectiVe ( e. g. measurable by a test or diagnostic method ) . In other aspects , the methods herein include those further comprising monitoring subject. response to the treatment administrations. Such monitoring may include periodic samp1ing. 10. l5. 20. 25. 30. WO 2009 / 150144 35 PCT / EP2009 / 057074. of subject tissue , ﬂuids , specimens , cells , proteins , chemica1 markers , genetic materials , etc. as markers or indicators of the treatment regimen. In other methods , the subject is prescreened or identiﬁed as in need of such treatment by assessment for a re1eVant marker or indicator of suitability for such treatment. In one embodiment , the inVention proVides a method of monitoring treatment progress. The method includes the step of determining a leVel of diagnostic marker ( Marker ) ( e. g. , any target or cel1 type delineated herein modulated by a compound herein ) or diagnostic measurement ( e. g. , screen , assay ) in a subject suffering from or susceptib1e to a disorder or symptoms thereof de1ineated herein , in which the subject has been administered a therapeutic amount of a compound herein sufﬁcient to treat the disease or symptoms thereof. The 1eVe1 of Marker determined in the method can be compared to known 1eVe1s of Marker in either healthy norma1 contro1s or in other afﬂicted patients to establish the subjects disease status. In preferred embodiments , a second leVel of Marker in the subject is determined at a time point 1ater than the determination of the ﬁrst leVel , and the two leVels are compared to monitor the course of disease or the efﬁcacy of the therapy. In certain preferred embodiments , a pre - treatment 1eVe1 of Marker in the subject is determined prior to beginning treatment according to this inVention ; this pre - treatment leVel of Marker can then be compared to the leVe1 of Marker in the subject after the treatment commences , to determine the efﬁcacy of the treatment. In certain method embodiments , a leVel of Marker or Marker actiVity in a subject is determined at least once. Comparison of Marker leVels , e. g. , to another measurement of Marker leVel obtained preVious1y or subsequently from the same patient , another patient , or a norma1 subject , may be useful in determining whether therapy according to the inVention is haVing the desired effect , and thereby permitting adjustment of dosage leVels as appropriate. Determination of Marker 1eVe1s may be performed using any suitab1e sampling / eXpression assay method known in the art or described herein. Preferably , a tissuc or ﬂuid samplc is ﬁrst rcmchd from a subjcct. EXamplcs of suitablc samp1cs include blood , urine , tissue , mouth or cheek cells , and hair samples containing roots. Other suitable samples would be known to the person skil1ed in the art. Determination of protein leVels and / or mRNA leVels ( e. g. , Marker 1eVels ) in the samp1e can be performed using any suitable technique known in the art , including , but not limited to , enzyme immunoassay , ELISA , radiolabelling / assay techniques , blotting / chemiluminescence methods , real - time. PCR , and the 1ike. 10. l5. 20. 25. 30. WO 2009 / 150144 3 6 PCT / EP2009 / 057074. DEFINITIONS. The following deﬁnitions shall apply throughout the speciﬁcation and the appended claims. Unless otherwise stated or indicated , the term “C1_6 - a1ky1” denotes a straight or branched alkyl group haVing from 1 to 6 carbon atoms. For parts of the range “C1_6 - alky1” , all subgroups thereof are contemp1ated , such as C1_5 - a1ky1 , C1_4 - alky1 , C1_3 - a1ky1 , C1_2 - a1ky1 , C2_6 - a1ky1 , C2_5 - a1ky1 , C2_4 - a1ky1 , C2_3 - a1ky1 , C3_6 - a1ky1 , C4_5 - a1kyl , etc. Examp1es of said C1_6 - alkyl include methyl , ethyl , n - propyl , isopropyl , n - butyl , isobutyl , sec - butyl , t - butyl and straight - and branched - chain pentyl and hexyl. Un1ess otherwise stated or indicated , the term “cyano - C1_6 - a1ky1” denotes a C1_6 - a1ky1 group , as deﬁned aboVe , substituted with a cyano group. Exemp1ary cyano - C1_6 - a1ky1 groups include 2—cyanoethy1 and 3—cyanopropy1. Unless otherwise stated or indicated , the term “amino - C1_6 - alky1” denotes a C1_6 - a1ky1 group , as deﬁned aboVe , substituted with an amino group. Exemp1ary amino - C1_6 - a1ky1 groups include 2 - aminoethyl and 3 - aminopropyl. Unless otherwise stated or indicated , the term “hydroxy - C1_6 - alky1” denotes a straight or branched alky1 group that has a hydrogen atom thereof replaced with OH. Examples of said hydroxy - C1 - 6 - alkyl include hydroxymethyl , 2 - hydroxyethyl , 2 - hydroxy - 1 , 1 - dimethy1ethyl , 2 - hydroxypropyl , 3 - hydroxy - 3 - methylbutyl , 2 - hydroxybutyl and 2 - hydroxy - 2 - methylpropyl. DeriVed expressions such as ”C1_6 - a1koxy” , “C1_6 - a1ky1thio” and ”C1_6 - a1ky1amino” are meant to refer to an C1_6 - alkyl group which is attached to the remainder of the mo1ecule through an oxygen , sulﬁ1r or nitrogen atom , respectiVely. For parts of the range “C1_6— a1koxy” a11 subgroups thereof are contemp1ated such as C1_5 - a1koxy , C1_4 - a1koxy , C1_3 - alkoxy , C1_2 - alkoxy , C2_6 - alkoxy , C2_5 - alkoxy , C2_4 - alkoxy , C2_3 - alkoxy , C3_6 - alkoxy , C4_5 - alkoxy , ctc. Examplcs of said “C1_5 - alkoxy” inc1udc mcthoxy , cthoxy , n - propoxy , isopropoxy , n - butoxy , isobutoxy , sec - butoxy , t - butoxy and straight - and branched - chain pentoxy and hexoxy etc. Subgroups of “C1_6 - alkylthio” and “C1_6 - alkylamino” are to be construed according1y. Unless otherwise stated or indicated , the term “C1_4 - a1kylsulﬁnyl” denotes a group C1_4 - alkyl - S ( O ) —. Exemp1ary C1 , 4 - a1kylsulﬁnyl groups include methylsulﬁnyl and ethylsulﬁnyl. Un1ess otherwise stated or indicated , the term “dihydroxy - C2_6 - a1ky1” denotes a C2_6 - a1ky1 group which is disubstituted with hydroxy and wherein said hydroxy groups are attached to. 10. l5. 20. 25. 30. WO 2009 / 150144 3 7 PCT / EP2009 / 057074. different carbon atoms. Exemplary dihydroxy - C2_6 - alkyl groups inc1ude 2 , 3 - dihydroxypropyl and 2 , 4 - dihydroxybutyl. Unless otherwise stated or indicated , the term “di ( C1_4 - a1kyl ) amino” denotes a group ( C 1_4 - alkyl ) 2N— , wherein the two alkyl portions may be the same or different. Exemp1ary di ( C1_4 - alkyl ) amino groups include N , N - dimethylamino , N - ethyl - N - methylamino and N , N - diethy1amino. Unless otherwise stated or indicated , the term “di ( C1_4 - a1ky1 ) amino - C2_4 - alkyl" denotes a group di ( C14 - a1ky1 ) amino , as deﬁned aboVe , attached to a C2_4 - a1ky1 group. Exemp1ary di ( C1_4 - alkyl ) amino - C2_4 - alkyl groups include 2 - ( dimethylamino ) ethy1 and 3 - ( diethylamino ) propyl. Un1ess otherwise stated or indicated , the term “di ( C1 - 2 - alky1 ) amino - C2 - 3 - a1koxy” denotes a group di ( C1_2 - alky1 ) amino , as deﬁned aboVe , attached to a C2_3 - a1koxy group. Exemp1ary di ( C1—2—alkyl ) amino—C2—3 - alkoxy groups include 2— ( dimethylamino ) ethoxy and 3— ( diethylamino ) propoxy. Unless otherwise stated or indicated , the term “ﬂuoro - C1_6 - alky1” denotes a C1_6 - a1kyl group substituted by one or more ﬂuorine atoms. Examp1es of said ﬂuoro - C1_6 - a1kyl include 2 - ﬂuoroethyl , ﬂuoromethyl , 2 - ﬂuoro - 1 - ( ﬂuoromethyl ) ethyl , triﬂuoromethyl , 3 , 3 , 3 - triﬂuoropropyl and 2 , 2 , 2 - triﬂuoroethyl. Unless otherwise stated or indicated , the term “ary1 - C1_6 - a1ky1” means a C1_6 - alky1 group substituted by an aryl group. Examples include benzyl , 2 - phenylethy1 , 1 - phenylethyl and 2 - methyl - 2 - phenylpropyl. Un1ess otherwise stated or indicated , the term “ary1carbony1 - C1_4 - a1ky1” denotes an arylcarbonyl group ( e. g. , benzoyl ) that is attached through a C1_4 - alkyl group. Examples of said arylcarbonyl - C1_4—alkyl include 3 - oxo—3—phenylpropyl , 2 - oxo—2—phenylethyl and 1 - methy1 - 3 - oxo - 3 - pheny1propy1. Unless otherwise stated or indicated , the term “heteroary1carbony1 - C1_4 - alkyl” denotes a hctcroarylcarbonyl group ( c. g. , 3 - pyridinylcarbonyl ) that is attachcd through a C1 - 4 - a1kyl group. Examples of said heteroarylcarbonyl - C1_4 - alkyl include 3 - oxo - 3 - ( 3 - pyridinyl ) - propyl , 2 - oxo - 2 - ( 3 - pyridinyl ) ethyl and 1 - methyl - 3 - oxo - 3 - ( 3 - pyridinyl ) propyl. Unless otherwise stated or indicated , the term “aryloxymethy1” denotes a group aryl - O - CH2—. An exemplary aryloxymethyl group is phenoxymethyl. Unless otherwise stated or indicated , the term “C1 - 6 - alkoxy - C16 - alky1” denotes a straight or branched a1koxy group haVing from 1 to 6 carbon atoms connected to an a1ky1 group. haVing from from 1 to 6 carbon atoms. Examples of said C1_6 - alkoxy - C1_6 - a1kyl include. 10. l5. 20. 25. 30. WO 2009 / 150144 3 8 PCT / EP2009 / 057074. methoxymethyl , methoxyethyl , ethoxyethyl , isopropoxyethyl , n - butoxyethyl , t - butoxyethyl and straight - and branched - chain pentoxyethyl. For parts of the range “C1_6 - alkoxy - C1_6 - alkyl” all subgroups thereof are contemp1ated such as C1_5 - alkoxy - C1_6 - alky1 , C1_4 - alkoxy - C1_6 - alkyl , C1_3 - alkoxy - C1_6 - alkyl , C1_2 - alkoxy - C1_6 - alkyl , C2_6 - alkoxy - C16 - alky1 , C2_5 - alkoxy - C16 - alky1 , C2_4 - alkoxy - C1_6 - alkyl , C2_3 - alkoxy - C1_6 - a1kyl , C3_6 - alkoxy - C1_6 - alkyl , C4_5 - alkoxy - C1_6 - alkyl , C1_6 - a1koxy - C1_5 - a1kyl , C1_6 - alkoxy - C1_4 - alkyl , etc. Unless otherwise stated or indicated , the term “C2_6 - alkeny1” denotes a straight or branched hydrocarbon chain radica1 containing one carbon - carbon double bond and haVing from 2 to 6 carbon atoms. Examples of said C2_6 - alkenyl include Vinyl , allyl , 2 - methylallyl , 2 , 3 - dimethy1allyl , 1 - butenyl , 1 - pentenyl , and 1 - hexenyl. For parts of the range “C2_6 - alkenyl” , a1l subgroups thereof are contemp1ated such as C2_5 - a1keny1 , C2_4 - a1keny1 , C2_3 - a1keny1 , C3_ 6 - alkeny1 , C4_5 - alkenyl , etc. Unless otherwise stated or indicated , the term “aryl—C2_6—alkenyl” means a C2_6—alkeny1 group substituted by an aryl group. Examples of said aryl - C2_6 - alkenyl include styryl and cinnamyl. Unless otherwise stated or indicated , the term “C2_6 - alkyny1” denotes a straight or branched hydrocarbon chain radical containing one carbon - carbon triple bond and haVing from 2 to 6 carbon atoms. Examples of said C2_6 - alkyny1 include ethynyl , 1 - propynyl , 2 - propynyl , 1 - butynyl , 2 - butynyl , and 1 - methylprop - 2 - yn - 1 - yl. Unless otherwise stated or indicated , the term “aryl - C2_6 - a1kynyl” means a C2_6 - a1kyny1 group substituted by an ary1 group. Examples of said aryl - C2_6 - alkynyl include phenylethyny1 , 3 - phenyl - 1 - propyn - 1 - y1 , 3 - pheny1 - 2 - propyn - 1 - y1 and 4 - pheny1 - 2 - butyn - 1 - yl. The term "oxo” denotes |‘|.=O. Unless otherwise stated or indicated , the term “C3_7 - cyc1oalky1” denotes a cyclic alky1 group haVing a ring size from 3 to 7 carbon atoms and includes cyclopropyl , cyclobutyl , cyclopentyl , cyclohexyl , and cycloheptyl. For parts of the range “C3_7 - cycloalkyl” all subgroups thereof are contemplated such as C3_6 - cyc1oa1ky1 , C3_5 - cyc1oa1ky1 , C3_4 - cycloalkyl , C4_7 - cycloalkyl , C4_6 - cycloalkyl , C4_5 - cycloalkyl , C5_7 - cycloalky1 and C6_7 - cycloa1ky1. Un1ess otherwise stated or indicated , the term “C3_7 - cyc1oa1ky1 - C1_4 - a1ky1” denotes a C3 - 7 - cycloalkyl group attached to a C1_4 - alkyl group. Exemplary C3_7 - cycloa1kyl - C1_4 - a1kyl groups include cyclopropylmethyl , 1 - cyclopropy1ethy1 , cyclohexy1methyl and 2 - cyc1o - hexy1ethy1. When the cyc1oa1ky1 portion as part of the group C3_7 - cyc1oa1ky1 - C1_4 - a1ky1 is. 10. l5. 20. 25. 30. WO 2009 / 150144 3 9 PCT / EP2009 / 057074. substituted with methyl , examples of such groups include ( 1 - methylcyclopropyl ) methyl and 2 - ( 4 - methylcyclohexyl ) ethyl. When the cycloalkyl portion as part of the group C3_6 - cycloalkyl - C1_4 - alkyl is substituted with hydroxy , examples of such groups include ( 1 - hydroxycyclopropyl ) methyl and 4 - hydroxycyclohexy1methyl. Unless otherwise stated or indicated , the term “C7_g - bicyclyl” denotes a bicyc1ic saturated hydrocarbon ring system haVing 7 or 8 carbon atoms , in which two non - adjacent carbon atoms of a monocyc1ic ring are 1inked by an a1ky1ene bridge of between one and three additional carbon atoms. Examples of said C7_g - bicyclyl include radicals obtainable from bicyclo [ 3.1.1 ] heptane , bicyclo [ 2.2.1 ] heptane ( norbornane ) and bicyc1o [ 2.2.2 ] octane. Un1ess otherwise stated or indicated , the term C7_g - bicyc1y1 - C1_6 - a1ky1 means a C1_6 - a1ky1 group substituted by a C7_g - bicyclyl group as deﬁned aboVe. An exemplary C7_g - bicycly1 - C1_6 - alkyl group is bicyclo [ 2.2.1 ] hept - 2 - y1methyl ( 2 - norbonylmethyl ) . Unless otherwise stated or indicated , the term “C5_g - cycloalkenyl” denotes a monocyc1ic or bicyc1ic alkeny1 group of 5 to 8 carbon atoms haVing one carbon - carbon double bond. Examples of monocyclic cycloalkenyl groups are cyclopent - 3 - en - 1 - yl and cyclohexen - 1 - yl. An exemplary bicyclic cycloalkeny1 group is bicyclo [ 2.2.1 ] hept - 5 - en - 2 - yl ( norbornen - 2 - yl ) . Unless otherwise stated or indicated , the term “oxo - C4_6 - cycloalky1” refers to a C4_6 - cycloalkyl wherein two hydrogens on a cycloalky1 carbon atom are replaced by an oxo group as deﬁned herein. Examp1es of “oxo - C4_6 - cyc1oalkyl” include 2 - oxocyclobutyl , 3 - oxocyc1obuty1 , 2 - oxocyc1openty1 and 4 - oxocyc1ohexy1. Unless otherwise stated or indicated , the term “ﬂuoro - C3_6 - cycloalkyl” denotes a C3_6 - cycloalkyl group substituted by one or two ﬂuorine atoms. Examples of said “ﬂuoro - C3_5— cyc1oa1ky1” inc1ude 2 , 2 - diﬂuorocyc1opropy1 and 4 - ﬂuorocyc1ohexy1. Unless otherwise stated or indicated , the term “C1_3 - alkoxy - C4_6 - cyc1oa1kyl" denotes a C4_6 - cycloalkyl group substitutcd by a C1_3 - a1koxy group. Examp1cs of said “C 1_3 - a1koxy - C4_6 - cycloalkyl” include 4 - methoxycyclohexyl and 2 - ethoxycyclopenty1. Unless otherwise stated or indicated , the term “methy1 - Cg_6 - cyc1oalky1” denotes a C3_5 - cycloalkyl group substituted by one or two methyl groups. Examp1es of said “methyl - C3_6 - cycloalkyl” include 4 - methylcyclohexyl and 3 , 3 - dimethylcyclopenty1. Unless otherwise stated or indicated , the term “acy1” , which may be straight or branched , denotes a carbony1 group that is attached through its carbon atom to a hydrogen atom to. form a C1 - acyl group ( i. e. , a formyl group ) or to an a1kyl group , where alkyl is deﬁned as. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 40 _ PCT / EP2009 / 057074. aboVe. For parts of the range “C1_6 - acy1” al1 subgroups thereof are contemplated such as C1_5 - acy1 , C1_4 - acyl , C1_3 - acyl , C1_2 - acyl , C24 , - acy1 , C2_5 - acyl , C2_4 - acyl , C2_3 - acyl , C3_6 - acy1 , C4_5 - acy1 , etc. Exemplary acyl groups include formyl , acetyl ( i. e. , C2 - acyl ) , propanoyl , butanoyl , pentanoyl , hexanoyl. Unless otherwise stated or indicated , the term “C2_6 - acy1 - C1_6 - a1ky1” refers to a group C1_5 - alkyl - ( C=O ) - C1_6 - alky1. Exemplary C2_6 - acyl - C1_6 - alkyl groups include 2 - acetylethyl and 3 - acetylpropyl. Un1ess otherwise stated or indicated , the term “C1_6 - a1ky1su1fony1” , which may be straight or branched , denotes a hydrocarbon haVing from 1 to 6 carbon atoms attached to a su1fonyl group. For parts of the range “C1_6 - alkylsu1fonyl” all subgroups thereof are contemplated such as C1_5 - a1ky1sulfonyl , C1_4 - a1kylsu1fony1 , C1_3 - alky1su1fonyl , C1_2 - a1ky1su1fonyl , C2_6 - alkylsulfony1 , C2_5 - alkylsulfonyl , C2_4 - alkylsulfonyl , C2_3 - alky1sulfony1 , C3_6 - alkylsulfonyl , C4_5 - alkylsulfonyl , etc. Exemplary C1_6—alkylsulfonyl groups include methylsulfonyl , ethylsulfony1 , propylsu1fonyl , n - butylsu1fonyl , sec - butylsulfonyl , tert - butylsulfonyl , pentylsulfonyl and hexylsu1fonyl. Unless otherwise stated or indicated , the term "hydroxy - C2_4 - a1ky1sulfony1" denotes a C2_4 - a1ky1sulfonyl group as deﬁned aboVe substituted with a hydroxy group. Examples of said hydroxy - C2_4 - alkylsulfonyl include 3 - hydroxypropylsulfonyl and 2 - hydroxyethylsu1fonyl. Unless otherwise stated or indicated , the term “amino - C2_4 - a1ky1su1fony1” denotes a C2_4 - alkylsulfonyl group as deﬁned aboVe substituted with a amino group. Examples of said amino - C2_4 - alkylsulfonyl include 3 - aminopropylsulfonyl and 2 - aminoethylsu1fonyl. Un1ess otherwise stated or indicated , the term “C1_4 - a1ky1su1fonamido” denotes a group C1_4 - alkyl - SO2NH—. Exemp1ary C1_4 - alkylsulfonamido groups include methylsulfonylamino and ethylsulfonylamino. The term “C1 - 4 - a1ky1su1foximine” refers to a group with the fo11owing chemica1 structure : . 9 WW. NH , where Ra is C1 - 4 - alkyl. Unless otherwise stated or indicated , the term “ha1ogen” sha1l mean ﬂuorine , chlorine , bromine or iodine. Unless otherwise stated or indicated , the term “ary1” refers to a hydrocarbon ring system haVing at least one aromatic ring , preferably mono - or bicyclic. Examples of aryls are pheny1 , indenyl , 2 , 3 - dihydroindenyl ( indanyl ) , 1 - naphthyl , 2 - naphthyl or 1 , 2 , 3 , 4 - tetrahydronaphthy1. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 41 _ PCT / EP2009 / 057074. Unless otherwise stated or indicated , the term “heteroary1” refers to a mono - or bicyc1ic heteroaromatic ring system haVing 5 to 10 ring atoms in which one or more of the ring atoms are other than carbon , such as nitrogen , sulphur or oxygen. Only one ring need be aromatic and said heteroaryl moiety can be linked to the remainder of the molecule Via a carbon or nitrogen atom in any ring. Examples of heteroaryl groups include furyl , pyrrolyl , thieny1 , oxazolyl , isoxazolyl , imidazolyl , thiazolyl , isothiazo1y1 , tetrazolyl , pyridyl , pyrimidinyl , quinazoliny1 , indolyl , isoindolyl , 1 , 3 - dihydro - isoindolyl , pyrazolyl , pyridazinyl , quinoliny1 , quinoxa1iny1 , thiadiazo1y1 , benzofurany1 , 2 , 3 - dihydrobenzofurany1 , 1 , 3 - benzodioxolyl , 1 , 4 - benzodioxinyl , 2 , 3 - dihydro - 1 , 4 - benzodioxinyl , benzothiazolyl , benzimidazolyl , benzothiadiazolyl , benzotriazolyl , indolinyl , isoindolinyl and chromanyl groups. Unless otherwise stated or indicated , the term “heterocyc1yl” or “heterocyclic ring” refers to a non—aromatic , ﬁ111y saturated or partially unsaturated , preferably fully saturated , monocyclic ring system haVing 4 to 7 ring atoms with at least one heteroatom such as O , N , or S , and the remaining ring atoms are carbon. Examp1es of heterocyclic groups include piperidiny1 , tetrahydropyranyl , tetrahydroﬁ1ranyl , oxetanyl , azepinyl , azetidinyl , pyrrolidinyl , morpho1inyl , imidazolinyl , imidazolidinyl , thiomorpholinyl , pyranyl , dioxanyl , piperazinyl , homopiperazinyl and 5 , 6 - dihydro - 4H - 1 , 3 - oxazin - 2 - yl. When present , the sulfur atom may be in an oxidized form ( i. e. , S=O or O=S=O ) . Exemp1ary heterocyclic groups containing sulfur in oxidized form are 1 , 1 - dioxido - thiomorpholinyl and 1 , 1 - dioxido - isothiazolidinyl. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with one or two oxo groups , examples of such groups include 4—piperidon—1—y1 , 2— pyrro1idon - 1 - y1 , 2 - piperidon - 1 - y1 , 2 - azetidinon - 1 - y1 , 2 , 5 - dioxopyrro1idin - 1 - y1 and hydantoin - 1 - yl ( i. e. , 2 , 5 - dioxoimidazolidin - 1 - yl ) . thn ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 togcthcr with R3 , or ( iV ) R2A togcthcr with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with one or two ﬂuoro atoms , examples of such groups include 4 - ﬂuoropiperidin - 1 - yl , 4 , 4 - diﬂuoropiperidin - 1 - yl , 3 - ﬂuoropyrrolidin - 1 - yl and 3 , 3 - diﬂuoropyrrolin - 1 - yl. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with hydroxy , examp1es of such groups include 4 - hydroxypiperidin - 1 - yl , 3 - hydroxypiperidin - 1 - yl , 3 - hydroxypyrrolidin - 1 - yl and 3 - hydroxyazetidin - 1 - yl. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 42 _ PCT / EP2009 / 057074. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with amino , examples of such groups include 4 - aminopiperidin - 1 - yl , 3 - aminopiperidin - 1 - yl , and 3 - aminopyrrolidin - 1 - yl. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with hydroxy - C1 - 2 - alkyl , examples of such groups include 2 - ( hydroxymethy1 ) pyrrolidin - 1 - yl , 2 - ( hydroxymethyl ) morpho1in - 4 - y1 , 4 - ( hydroxymethy1 ) piperidin - 1 - yl and 4 - ( 2 - hydroxyethyl ) pip erazin - 1 - yl. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with methylamino or dimethylamino , examples of such groups include 3 - dimethylaminopyrrolidin - 1 - yl and 3 - methylaminopyrrolidin— 1 —yl. When ( i ) two groups R5 , ( ii ) two groups R5A , ( iii ) R2 together with R3 , or ( iV ) R2A together with R3A described herein form a heterocyc1ic ring and said heterocyclic ring is substituted with C1 - 3 - a1kyl , examples of such groups include 4 - methylpiperidin - 1 - y1 and 4 - methylpip erazin - 1 - yl. Unless otherwise stated or indicated , the term “heteroaryl - C1_4 - alkyl” denotes a heteroaryl group that is attached through a C1_4 - alkyl group. Examples of said heteroaryl - C1_4 - a1kyl include 2 - ( pyridin - 2 - yl ) ethyl , 1 , 3 benzodioxol - 5 - ylmethyl and 2 - ( 2 - furyl ) ethyl. ”C - heterocyclyl” indicates bonding Via a carbon atom of said heterocyc1yl , for examp1e piperidin - 4 - yl , tetrahydroﬁJran - 2 - y1 , oxetan - 3 - yl , tetrahydrofuran - 3 - yl and 5 , 6 - dihydro - 4H - 1 , 3 - oxazin - 2 - yl , while ”N - heterocyclyl” indicates bonding through nitrogen in a nitrogencontaining heterocyclyl group , for example piperidin—1—yl and piperazin—1—yl. When C - heterocyc1y1 is substituted by C1 - 4 - a1ky1 , said C1 - 4 - a1ky1 is attached to a ring nitrogen atom or a ring carbon atom thereof. Exemp1ary C - heterocycly1 groups substituted by C1 - 4 - alkyl includc 1 - mcthylpipcridin - 4 - yl and 3 - mcthyloxctan - 3 - yl. thn N - hctcrocyclyl is substituted by methy1 , said methyl is attached to a ring nitrogen atom or a ring carbon atom thereof. Exemp1ary N - heterocyclyl groups substituted by methyl include 4 - methylpiperidin - 1 - yl and 4 - methy1piperazin - 1 - yl. Unless otherwise stated or indicated , the term "N - heterocyclyl - C2_4 - a1kyl" refers to a nitrogen - containing heterocyclyl group that is directly linked to a C2 , 4 - alkyl group Via a nitrogen atom of said heterocycly1. Exemplary N - heterocyclyl - C2_4 - alkyl groups include 2 - ( pyrro1idin - 1 - yl ) ethy1 , 3 - ( 4 - morpho1inyl ) propyl , 2 - ( piperazin - 1 - yl ) ethy1 and 2 - ( 4 - . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 43 _ PCT / EP2009 / 057074. morpholinyl ) ethyl. Simi1arly , the term “N - heterocyclylmethyl” means a methyl group substituted by a heterocyclyl group Via a nitrogen atom thereof. Exemp1ary N - heterocyclylmethy1 groups include morpholin - 4 - y1methyl and piperazin - 1 - ylmethyl. When heterocyclyl as part of the group N - heterocyclyl - C2_4 - alkyl is substituted by methyl , said heterocycly1 is se1ected from 1 - piperazinyl or 1 - homopiperaziny1 and said methyl is attached to the 4 - position of the piperazine or homopiperazine ring. Exemp1ary N - heterocyclyl - C2 - 4 - alky1 groups wherein heterocyc1y1 is substituted with methy1 are 2 - ( 4 - methy1piperazin - 1 - y1 ) ethy1 and 2 - ( 4 - methy1homopiperazin - 1 - y1 ) ethy1. Unless otherwise stated or indicated , the term “C - heterocyclyl - C1_4 - a1kyl” refers to a heterocyclyl group that is directly linked to a C1_4 - alkyl group Via a carbon atom of said heterocycly1. Exemp1ary C - heterocyc1y1 - C1_4 - a1ky1 groups include tetrahydropyran - 4 - y1 - methyl , piperidin - 4 - y1methyl , tetrahydrofuran - 2 - ylmethyl , oxetan - 3 - ylmethyl and 2 - ( piperidinyl—4—yl ) ethyl. When heterocyclyl as part of the group C - heterocyclyl - C1_4 - alkyl is substituted by methyl , said methyl is attached to a ring nitrogen atom or ring carbon atom thereof. Exemplary C - heterocyclyl - C1 - 4 - alkyl groups wherein heterocycly1 is substituted with methy1 are 2 - ( 1 - methylpiperidin - 4 - yl ) ethyl and 3 - methyloxetan - 3 - ylmethyl. Unless otherwise stated or indicated , the term “oxo - N - heterocycly1” denotes a nitrogencontaining heterocyc1y1 group that is substituted with one or two oxo groups. Unless otherwise stated or indicated , the term "oxo - N - heterocyc1y1 - C2_4 - alky1” refers to an oxo - N - heterocyclyl group that is directly linked to a C2_4 - alkyl group through a nitrogen atom of its heterocyc1y1 portion and where oxo - N - heterocyc1y1 is as deﬁned aboVe. Exemplary oxo - N - heterocyclyl - C2_4 - alkyl groups include 2 - ( 2 - pyrro1idon - 1 - yl ) ethyl , 3 — ( 2 - pyrrolidon— 1 —yl ) propy1 and 2— ( 2 , 5 —dioxo imidazolidin— 1 —yl ) ethyl. Un1ess otherwise stated or indicated , the term “ﬂuoro - N - heterocyc1y1” denotes a nitrogencontaining heterocyclyl group that is substituted at a position other than a1pha to a ring hctcroatom with onc or two ﬂuorinc atoms. Unless otherwise stated or indicated , the term "ﬂuoro - N - heterocyc1yl - C2_4 - a1kyl" refers to a ﬂuoro - N - heterocyclyl group that is direct1y linked to a C2_4 - alkyl group through a nitrogen atom of its heterocyclyl portion and where ﬂuoro - N - heterocyclyl is as deﬁned aboVe. Exemplary ﬂuoro - N - heterocyclyl - C2_4 - alkyl groups include 2 - ( 3 - ﬂuoropyrrolidin - 1 - yl ) - ethyl and 3 - ( 3 - ﬂuoropyrrolidin - l - yl ) propyl. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 44 _ PCT / EP2009 / 057074. Unless otherwise stated or indicated , the term "hydroxy - N - heterocyclyl" denotes a nitrogen - containing heterocyclyl group that is substituted at a position other than alpha to a ring heteroatom with a hydroxy group. Unless otherwise stated or indicated , the term "hydroxy - N - heterocycly1 - C2_4 - a1kyl" refers to a hydroxy - N - heterocyclyl group that is directly linked to a C2_4 - alkyl group through a nitrogen atom of its heterocyc1yl portion and where hydroxy - N - heterocyc1y1 is as deﬁned aboVe. Exemplary hydroxy - N - heterocyc1y1 - C2_4 - a1kyl groups inc1ude 2 - ( 4 - hydroxypiperidin - 1 - y1 ) ethy1 and 3 - ( 3 - hydroxypiperidin - 1 - y1 ) propyl. Unless otherwise stated or indicated , the term “amino - N - heterocyc1y1” denotes a nitrogencontaining heterocyclyl group that is substituted at a position other than alpha to a ring heteroatom with an amino group. Unless otherwise stated or indicated , the term "amino - N - heterocyc1y1 - C2_4 - alky1" refers to a amino—N—heterocyclyl group that is directly linked to a C2_4—alkyl group through a nitrogen atom of its heterocyclyl portion and where amino - N - heterocyclyl is as deﬁned aboVe. Exemp1ary amino - N - heterocyclyl - C2_4 - a1kyl groups include 2 - ( 4 - aminopiperidin - 1 - yl ) ethyl and 3 - ( 3 - aminopiperidin - 1 - yl ) propyl. Unless otherwise stated or indicated , the term “azabicyc1y1” denotes a bicyclic heterocycly1 group with seVen or eight atoms ( including bridgehead atoms ) , wherein at least one ring member is a nitrogen atom and the remainder ring atoms being carbon. The said azabicyclyl may optionally contain a carbon - carbon double bond. Examples of azabicyclyl groups include carbon radica1s obtainab1e from 1 - azabicyc1o [ 2.2.2 ] octane , 1 - azabicyc1o [ 2.2. 1 ] heptane and azabicyc1o [ 2.2.2 ] oct - 2 - ene. "C - heterocycly1su1fony1” refers to a heterocyclyl group that is direct1y bonded to SO2 Via a carbon atom. Exemplary C—heterocyclylsulfonyl groups include 4—piperidinylsulfonyl and tetrahydropyran - 4 - y1su1fony1. When C - heterocyclylsulfonyl is substituted by C1_4 - alkyl , said heterocyclyl is selected from a nitrogcn - containing hctcrocyclyl , and said C1_4 - alky1 is attachcd to a ring nitrogcn atom thereof. An exemplary C - heterocyclylsu1fonyl group substituted by C1_4 - alkyl includes 1 - methylpiperidin - 4 - y1sulfonyl. Unless otherwise stated or indicated , the term “C2_4 - acy1amino” denotes a group Rb ( C=O ) NH— wherein Rb is selected from C1_3 - alkyl. Exemplary C2_4 - acylamino groups. include acetylamino and propionylamino. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 45 _ PCT / EP2009 / 057074. Unless otherwise stated or indicated , the term “C24 - acylamino - C1_4 - a1kyl” denotes a C2_4 acylamino group , as deﬁned aboVe , attached to a C1_4 - alky1 group. Examplary C2_4 - acylamino - C1_4 - alkyl groups include ( acetylamino ) methyl and 2 - ( acety1amino ) ethyl. Unless otherwise stated or indicated , the term “aminocarbony1” refers to the radical NH2 ( C=O ) —. Unless otherwise stated or indicated , the term “aminocarbonyl - C1_4 - alky1” denotes a C1_4 - alkyl group , as deﬁned aboVe , substituted with an aminocarbonyl group. Exemp1ary aminocarbonyl - C1_4 - a1ky1 groups include 2 - ( aminocarbony1 ) ethyl and 3 - ( aminocarbony1 ) - propyl. Unless otherwise stated or indicated , the term “C1_3 - alky1aminocarbony1” refers to the radica1 ( C1_3 - a1kyl ) NH ( C=O ) —. Unless otherwise stated or indicated , the term “C1_3 - a1ky1aminocarbony1 - C2_6 - a1kyl” denotes a group C1_3—alkylaminocarbonyl , as deﬁned aboVe , attached to a C2_6—alkyl group. Exemplary C13 - alkylaminocarbonyl - C2_6 - alkyl groups include 2 - ( methylaminocarbonyl ) - ethyl and 2 - ( ethylamino carbonyl ) ethyl. Unless otherwise stated or indicated , the term “di ( C1_3 - a1ky1 ) aminocarbonyl” refers to the radica1 ( C1_3 - alkyl ) 2N ( C=O ) — , wherein the two alky1 portions may be the same or different. Unless otherwise stated or indicated , the term “di ( C1_3 - alkyl ) aminocarbony1 - C2_6 - alkyl” denotes a group di ( C1_3 - alkyl ) aminocarbony1 , as deﬁned aboVe , attached to a C2_6 - a1ky1 group. Exemplary di ( C1_3 - alkyl ) aminocarbonyl - C2_6 - alkyl groups inc1ude 2 - ( dimethylaminocarbonyl ) ethyl and 2 - ( diethylaminocarbonyl ) ethyl. Un1ess otherwise stated or indicated , the term —C ( O ) — means a carbony1 group. Unless otherwise stated or indicated , the term “carboxy” denotes a group —C ( O ) OH. Unless otherwise stated or indicated , the term “carboxy—C1_3—a1kyl” refers to a carboxy group , as deﬁned aboVe , attached to a C1_3 - a1ky1 group. Exemp1ary carboxy - C1_3 - a1ky1 groups include 2 - carboxyethy1 and 3 - carboxypropy1. Unlcss othcrwisc statcd or indicatcd , thc tcrm “carboxy - C1_3 - a1ky1carbony1amino” rcfcrs to a carboxy - C1_3 - a1kyl groups , as deﬁned aboVe , attached to the carbonyl carbon of carbonylamino ( i. e. , —C ( O ) NH— ) . Exemplary carboxy - C1_3 - a1kylcarbonylamino groups include ( 2 - carboxyethyl ) carbonylamino and ( 3 - carboxypropyl ) carbonylamino. "C - heterocyclylcarbonyl” refers to a heterocyclyl group that is direct1y bonded to a carbonyl group Via a carbon atom while “N - heterocyclylcarbonyl” refers to a nitrogencontaining heterocyc1y1 group that is direct1y bonded to a carbony1 group Via a nitrogen. atom. Examples of N - heterocyclylcarbonyl groups inc1ude 1 - piperidiny1carbonyl , . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 46 _ PCT / EP2009 / 057074. 1 - piperazinylcarbonyl and 1 - pyrrolidincarbonyl. Exemplary C - heterocyclylcarbonyl groups include 3 - piperidinylcarbonyl , 4 - piperidinylcarbonyl and tetrahydropyranyl - 4 - ylcarbonyl. When C - heterocyclylcarbonyl is substituted by C1_4 - a1kyl , said heterocyclyl is selected from a nitrogen - containing heterocyclyl , and said C1_4 - alky1 is attached to a ring nitrogen atom thereof An exemp1ary C - heterocyclylcarbonyl group substituted by C1_4 - a1kyl includes 1 - methylpiperidin - 4 - y1carbonyl. The term "N - heterocyc1y1carbonyl - C2_4 - a1ky1” refers to a N - heterocycly1carbonyl group that is direct1y linked to a C2_4 - alkyl group through its carbonyl carbon atom and where N - heterocyclylcarbonyl is as deﬁned aboVe. Exemp1ary N - heterocyc1y1carbonyl - C2_4 - a1ky1 groups include 2 - ( pyrrolidin - 1 - y1carbonyl ) ethy1 , 2 - ( piperazin - 1 - y1carbony1 ) ethy1 and 2 - ( p ip eridin - 1 - ylcarbony1 ) ethyl. When heterocyclyl as part of the group N—heterocyclylcarbonyl—C2_4—alkyl is substituted by methy1 , said heterocyclyl is selected from 1 - piperazinyl or 1 - homopiperazinyl and said methyl is attached to the 4 - position of the piperazine or homopiperazine ring. Exemp1ary N - heterocyclylcarbony1 - C2_4 - alkyl groups wherein heterocycly1 is substituted with methyl are 2 - ( 4 - methylpiperazin - 1 - ylcarbony1 ) ethyl , 2 - ( 4 - methylhomopiperazin - 1 - ylcarbonyl ) - ethyl. The term "N - heterocyclylcarbony1Vinyl" refers to a N - heterocyc1ylcarbonyl group , as deﬁned aboVe , that is directly linked to a Vinyl group ( i. e. , —CH=CH2 ) through its carbonyl carbon atom. Exemplary N - heterocyclylcarbonylVinyl groups include 2 - ( pyrrolidin - 1 - y1carbony1 ) Viny1 , 2 - ( piperazin - 1 - ylcarbony1 ) Viny1 and 2 - ( piperidin - 1 - y1carbony1 ) Viny1. When the N - heterocyclyl portion as part of the group N - heterocyclylcarbonylVinyl is substituted with C1 - 4 - alkyl , an exemplary group is 2— ( 4 - methylpiperazin—1—ylcarbony1 ) Viny1. The term "C - heterocyclylcarbonyl - C2_4 - alkyl” refers to a C - heterocycly1carbonyl group that is dircctly linkcd to a C2_4 - alkyl group through its carbonyl carbon atom and whcrc C - heterocyclylcarbonyl is as deﬁned aboVe. Exemp1ary C - heterocycly1carbonyl - C2_4 - a1ky1 groups include 2 - ( tetrahydropyran - 4 - ylcarbonyl ) ethyl , 2 - ( piperidin - 3 - ylcarbonyl ) ethyl and 2 - ( piperidin - 4 - ylcarbonyl ) ethyl. When heterocycly1 as part of the group C - heterocyclylcarbonyl - C2_4 - alkyl is substituted by methyl , said heterocyclyl is selected from a nitrogen - containing heterocyclyl and said. methy1 is attached to a ring nitrogen atom thereof. An exemp1ary C - heterocyc1y1carbony1 - . 10. 15. 20. 25. WO 2009 / 150144 _ 47 _ PCT / EP2009 / 057074. C2_4 - alkyl group wherein heterocyc1yl is substituted with methyl is 2 - ( 1 - methylpiperidin - 4 - ylcarbonyl ) ethyl. The term “C - heterocyclyloxy” refers to a heterocyclic group that is directly bonded to an oxygen atom Via a carbon atom. Examp1es of C - heterocyclyloxy groups include 3 - piperidiny1oxy , 4 - piperidinyloxy , 3 - tetrahydroﬁ1ranyloxy , and 4 - tetrahydropyranyloxy. When C - heterocyclyloxy is substituted by C1_4 - alkyl , said heterocycly1 is se1ected from a nitrogen - containing heterocyclyl , and said C1_4 - alkyl is attached to a ring nitrogen atom thereof. An exemp1ary C - heterocyc1y1oxy group substituted by C1_4 - a1ky1 inc1udes 1 - methylpip eridin - 4 - ylo xy. The term “hydroxy - C2_4 - alkoxy - C1_4 - alkyl” refers to a hydroxy - C2_4 - alkoxy group that is. direct1y attached to a C1_4 - a1ky1 group. RepresentatiVe examp1es of such groups inc1ude : HO / \ / O\ / \ , " Ho / \ / O\ / \ / ‘ - Ho / V\o / \ / ‘—. The term “amidino” refers to a group with the following chemical structure : . NH. H2N , ' ' . The term “guanidino” refers to a group with the following chemical structure : NH H N NX‘. H. 2. The chemical formula - C ( OH ) CH3CF3 refers to a group with the following chemical. structure : OH ; cF3 CH3 The term [ CF3CH3 ( OH ) C ] —C1_5—alky1 refers to a CF3CH3 ( OH ) C— group that is direct1y. attached to a C1_6 - a1ky1 group. RepresentatiVe examp1es of such groups inc1ude : . CH3 - CH3 . CH CH3 , CFTi - CHFE CF3—|‘CH2 - CH2—E CF3—|~3CH2CH2 ( |3H—E OH OH and OH The chemica1 formu1a CF3SO3 refers to a group with the fo11owing chemical structure : O\\ 00 F3C / S\O } ". The carbon - carbon doub1e or triple bonds present in the groups C3_6 - alkenyl , C3_6 - alkynyl , ary1 - C3_6 - a1keny1 and ary1 - C3_6 - alkyny1 as Values for any R2 , R5 or R5A groups described. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 48 _ PCT / EP2009 / 057074. herein are meant to be located at positions other than conjugated with a carbonyl group or adjacent to a nitrogen , oxygen or sulfur atom. “Optional” or “optiona11y” means that the subsequently described eVent or circumstance may but need not occur , and that the description includes instances where the eVent or circumstance occurs and instances in which it does not. The term “coupling agent” refers to a substance capable of cata1yzing a coupling reaction , such as amidation , or esteriﬁcation. Examp1es of coupling agents include , but are not limited to , carbonyldiimidazo1e , dicyc1ohexylcarbodiimide , pyridine , 4 - dimethy1aminopyridine , and triphenylphosphine. Another example of a coup1ing agent is 1 - ethyl - 3 - ( 3 - dimethy1aminopropy1 ) carbodiimide hydrochloride , which is used in the presence of 1 - hydroxybenzotriazo1e and a base such as triethy1amine. The terms “ex0” and “end0” are stereochemical preﬁxes that describe the re1atiVe conﬁguration of a substituent on a bridge ( not a bridgehead ) of a bicyclic system such as 1 - azabicyclo [ 2.2.1 ] heptane and bicyclo [ 2.2.1 ] heptane. If a substituent is oriented toward the 1arger of the other bridges , it is end0. If a substituent is oriented toward the smaller bridge it is ex0. Both ex0 and end0 forms and their mixtures are part of the present inVention. The term “Syndrome X” ( also called metabolic syndrome ) refers to a syndrome comprising of some or all of the fo1lowing diseases : 1 ) dyslipoproteinemia ( combined hypercholesterolemia - hypertriglyceridemia , low HDL - cholesterol ) , 2 ) obesity ( in particular upper body obesity ) , 3 ) impaired g1ucose tolerance ( IGT ) 1eading to noninsu1in - dependent diabetes me11itus ( NIDDM ) , 4 ) essentia1 hypertension and ( 5 ) thrombogenic / ﬁbrino1ytic defects. The term "agonists" refers to compounds that haVe afﬁnity for a biochemical receptor and that increase the receptors pharmaco1ogica1 response upon binding. Depending on the efﬁcacy with which they actiVate the receptor , agonists can be either full agonists or partial agonists. Thc tcrm agonists as uscd hcrcin shall includc both full agonists and partial agonists. “Pharmaceutica1ly acceptable” means being useful in preparing a pharmaceutical composition that is generally safe , non - toxic and neither bio1ogica1ly nor otherwise undesirable and includes being useful for Veterinary use as we1l as human pharmaceutica1 use. “Treatment” as used herein includes prophy1axis of the named disorder or condition , or. amelioration or elimination of the disorder once it has been established. 10. l5. 20. 25. 30. WO 2009 / 150144 _ 49 _ PCT / EP2009 / 057074. “An effectiVe amount” refers to an amount of a compound that confers a therapeutic effect ( e. g. , treats , controls , ameliorates , preVents , delays the onset of , or reduces the risk of deVeloping a disease , disorder , or condition or symptoms thereof ) on the treated subject. The therapeutic effect may be objectiVe ( i. e. , measurable by some test or marker ) or subjectiVe ( i. e. , subject giVes an indication of or fee1s an effect ) . “Prodrugs” refers to compounds that may be conVerted under physiological conditions or by solVolysis to a biologically actiVe compound of the inVention. A prodrug may be inactiVe when administered to a subject in need thereof , but is conVerted in viv0 to an actiVe compound of the inVention. Prodrugs are typically rapidly transformed in viv0 to yield the parent compound of the inVention , e. g. by hydrolysis in the blood. The prodrug compound usua1ly offers adVantages of so 1ubi1ity , tissue compatibi1ity or de1ayed re1ease in a mammalian organism ( see SilVerman , R. B. , T he 0rganic Chemistry 0f Drug Design and Drag Acti0n , 211d Ed. , ElseVier Academic Press ( 2004 ) , pp. 498—549 ) . Prodrugs of a compound of the inVention may be prepared by modifying functional groups , such as a hydroxy , amino or mercapto groups , present in a compound of the inVention in such a way that the modiﬁcations are cleaVed , either in routine manipulation or in viv0 , to the parent compound of the inVention. Examples of prodrugs include , but are not limited to , acetate , formate and succinate deriVatiVes of hydroxy functional groups or pheny1 carbamate deriVatiVes of amino functional groups. Throughout the speciﬁcation and the appended claims , a giVen chemical formula or name sha11 a1so encompass a11 salts , hydrates , solVates , N - oxides and prodrug forms thereof Further , a giVen chemica1 formu1a or name sha11 encompass a11 tautomeric and stereoisomeric forms thereof. Stereoisomers include enantiomers and diastereomers. Enantiomers can be present in their pure forms , or as racemic ( equal ) or unequal mixtures of two enantiomers. Diastereomers can be present in their pure forms , or as mixtures of diastereomers. Diastereomers also inc1ude geometrical isomers , which can be present in their pure cz ' s or trans forms or as mixtures of those. The compounds of the Formula ( Ia ) to ( Id ) may be used as such or , where appropriate , as pharmacological1y acceptable salts ( acid or base addition salts ) thereof. The pharmacological1y acceptable addition salts mentioned below are meant to comprise the therapeutically actiVe non - toxic acid and base addition salt forms that the compounds are able to form Compounds that haVe basic properties can be conVerted to their pharmaceutically acceptable acid addition salts by treating the base form with an. appropriate acid. Exemp1ary acids inc1ude inorganic acids , such as hydrogen chloride , . 10. l5. 20. 25. 30. WO 2009 / 150144 5 0 PCT / EP2009 / 057074. hydrogen bromide , hydrogen iodide , sulphuric acid , phosphoric acid ; and organic acids such as formic acid , acetic acid , propanoic acid , hydroxyacetic acid , lactic acid , pyruVic acid , glycolic acid , maleic acid , malonic acid , oxalic acid , benzenesulphonic acid , to1uenesulphonic acid , methanesulphonic acid , triﬂuoroacetic acid , fumaric acid , succinic acid , malic acid , tartaric acid , citric acid , salicylic acid , p - aminosalicylic acid , pamoic acid , benzoic acid , ascorbic acid and the like. Exemp1ary base addition sa1t forms are the sodium , potassium , calcium sa1ts , and salts with pharmaceutically acceptable amines such as , for examp1e , ammonia , a1ky1amines , benzathine , and amino acids , such as , e. g. arginine and lysine. The term addition salt as used herein also comprises solVates which the. compounds and sa1ts thereof are ab1e to form , such as , for examp1e , hydrates , a1coho1ates. and the 1ike. COMPOSITIONS. For clinical use , the compounds of the inVention are formulated into pharmaceutical formu1ations for oral , rectal , parenteral or other mode of administration. Pharmaceutical formu1ations are usually prepared by mixing the actiVe substance , or a pharmaceutical1y acceptable sa1t thereof , with conVentional pharmaceutical excipients. Examples of excipients are water , gelatin , gum arabicum , lactose , microcrystalline cel1ulose , starch , sodium starch glycolate , calcium hydrogen phosphate , magnesium stearate , talcum , colloidal silicon dioxide , and the like. Such formulations may a1so contain other pharmaco1ogica11y actiVe agents , and conVentiona1 additiVes , such as stabi1izers , wetting agents , emulsiﬁers , ﬂaVouring agents , buffers , and the 1ike. Usually , the amount of actiVe compounds is between 0.1—95% by weight of the preparation , preferab1y between 0.2—20% by weight in preparations for parentera1 use and more preferably between 1 - 50% by weight in preparations for oral administration. Thc dosc lchl and frcqucncy of dosagc of thc spcciﬁc compound will Vary dcpcnding on a Variety of factors inc1uding the potency of the speciﬁc compound emp1oyed , the metabolic stability and length of action of that compound , the patient ' s age , body weight , general health , sex , diet , mode and time of administration , rate of excretion , drug combination , the seVerity of the condition to be treated , and the patient undergoing therapy. The dai1y dosage may , for example , range from about 0.00l mg to about lO0 mg per kilo of body. weight , administered sing1y or mu1tip1y in doses , e. g. from about 0.01 mg to about 25 mg. 10. l5. 20. 25. WO 2009 / 150144 _ 51 _ PCT / EP2009 / 057074. each. Normally , such a dosage is giVen oral1y but parenteral administration may a1so be chosen. The formulations can be further prepared by known methods such as granulation , compression , microencapsulation , spray coating , etc. The formulations may be prepared by conVentional methods in the dosage form of tablets , capsules , granules , powders , syrups , suspensions , suppositories or injections. Liquid formu1ations may be prepared by dissolVing or suspending the actiVe substance in water or other suitable Vehic1es. Tab1ets and granu1es may be coated in a conVentiona1 manner. The compounds of Formula ( Ia ) to ( Id ) may be administered with other actiVe compounds for the treatment of diabetes and / or obesity , for example insulin and insulin analogs , DPP - IV inhibitors , su1fony1 ureas , biguanides , ( x2 agonists , g1itazones , PPAR - y agonists , mixed PPAR - ( x / y agonists , RXR agonists , ( i - glucosidase inhibitors , PTP1B inhibitors , 11 - [ 3 - hydroxy steroid dehydrogenase Type 1 inhibitors , phosphodiesterase inhibitors , glycogen phosphorylase inhibitors , MCH - 1 antagonists , CB - 1 antagonists ( or inVerse agonists ) , amylin antagonists , CCK receptor agonists , B3 - agonists , leptin and leptin mimetics , serotonergic / dopaminergic antiobesity drugs , gastric lipase inhibitors , pancreatic lipase inhibitors , fatty acid oxidation inhibitors , 1ipid lowering agents and thyromimetics. It is particular1y preferred that the compounds of Formula ( Ia ) to ( Id ) are administered in combination with a DPP - IV inhibitor. The term “DPP - IV inhibitor” means a compound which inhibits , antagonizes or decreases the actiVity of dipeptidyl peptidase IV ( EC 3.4.14.5 ) . The said DPP - IV inhibitor can e. g. be a compound as disclosed in WO 2005 / 056003 ; WO 2005 / 056013 ; WO 2005 / 095343 ; WO 2005 / 113510 ; WO 2005 / 120494 ; WO 2005 / 121131 ; WO 2005 / 121089 ; WO 2006 / 013104 ; or WO 2006 / 076231 , including. references therein. 10. 15. 20. 25. WO 2009 / 150144 _ 52 _ PCT / EP2009 / 057074. PREPARATION OF COMPOUNDS OF THE INVENTION. The compounds of the Formula ( Ia ) to ( Id ) aboVe may be prepared by , or in ana1ogy with , conVentional methods. The preparation of intermediates and compounds according to the examples of the present inVention may in particular be illuminated by the following. Schemes 1 - 4. Scheme 1. * 6 mm mm mm. ‘©9224! mm mm. wherein Ar1 and R1 are as deﬁned in Formula ( Ia ) ; and. R is benzyl , Boc or CBz ; . Reagents and conditions : . ( a ) 4 - bromo - 2 - ( hydroxymethyl ) phenol ; a suitab1e acid , such as p - toluenesulfonic acid or sulﬁJric acid ; in a suitab1e solVent , such as chloroform or benzene ; at reﬂux temperature ; . ( b ) appropriate aryl - or heteroarylboronic acid ; appropriate catalyst , such as Pd ( PPh3 ) 4 or PdC12 ( dppf ) - DCM ; a suitable base , such as K2CO3 or NaHCO3 ; in a suitable solVent mixture such as 1 , 4 - dioxane and water ; at e1eVated temperature , for examp1e 90 0C or 160 °C ( microanes ) ; . ( c ) ( i ) 5 , 5 , 5 ' , 5 ' - tetramethyl - 2 , 2 ' - bi - 1 , 3 , 2 - dioxaborinane ; a suitable base , such as KOAc ; appropriate catalyst , such as PdCl2 ( dppf ) - DCM ; in a suitable solVent , such as DME ; at eleVated temperature , for example 120 OC ( microanes ) ; ( ii ) appropriate aryl or. heteroaryl halide ; suitable base , such as NaHCO3 ; appropriate catalyst , such as. 10. l5. 20. 25. WO 2009 / 150144 PCT / EP2009 / 057074. ( d ) . ( C ) . ( 0. ( g ) . ( h ) . _53_. Pd ( PPh3 ) 4 ; in a suitable solVent mixture , such as water and DME ; at eleVated temperature , for examp1e 120 OC ( microanes ) ; . a suitable deprotecting agent , such as TFA , HCl ( g ) or aqueous concentrated HC1 ; in a suitable solVent , such as DCM or ethanol ; at ambient or eleVated temperature ; when R : Boc ; . hydrogeno1ysis , a suitab1e catalyst , such as 10% Pd / C ; a suitable hydrogen source , such as ammonium formate or H2 ( g ) ; in a suitable solVent , such as n - propanol , ethano1 , water , or mixtures thereof ; at e1eVated temperature , for example 90 °C ; when R = benzyl or CBz ; . hydrolysis , a suitable base , such as NaOH or KOH ; in a suitab1e solVent mixture , such as water and ethano1 ; at eleVated temperature , for example 90 OC ; when R = CBz ; . ( i ) appropriate carboxy1ic acid ; a suitab1e base , such as triethylamine or DIPEA ; in a suitable solVent , such as THF , dioxane or DMF ; ( ii ) appropriate coupling reagent , such as HOBT / EDC , propylphosphonic anhydride or TBTU ; . appropriate acid chloride or chloroformate ; a suitable base , such as triethy1amine ; in. a suitable solVent , such as THF or DMF ; at r. t. Scheme 2. \o Br 0 \O / ||3 0 Ar1 0 m ( a ) m ( b ) m ( ‘3 ) N‘R N‘R N‘R. Ar1 Ar1 0 ﬁo m ( d ) 1 ( e ) 1 ( f ) 0r ( g ) OkO NH N\ R1. wherein Ar1 and R1 are as deﬁned in Formula ( Ia ) ; and. R is Boc. Reagents and conditions : . ( a ) . ( i ) BuLi , THF , - 78 cc ( ii ) B ( OMe ) 3 ; . 10. l5. 20. 25. 30. WO 2009 / 150144 _ 54 _ PCT / EP2009 / 057074. ( b ) appropriate aryl or heteroary1 ha1ide ; a suitable base , such as K2CO3 or NaHCO3 ; appropriate catalyst , such as PdCl2dppf - DCM or Pd ( PPh3 ) 4 ; in a suitab1e solVent mixture , such as water and DME or MeCN and water ; at eleVated temperature , for example 160 OC ( microanes ) ; . ( c ) a suitable deprotecting agent , such as TFA , HCl ( g ) or aqueous HC1 ; in a suitable solVent , such as DCM , dioxane , methanol or ethanol ; at ambient or eleVated temperature ; . ( d ) ( i ) appropriate carboxy1ic acid ; a suitab1e base , such as triethylamine or DIPEA ; in a suitable solVent , such as THF , dioxane or DMF ; ( ii ) appropriate coupling reagent , such as HOBT / EDC , propylphosphonic anhydride , HBTU or TBTU ; at r. t. ; . ( e ) appropriate acid chloride or ch1oroformate ; a suitab1e base , such as triethy1amine ; in a suitable solVent , such as THF or DMF ; at r. t. ; . ( f ) appropriate alcohol ; a suitab1e coup1ing reagent , such as 1 , 1 ' —carbonylbis ( 1H— imidazole ) ; in a suitable solVent , such as DCM , acetonitrile or DCM / T HF ; at eleVated temperature ; . ( g ) appropriate heteroaryl ha1ide , such as 2 - bromopyrimidine ; in a suitable solVent , such. as DMSO or acetonitrile ; at e1eVated temperature. Scheme 3. R5 |. HO\n / A O N A ° 23 Y CO 0 — o OO N\R1. wherein A is phenyl or heteroaryl ; and. R1 and R5 are as deﬁned in Formula ( Ia ) ; . Reagents and conditions : . ( a ) ( i ) appropriate amine ; a suitable base , such as triethylamine or or DIPEA ; in a suitable solVent , such as THF , dioxane or DMF ; ( ii ) appropriate coupling reagent , such as HOBT , EDC , propylphosphonic anhydride , HBTU or TBTU ; at 0 °C or at. eleVated temperature. 10. l5. 20. WO 2009 / 150144 55 PCT / EP2009 / 057074. Scheme 4. Br OH Br OH O N H N 2 U0>_ ( a ) 2 U0 ) _ ( b ) \ [ : Ej : | ( c ) UNH N 2 O. N. o O O HO ( d ) . ( e ) XO ( f ) E ; erO ( g ) . ( h ) kOkR N‘R N‘R. Br 0 Ari 0 Ar1 0 @%4@%&@% N\R N\R N\. wherein Ar1 and R1 are as deﬁned in Formula ( Ia ) ; and. R is Boc. Rcagcnts and conditions : . ( a ) iron powder , NH4Cl , methanol and water , 70 0C ; . ( b ) ( i ) 1 M HBr , NaNO2 , water , 0 OC ; ( ii ) CuBr , water , 0 0C —> r. t. ; . ( c ) 3 M HC1 , EtOH , 100 0C ; . ( d ) ( i ) EDC , HOBT , DMF ; ( ii ) 1 , 2 - dimethy1hydroxylamine hydrochloride , DIEA ; . ( e ) bromo ( methyl ) magnesium , diethylether , 0 0C —> r. t. ; . ( f ) ( i ) 1ithium bis ( trimethy1si1y1 ) amide , THF , - 78 OC ; ( ii ) trimethy1si1y1 ch1oride , - 78 0C —> r. t. ( iii ) Br2 , - 78 °C ; . ( g ) K2CO3 , DMF , r. t ; . ( h ) NaBH4 , ethano1 , HOAc , r. t ; . ( i ) appropriate aryl - or heteroarylboronic acid , NaHCO3 , PPh3 , Pd ( OAc ) 2 , 80% aqueous ethanol , 80 0C ; . ( j ) DCM , TFA , r. t. ; . ( k ) appropriate carboxylic acid , triethylamine , TBTU , DMF , r. t. 10. l5. 20. 25. 30. WO 2009 / 150144 56 PCT / EP2009 / 057074. Deﬁnitions of Variables in the structures in schemes herein are commensurate with those of. corresponding positions in the formu1ae delineated herein. The necessary starting materials for preparing the compounds of Formula ( Ia ) to ( Id ) and other compounds herein are either commercially aVailable or may be prepared in analogy with the preparation of known compounds. The processes described be1ow in the examp1e section may be carried out to giVe a compound of the inVention in the form of a free base or as an acid addition salt. A pharmaceutically acceptab1e acid addition sa1t may be obtained by disso1Ving the free base in a suitab1e organic solVent and treating the solution with an acid , in accordance with conVentional procedures for preparing acid addition salts from base compounds. Examples of addition sa1t forming acids are mentioned aboVe. The compounds of Formula ( Ia ) to ( Id ) may possess one or more chiral carbon atoms , and they may therefore be obtained in the form of optical isomers , e. g. as a pure enantiomer , or as a mixture of enantiomers ( racemate ) or as a mixture containing diastereomers. The separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may , for example , be achieVed by fractional crystallization of salts with optical1y actiVe ( chira1 ) acids or by chromatographic separation on chiral columns. The chemicals used in the synthetic routes delineated herein may include , for example , solVents , reagents , catalysts , and protecting group and deprotecting group reagents. The methods described aboVe may a1so additiona11y inc1ude steps , either before or after the steps described speciﬁca1ly herein , to add or remoVe suitable protecting groups in order to u1timate1y al1ow synthesis of the compounds. In addition , Various synthetic steps may be performed in an a1ternate sequence or order to giVe the desired compounds. Synthetic chemistry transformations and protecting group methodologies ( protection and dcprotcction ) uscﬁ11 in synthcsizing app1icablc compounds arc known in thc art and inc1ude , for example , those described in R. Larock , C0mprehensive Organic Transf0rmati0ns , VCH Pub1ishers ( 1989 ) ; T. W. Greene and P. G. M. Wuts , Pr0tective Gr0aps in 0rganic Synthesis , 3rd Ed. , John Wi1ey and Sons ( 1999 ) ; L. Fieser and M. Fieser , Fieser and F ieser ' s Reagents f0r 0rganic Synthesis , John Wiley and Sons ( 1994 ) ; and L. Paquette , ed. , Encycl0pedia 0f Reagents f0r 0rganic Synthesis , John Wiley and Sons ( 1995 ) and subsequent editions thereof. WO 2009 / 150144. 5 7 PCT / EP2009 / 057074. The fo11owing abbreViations haVe been used : . Boc Brine CBz DCM DIEA DIPEA DME DMF DMSO EDC. ESI EtOAc GC GCMS. h. HDL HBTU HOBT HPLC HRESIMS LCMS LRESIMS MCPBA MeCN McOH. PdCl2dppf - DCM. Pd2 ( dba ) 3 Pd ( OAc ) 2 Pd ( PPh3 ) 4 r. t. tert - butylo xycarbonyl. water saturated or nearly saturated with sodium chloride carbobenzy1oxy. dichloromethane. N - ethyl - N , N - diisopropylamine. N , N - diisopropylethy1 amine. 1 , 2 - dimethoxyethane. dimethylformamide. dimethyl sulphoxide N - ( 3 - dimethy1aminopropy1 ) - N - ethy1carbodiimide , or 1 - ethyl - 3 - ( 3 - dimethylaminopropyl ) carbodiimide hydrochloride electrospray ionization. ethyl acetate. Gas Chromatography. Gas Chromatography Mass Spectrometry. hour ( s ) . High - Density Lipoprotein. 0 - benzotriazo1e - N , N , N , N - tetramethyl - uronium - hexaﬂuorophosphate 1 - hydroxybenzotriazole hydrate. High Performance Liquid Chromatography High - Reso1ution E1ectrospray Ionization Mass Spectra Liquid Chromatography Mass Spectrometry Low—Resolution E1ectrospray Ionization Mass Spectra 3 - ch1oroperoxybenzoic acid. acetonitrile. mcthanol. [ 1 , 1 - bis ( dipheny1phosphino ) - ferrocene ] dichloropalladium ( II ) complex with DCM ( 1 : 1 ) tris ( dibenzylideneacetone ) dipalladium ( 0 ) palladium ( II ) acetate tetrakis ( triphenylphospine ) palladium ( 0 ) . room temperature. 10. WO 2009 / 150144 PCT / EP2009 / 057074. _ 5 8 _ sec second ( s ) TBTU N , N , N ' , N ' - tetramethyl - O - ( benzotriazo l - 1 - yl ) uronium tetraﬂuoroborate , THF tetrahydroﬁJran Xantphos ( 9 , 9 - dimethyl - 9H - xanthene - 4 , 5 - diyl ) bis ( diphenylphosphine ) A Angstrom. The recitation of a listing of chemical groups in any deﬁnition of a Variable herein includes deﬁnitions of that Variab1e as any sing1e group or combination of listed groups. The recitation of an embodiment for a Variable herein includes that embodiment as any single. embodiment or in combination with any other embodiments or portions thereof. The inVention will now be further illustrated by the following non - limiting Examples. The speciﬁc examples below are to be construed as mere1y il1ustratiVe , and not 1imitatiVe of the remainder of the disclosure in any way whatsoeVer. Without further elaboration , it is belieVed that one skilled in the art can , based on the description herein , utilize the present inVention to its fullest extent. Al1 references and publications cited herein are hereby. incorporated by reference in their entirety. 10. l5. 20. 25. 30. WO 2009 / 150144 5 9 PCT / EP2009 / 057074. EXAMPLES AND INTERMEDIATE COMPOUNDS. Experimental Meth0ds. All reagents were commercia1 grade and were used as receiVed without further puriﬁcation , un1ess otherwise speciﬁed. Commercially aVailable anhydrous solVents were used for reactions conducted under inert atmosphere. Reagent grade solVents were used in a1l other cases , un1ess otherwise speciﬁed. Low - reso1ution e1ectrospray ionization mass spectra ( LRESIMS ) were obtained using an Agilent MSD mass spectrometer or a Waters ZQ mass spectrometer. High - resolution electrospray ionization mass spectra ( HRESIMS ) were obtained on an Agi1ent LC / MSD TOF connected to an Agi1ent 1100 LC - system , Ion Source : ESI , Ion polarity : pos , Data : proﬁ1e mode , Scan range : 100 - 1100 Da , MS parameters : Fragmentor 215V , Skimmer 560V och OCT RF ( octpole rods ) 250 V. ; Reference Masses 121.050873 and 922.009798 ( Agi1ent reference Mix ) ; LC : A 15 mM ammonium acetate ; B 100 MeCN ; ﬂow rate 400 uL / min isocratic. Analytical GCMS was performed on a Hewlett - Packard 5890 / 6890 gas chromatograph equipped with a HP - 5MS crosslinked 5% PhMe Siloxane column ( 30 m x 0.25 mm x 0.25 um ﬁ1m thickness ) with a Hewlett - Packard 5971A / 5972A mass selectiVe detector using e1ectron impact. F1ash chromatography was performed on Merck si1ica gel 60 ( 230 - 400 mesh ) . The compounds. were automatica1ly named using ACD 8.0. Analytical LCMS data were 0btained with.‘. System A : Agilent MSD mass spectrometer ; Agilent 1100 system ; ACE 3 C8 column ( 50x30 mm ) ; Water containing 0.1% TFA and acetonitrile were used as mobile phases at a ﬂow rate of 1 mL / min with gradient times of 3.0 min ( gradient 10 - 97% acetonitri1e ) ; or System B : Agilent MSD mass spectrometer ; Agilent 1100 system ; YMC ODS - AQ column ( 33x30 mm ) ; Watcr containing 0.1% TFA and acctonitrilc wcrc uscd as mobilc phascs at a ﬂow rate of 1 mL / min with gradient times of 3.0 min ( gradient 10 - 97% acetonitrile ) ; or System C : Waters ZQ mass spectrometer ; Waters 996 PDA detector ( DAD 215 - 395 nm ) ; ACE C8 ( 3 um ) column ( 30x30 mm ) ( from ACT ) ; Water containing 10 mM ammonium acetate ( pH=7 ) and acetonitrile were used as mobile phases at a ﬂow rate of 1 mL / min with. gradient times of3.2 min ( gradient 5 - l 00% acetonitrile ) . 10. 15. 20. 25. 30. WO 2009 / 150144 60 PCT / EP2009 / 057074. Preparative HPLC was perf0rmed 0n Gils0n system eqaipped with : . System D : ACE C8 5 um ( 21.2x50mm ) column. Water containing 0.1% TFA and acetonitrile were used as mobile phases at a ﬂow rate of 25 mL / min with gradient times of 6 min. ; or. System E : XTerra Prep MS C18 5 mm ( 19x50 mm ) co1umn. Water containing 50mM NH4HCO3 ( pH=10 ) and acetonitrile were used as mobile phases at a ﬂow rate of 25 mL / min with gradient times of 6 min ; or Xterra MS C18 5 mm ( 30x100 mm ) column. Water containing 50mM NH4HCO3 ( pH=10 ) and acetonitri1e were used as mobile phases. at a ﬂow rate of 40 mL / min with gradient times of 8.5 min. General Meth0d A1 : Suzuki - type cr0ss - c0upling reacti0n. A suspension of benzyl 4 - ( 6 - bromo - 4H - l , 3 - benzodioxin - 2 - yl ) piperidine - l - carboxylate ( Intermediate A1 ; 20 mg , 0.046 mmo1 ) , the appropriate boronic acid ( 0.051 mmo1 ) , K2CO3 ( 16 mg , 0.12 mmol ) and Pd ( PPh3 ) 4 ( 3 mg , 0.0023 mmo1 ) in 1 , 4 - dioxane ( 2 mL ) and water ( 0.5 mL ) was heated at 90 OC oVemight. The solVents were remoVed under reduced. pressure and the residue was puriﬁed by preparatiVe HPLC ( System E ) . General Meth0d A2 : Suzuki - type cr0ss - c0upling reacti0n Prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ( Intermediate A11 ; 20 mg , 0.05 mmo1 ) and the appropriate boronic acid in accordance with. general method A1 . General Meth0d B : Suzuki - type cr0ss - c0upling reacti0n ( micr0ane c0nditi0ns ) . A suspension of tert - butyl 4 - [ 6 - ( dimethoxyboryl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ( Intermediate A19 ; 30 mg , 0.078 mmol ) , the appropriate aryl - or heteroarylbromide ( 0.10 mmo1 ) , K2CO3 ( 26 mg , 0.19 mmo1 ) , PdC12dppf - DCM ( 6 mg , 0.0077 mmol ) in MeCN / H2O ( 1.5 mL ; 2 : 1 ) was heated at 160 °C for 20 min in a microane reactor. The mixture was ﬁ1tered through a pad of silica , concentrated and the. residue was puriﬁed by preparatiVe HPLC ( System E ) . General Meth0d C1 : Preparati0n 0f amides fr0m carb0xylic acids using HOBT and EDC as c0upling reagents To a Via1 containing the appropriate carboxy1ic acid ( 0.030 mmol ) was added a solution of. N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ; . 10. 15. 20. 25. 30. WO 2009 / 150144 _ 6l _ PCT / EP2009 / 057074. 10 mg , 0.027 mmol ) in THF ( 2 mL ) and triethylamine ( 15 uL , 0.11 mmol ) . HOBT ( 7 mg , 0.054 mmol ) and EDC ( 10 mg , 0.054 mmol ) were added and the resulting mixture was. shaken oVemight and then concentrated. The residue was puriﬁed by preparatiVe HPLC. ( System E ) . General Meth0d C2 : Preparati0n 0f amides fr0m carb0xylic acids using HOBT and EDC as c0upling reagents. Prepared from 4 - { 6 - [ 4 - ( methy1su1fony1 ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ; 15 mg , 0.040 mmol ) and the appropriate carboxylic acid in accordance. with general method C1. General Meth0d D : Preparati0n 0f amides fr0m carb0xylic acids using pr0pyl - ph0sph0nic anhydride as coupling reagent. A suspension of the appropriate carboxylic acid ( 0.05 mmol ) in dry DMSO ( 75 uL ) and DMF ( 0.75 uL ) was treated with propylphosphonic anhydride ( 44 uL , 0.075 mmol ; as a 50% solution in EtOAc ) and stirred for 10 min. To the mixture were added a solution of the appropriate amine ( 0.06 mmol ) and triethylamine ( 21 uL , 0.20 mmol ) in dry DMF ( 100 uL ) and the resu1ting mixture was shaken at r. t. oVemight. Puriﬁcation by preparatiVe. HPLC ( System E ) gaVe the title compound. INTERMEDIATE A1 Benzyl 4 - ( 6 - br0m0 - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carboxylate. rCCiONTon. o A suspension of benzy1 4 - formylpiperidine - 1 - carboxy1ate ( 2.81 g , 11.4 mmol ) , 4 - bromo - 2 - ( hydroxymethy1 ) phenol ( 2.31 g , 11.4 mmol ) and p - to1uenesu1fonic acid and mo1ecular sieVes ( 4 A ) in chloroform ( 100 mL ) was reﬂuxed for 3 hours using a Dean - Stark apparatus. The reaction mixture was then washed with 5% aqueous KHCO3 ( 20 mL ) and the water phase was extracted with ch1oroform ( 3 x 15 mL ) . The combined organic phases were washed with 5% aqueous KHCO3 ( 20 mL ) and then concentrated. Yie1d 4.75 g ( 97% ) . Analytical HPLC : purity 78% ( System C ) ; LRESIMS ( ESL ) m / z = 433 ( M + H ) + . 10. l5. 20. 25. WO 2009 / 150144 _ 62 _ PCT / EP2009 / 057074. INTERMEDIATE A2 4 - ( 6 - Br0m0 - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine. A suspension of benzy1 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A1 ; 550 mg , 1.27 mmol ) in 30% aqueous NaOH ( 10 mL ) and MeOH ( l5 mL ) was heated in a sea1ed tube at 90 0C for 15 h. The MeOH was remoVed under reduced pressure and the remaining aqueous mixture was extracted with chloroform ( 3 x 15 mL ) . The organic 1ayers were combined , dried ( MgSO4 ) and concentrated. Yield 370 mg ( 97% ) . Ana1ytical HPLC : purity 93% ( System A ) ; LRESIMS ( ESI + ) m / z : 298 / 300 ( M + H ) + . Alternative synthetic r0ate : . A suspension of tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A11 ; 5.0 g , 0.017 mol ) in TFA / DCM ( 50 mL ; 1 : 4 ) was stirred at r. t. for 2 h. The solVents were remoVed under reduced pressure and the residue was partitioned between DCM and 1 M NaOH. The aqueous 1ayer was extracted with DCM ( 3 x 50 mL ) . The organic 1ayers were combined , washed with water and brine , dried ( MgSO4 ) and concentrated to giVe the tit1e compound. Yield 4.7 g ( 94% ) . Analytical HPLC : purity 90% ( System A ) ; LRESIMS m / z = 298 / 300 ( M + H ) + . INTERMEDIATE A3 N , N - Dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodi0xin - 6 - yl ) benzamide. “ ( Ce. A suspension of 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine ( Intermediate A2 ; 370 mg , 1.24 mmol ) , { 4 - [ ( dimethylamino ) carbonyl ] pheny1 } boronic acid ( 264 mg , 1.36 mmol ) , Pd ( PPh3 ) 4 ( 72 mg , 0.0620 mmol ) and K2CO3 ( 428 mg , 3.10 mmol ) in 1 , 4 - dioxane ( 10 mL ) and water ( 3 mL ) was heated at 90 0C for lS h. The solVents were remoVed under reduced. pressure. The residue was puriﬁed by ﬂash chromatography on si1ica using EtOAc / DCM. 10. l5. 20. 25. WO 2009 / 150144 6 3 PCT / EP2009 / 057074. ( 1 : 1 ) fo1lowed by DCM / MeOH / 25% aqueous NH3 ( 90 : 9 : 1 ) as e1uents. Yield 209 mg ( 46% ) . Analytical HPLC : purity 85% ( System A ) ; LRESIMS ( EsP ) m / z = 367 ( M + H ) + . INTERMEDIATE A4 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine. \S / O / / . O ‘ ( \o 0 * ©. A suspension of benzy1 4 - { 6 - [ 4 - ( methy1su1fonyl ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - piperidine - 1 - carboxylate ( Examp1e A2 ; 1.75 g , 3.40 mmol ) in 30% aqueous NaOH ( 10 mL ) and MeOH ( 15 mL ) was heated in a sea1ed tube at 90 °C for 72 h. The solVents were remoVed under reduced pressure and the residue was partitioned between water ( 75 mL ) and chloroform ( 2 x 100 mL ) . The organic layers were combined , dried ( MgSO4 ) and concentrated. Yield 1.23 g ( 97% ) . Ana1ytical HPLC : purity 80% ( System A ) ; LRESIMS ( Esr ) m / z = 374 ( M + H ) + . INTERMEDIATE A5. 6 - Br0m0 - 3 - hydr0xypyridine - 2 - carb0xylic acid. \OH. Br N. / OH. 0 To a stirred suspension of 3 - hydroxypyridine - 2 - carboxylic acid ( 2.00 g , 0.0144 mol ) in DMF ( 30 mL ) was added a so1ution of N - bromosuccinimide ( 2.56 g , 0.0144 mo1 ) in DMF ( 30 mL ) . After 1 h , water ( 50 mL ) and 1 M aqueous NaOH ( 25 mL ) were added and the resu1ting mixture was extracted with chloroform ( 3 x 150 mL ) . The organic layers were combined and concentrated and the residue was puriﬁed by preparatiVe HPLC ( System D ) . Yield 366 mg ( 12% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; LRESIMS ( ESI + ) m / z = 218 / 220 ( M + H ) + . 10. 15. 20. WO 2009 / 150144 _ 64 _ PCT / EP2009 / 057074. INTERMEDIATE A6 Benzyl 4 - { 6 - [ 2 - i0d0 - 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. To a stirred and cooled ( 0 °C ) suspension of benzy1 4 - { 6 - [ 2 - amino - 4 - ( methylsu1fony1 ) - phenyl ] - 4H - l , 3 - benzodioxin - 2 - yl } piperidine - l - carboxylate ( Example A56 ; 450 mg , 0.86 mmo1 ) in acetonitri1e ( 2 mL ) and 1 M HC1 ( 6 mL ) was added a solution of sodium nitrite ( 89 mg , 1.3 mmol ) in water ( 1.5 mL ) . The mixture was stirred at 0 0C for 20 min and then potassium iodide ( 214 mg , 1.29 mmol ) was added. After stirring at r. t. for 2 h , water ( 20 mL ) was added and the resu1ting solution was extracted with ch1oroform ( 3 x 30 mL ) . The organic 1ayers were combined and concentrated. Yield 253 mg ( 46% ) . Ana1ytica1 HPLC : purity 85% ( System A ) . INTERMEDIATE A7 Benzyl 4 - ( 6 - br0m0 - 4H - 1 , 3 - benz0dioxin - 2 - yl ) piperidine - 1 - carboxylate. BCCSwe. A mixture of 5 - bromo - 2 - hydroxybenzy1 alcoho1 ( 10.32 g , 50.85 mmol ) , benzy1 4 - formy1 - tetrahydro - 1 ( 2H ) - pyridinecarboxylate ( 14.85 g , 60.05 mmol ) and p - to1uenesulfonic acid ( 0.97 g , 5.08 mmol ) was stirred under reﬂux for 1 h in benzene ( 111 mL ) using a DeanStark apparatus. The organic phase was washed with 1 M NaOH , dried ( Na2SO4 ) , and concentrated to giVe the title compound. Yield 20.94 g ( 95% ) . 10. l5. 20. 25. WO 2009 / 150144 65 PCT / EP2009 / 057074. INTERMEDIATE A8 Methyl 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benz0dioxin - 6 - yl ) benz0ate. O. A suspension of benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A7 ; 5.00 g , 11.6 mmol ) , 4 - methoxycarbonyl - phenylboronic acid ( 2.29 g , 12.7 mmol ) , Pd ( PPh3 ) 4 ( 0.67 g , 0.58 mmol ) and K2CO3 ( 4.00 g , 28.9 mmo1 ) in 1 , 4 - dioxane ( 40 mL ) and water ( 10 mL ) was stirred at 90 OC oVemight. To the mixture was added water ( 50 mL ) and the product was extracted with EtOAc ( 50 mL ) . The organic phase was dried ( Na2SO4 ) and the solvent was remoVed under reduced pressure to giVe benzyl 4 - { 6 - [ 4 - ( methoxycarbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine - 1 - carboxy1ate. To a stirred suspension of this material in 1 , 4 - dioxane ( 150 mL ) and ethanol ( 100 mL ) was added 10% Pd / C ( 0.5 g ) and the mixture was heated at 60 °C under H2 oVemight. The mixture was ﬁltered ( Celite ) and the ﬁltrate was concentrated and then dissolVed in 1 M HCl ( 100 mL ) and washed with Et2O ( 100 mL ) . The aqueous phase was collected and basiﬁed with 2 M NaOH ( 50 mL ) and then extracted with EtOAc ( 100 mL ) . The organic phase was dried ( Na2SO4 ) and concentrated to giVe the title compound. Yield 3.07 g ( 75% , oVer 2 steps ) . Ana1ytical HPLC : purity 94% ( System A ) ; LRESIMS m / z : 354 ( M + H ) + . INTERMEDIATE A9 ( 1 - Methylcycl0pr0pyl ) methyl 4 - { 6 - [ 4 - ( meth0xycarb0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - carb0xylate. 0 me. To a suspension of 1 , 1 ' - carbony1diimidazo1e ( 1.15 g , 7.10 mmo1 ) in acetonitri1e ( 2 mL ) and DMF ( 2 mL ) was added 1 - methylcyclopropane methanol ( 0.59 g , 7.10 mmol ) and the mixture was stirred for 5 minutes. A solution of methyl 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - . benzodioxin - 6 - y1 ) benzoate ( Intermediate A8 ; 0.50 g , 1.41 mmo1 ) in DMF ( 2 mL ) was. 10. l5. 20. 25. WO 2009 / 150144 66 PCT / EP2009 / 057074. added and the mixture was stirred at 50 0C for 2 h. EtOAc was added and the mixture was washed with 1 M NaOH. The organic phase was dried ( Na2SO4 ) and concentrated. Gradient ﬂash chromatography on si1ica using EtOAc and n - pentane ( 10 : 90 to 50 : 50 ) as eluent gaVe the title compound. Yield 0.4 g ( 51% ) . Analytical HPLC : purity 100% ( System A ) ; LRESIMS m / z : 466 ( M + H ) + . INTERMEDIATE A10 4 - [ 2 - ( 1 - { [ ( 1 - Methylcycl0pr0pyl ) meth0xy ] carb0nyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benz0 - . dioxin - 6 - yl ] benz0ic acid. 0. A suspension of ( 1 - methylcyclopropyl ) methyl 4 - { 6 - [ 4 - ( methoxycarbonyl ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine - 1 - carboxy1ate ( Intermediate A9 ; 0.40 g , 0.86 mmol ) in THF ( 15 mL ) and MeOH ( 10 mL ) was treated with 6 M KOH ( 0.86 mL , 5.16 mmol ) and stirred at 50 °C for 1 h. The mixture was diluted with water , neutralized with 4 M HCl ( aq ) and extracted with EtOAc. The organic phase was dried ( Na2SO4 ) and concentrated to giVe the tit1e compound. Yield 0.38 g ( 99% ) . Analytica1 HPLC : purity 95% ( System A ) ; LRESIMS m / z = 452 ( M + H ) + . INTERMEDIATE A11 tert - Butyl 4 - ( 6 - brom0 - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. Br\ [ I ‘o oxO. N o. I ) < A suspension of tert - butyl 4 - formylpiperidine - 1 - carboxylate ( 7.62 g , 35.7 mmol ) , 4 - bromo - 2 - ( hydroxymethy1 ) phenol ( 7.25 g , 35.7 mmol ) , p - toluenesulfonic acid ( catalytic amount ) and mo1ecu1ar sieVes ( 4 A ) in benzene ( 100 mL ) was stirred under reﬂux for 24 h using a Dean - Stark apparatus. The mixture was washed with 5% aqueous NaHCO3 ( 50. mL ) and the water phase was then extracted with chloroform ( 3 x 50 mL ) . The organic phases were combined and washed with 5% aqueous NaHCO3 ( 20 mL ) , dried ( K2CO3 ) and. 10. l5. 20. 25. 30. WO 2009 / 150144 67 PCT / EP2009 / 057074. concentrated to giVe the title compound. Yield 14.2 g ( 70% ) . LRESIMS ( ESI + ) m / z = 298 / 300 ( M + H - Boc ) + . Alternative synthetic r0ate. To a suspension of 4 - bromo - 2 - ( hydroxymethy1 ) pheno1 ( 9.00 g , 44.3 mmo1 ) in ch1oroform ( 100 mL ) were added tert - butyl 4 - formylpiperidine - 1 - carboxylate ( 9.45 g , 44.3 mmol ) , p - to1uenesulfonic acid ( 0.38 g , 2.2 mmol ) and mo1ecu1ar sieVes ( 4 A ) . The mixture was stirred at reﬂux for 12 h and then al1owed to reach r. t. The so1ution was ﬁltered , the ﬁltrate was washed with saturated aqueous NaHCO3 ( 3 x 30 mL ) and the aqueous layer was extracted with chloroform ( 100 mL ) . The organic layer was washed with brine ( 50 mL ) , dried ( Na2SO4 ) and concentrated and the residue was puriﬁed by ﬂash chromatography on silica using 5% MeOH in DCM as eluent. Yield 14.5 g ( 85% ) . Analytical HPLC : purity 98% ( System A and B ) ; LRESIMS ( ESI + ) m / z = 298 / 300 ( M + H—Boc ) + . INTERMEDIATE A12 1 - Benz0yl - 4 - ( 6 - br0m0 - 4H - 1 , 3 - benz0di0Xin - 2 - yl ) piperidine. A suspension of 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine ( Intermediate A2 ; 4.7 g , 15.8 mmol ) , benzoic acid ( 2.3 g , 18.9 mmo1 ) , N , N - diisopropy1ethylamine ( 11 mL , 63 mmol ) and propylphosphonic anhydride ( 26 mL , 41 mmol ; as a 50% solution in EtOAc ) in dry DCM ( 80 mL ) was stirred at r. t. for 2 h and then di1uted with DCM ( 20 mL ) . The mixture was washed with 0.5 M HCl ( aq ) , water , 5% aqueous NaHCO3 and brine , dried ( MgSO4 ) and conccntratcd. Yicld 6.3 g ( 100% ) . Ana1ytica1 HPLC : purity 95% ( Systcm A and B ) , LRESIMS m / z = 403 ( M + H ) + . INTERMEDIATE A13 2 - [ ( 4 - Br0m0phenyl ) sulf0nyl ] ethanamine hydr0chl0ride. H2N\ / \S”O ll. Br. A suspension of 4 - bromothiopheno1 ( 3.52 g , 18.6 mmo1 ) , tert - buty1 2 - bromo - ethy1 - carbamate ( 5.00 g , 22.3 mmol ) and K2CO3 ( 9.25 g , 66.9 mmol ) in acetone ( 100 mL ) was. 10. 15. 20. 25. WO 2009 / 150144 6 8 PCT / EP2009 / 057074. stirred at r. t. for 48 h. The mixture was ﬁltrated and the ﬁltrate was concentrated and dissolVed in DCM ( 100 mL ) . The solution was cooled in an ice - bath and MCPBA ( 7.70 g , 44.6 mmol ) was added. After stirring at r. t. for 48 h , additional MCPBA ( 3.85 g , 22.3 mmol ) was added and the mixture was stirred for another 24 h. The mixture was ﬁltrated and the so1id was washed with DCM. The ﬁ1trate was washed with aqueous saturated NaHSO3 , 5% aqueous NaHCO3 and water , dried ( MgSO4 ) and concentrated to giVe 6.4 g of tert - butyl 2 - [ ( 4 - bromophenyl ) su1fonyl ] ethylcarbamate. The material was stirred in 1.25 M ethano1ic HC1 ( 100 mL ) oVemight. The mixture was concentrated and the residue was triturated with ethanol / Et2O. The solid was col1ected by ﬁltration and dried. Yield 4.23 g ( 80% ) . Analytical HPLC : purity 99% ( System A ) ; LRESIMS m / z = 264 / 266 ( M + H ) + . INTERMEDIATE A14 4 - { 2 - [ 1 - ( tert - But0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } benz0ic acid. 0 OKONIOB. A suspension of tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A11 ; 4.0 g , 10 mmol ) , 4 - ( dihydroxyboryl ) benzoic acid ( 1.8 g , 11 mmol ) , Pd ( PPh3 ) 4 ( 577 mg , 0.05 mmol ) , K2CO3 ( 3.5 g , 25 mmol ) in 1 , 4 - dioxane ( 200 mL ) and water ( 50 mL ) was heated at 90 OC oVemight. The reaction mixture was ﬁltered and concentrated and the residue was puriﬁed by ﬂash chromatography on silica using EtOAc / n—pentane ( 1 : 4 ) as eluent. Yield 2.3 g ( 53% ) . Analytical HPLC : purity 90% ( system A and B ) , LRESIMS m / z = 440 ( M + H ) + . INTERMEDIATE A15 Methyl 4 - [ 2 - ( 1 - benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] benz0ate. 10. 15. 20. 25. WO 2009 / 150144 69 PCT / EP2009 / 057074. A suspension of methyl 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzoate ( Intermediate A8 ; 1.1 g , 3.0 mmol ) , benzoic acid ( 0.55 g , 4.49 mmol ) , triethylamine ( 1.8 g , 18 mmol ) , propylphosphonic anhydride ( 3 mL , 47 mmol ; as a 50% solution in EtOAc ) in DMF ( 30 mL ) was stirred at r. t. for 2 h and then di1uted with DCM ( 20 mL ) . The mixture was extracted with 1 M NaOH ( 20 mL ) and DCM ( 3 x 20 mL ) . The organic layers were combined , washed with water ( 10 mL ) and brine ( 10 mL ) , dried ( MgSO4 ) and concentrated. The residue was puriﬁed by ﬂash chromatography on si1ica using EtOAc / n - heptane ( 1 : 4 ) as eluent. Yie1d 1.2 g ( 90% ) . Ana1ytica1 HPLC : purity 94% ( System A and B ) , LRESIMS m / z = 458 ( M + H ) + . INTERMEDIATE A16 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] benz0ic acid. 0. Methyl 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzoate ( Intermediate A15 ; 1.2 g , 2.6 mmo1 ) was reacted with aqueous 6 M KOH ( 3 mL ) in MeOH / THF ( 1 : 2 , 30 mL ) at 60 0C for 1 h. The solVents were remoVed under reduced pressure and the residue was dissolVed in water ( 30 mL ) . The water so1ution was acidiﬁed to pH 2 with 6 M HC1 and then extracted with DCM ( 3 x 30 mL ) . The organic 1ayers were combined and washed with water ( 10 mL ) and brine ( 10 mL ) , dried ( MgSO4 ) and concentrated to giVe the title compound. Yield 0.7 g ( 58% ) . Analytical HPLC : purity 95% ( System A and B ) ; LRESIMS m / z = 444 ( M + H ) + . INTERMEDIATE A17 Ethyl 4 - { 6 - [ 4 - ( methoxycarb0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. O. 10. 15. 20. 25. WO 2009 / 150144 70 PCT / EP2009 / 057074. A suspension of methyl 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzoate ( Intermediate A8 ; 1.4 g , 4.0 mmo1 ) , triethylamine ( 2.4 g , 24 mmol ) , ethyl chloridocarbonate ( 0.6 g , 5.9 mmo1 ) in DMF ( 50 mL ) was stirred at r. t. for 30 min. The mixture was concentrated and the residue was partitioned between 1 M NaOH ( 20 mL ) and DCM ( 3 x 20 mL ) . The organic layers were combined , washed with water ( 10 mL ) and brine ( 10 mL ) , dried ( MgSO4 ) and concentrated. The residue was puriﬁed by ﬂash chromatography on silica using EtOAc / n - heptane ( 1 : 4 ) as eluent. Yield 1.1 g ( 65% ) . Ana1ytica1HPLC : purity 97% ( System A and B ) ; LRESIMS m / z = 426 ( M + H ) + . INTERMEDIATE A18 4 - { 2 - [ 1 - ( Eth0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } benz0ic acid. 0. A suspension of ethyl 4 - { 6 - [ 4 - ( methoxycarbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - piperidine - 1 - carboxylate ( Intermediate A17 ; 1.1 g , 2.5 mmol ) in 6 M aqueous KOH ( 3 mL ) and MeOH / THF ( 1 : 2 , 30 mL ) was heated at 60 0C for 1 h. The solvents were remoVed under reduced pressure and the residue was dissolVed in water ( 30 mL ) . The water so1ution was acidiﬁed to pH 2 using 6 M HCl and then extracted with DCM ( 3 x 30 mL ) . The organic layers were combined , washed with water ( 10 mL ) and brine ( 10 mL ) , dried ( MgSO4 ) and then concentrated. Yield 0.6 g ( 60% ) . Analytical HPLC : purity 95% ( System A and B ) , LRESIMS m / z = 412 ( M + H ) + . INTERMEDIATE A19 tert - Butyl 4 - [ 6 - ( dimeth0xyb0ryl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. \o B\ [ I ‘o o / KO N O I ) < A stirred suspension of tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxylate ( Intermediate A11 ; 2.5 g , 6.27 mmol ) in dry THF ( 100 mL ) under N2 ( g ) was. 10. 15. 20. 25. WO 2009 / 150144 _ 71 _ PCT / EP2009 / 057074. cooled to - 78 °C and n - BuLi ( 10 mL ; 2 M in hexanes ) was added dropwise. The mixture was stirred for 30 min at - 78 OC and trimethylborate ( 0.84 mL , 0.78 g ) was added oVer 10 min. Stirring was continued at - 78 0C for 30 min and then at r. t. for 10 h before the reaction was quenched with saturated aqueous NaHCO3 ( 10 mL ) . The mixture was dried ( Na2SO4 ) and concentrated and the residue was puriﬁed by ﬂash chromatography on si1ica. using 5% MeOH in DCM as eluent. Yield 1.09 g ( 45% ) . INTERMEDIATE A20 5 - { 2 - [ 1 - ( tert - But0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } pyridine - 2 - . carb0xylic acid. 0. N HO / . \. 50W. A suspension of tert—butyl 4— [ 6— ( dimethoxyboryl ) —4H—1 , 3—benzodioxin—2 - yl ] piperidine—1— carboxylate ( Intermediate A19 ; 300 mg , 0.766 mmo1 ) , 5 - bromopyridine - 2 - carboxylic acid ( 201 mg , 0.996 mmol ) , K2CO3 ( 265 mg , 1.92 mmol ) , PdCl2dppf - DCM ( 63 mg , 0.077 mmol ) in MeCN / H2O ( 5 mL ; 2 : 1 ) was heated at 160 0C for 20 min in a microane reactor. The mixture was ﬁltered through a pad of silica and concentrated to giVe the title. compound. Yield 338 mg ( 100% ) . Analytical HPLC : purity 80% ( System A ) . INTERMEDIATE A21 6 - { 2 - [ 1 - ( tert - But0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } nic0tinic acid 0 HO / N \ |. o / KO. N O. I ) <. A suspension of tert - butyl 4 - [ 6 - ( dimethoxyboryl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxy1ate ( Intermediate A19 ; 300 mg , 0.766 mmo1 ) , 2 - bromopyridine - 5 - carboxy1ic acid. ( 201 mg , 0.996 mmol ) , K2CO3 ( 265 mg , 1.92 mmol ) , PdCl2dppf - DCM ( 63 mg , 0.077. mmol ) in MeCN / H2O ( 5 mL ; 2 : 1 ) was heated at 160 0C for 20 min in a microane reactor. 10. l5. 20. 25. WO 2009 / 150144 _ 72 _ PCT / EP2009 / 057074. The mixture was ﬁltered through a pad of silica and concentrated to giVe the title. compound. Yield 338 mg ( 100% ) . Analytical HPLC : purity 80% ( System A ) . INTERMEDIATE A22 ( 2E ) - 3 - ( 5 - { 2 - [ 1 - ( tert - But0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodi0xin - 6 - yl } - 2 - thienyl ) acrylic acid. HO. OkONIOB. A suspension of tert—butyl 4— [ 6— ( dimethoxyboryl ) —4H—1 , 3—benzodioxin—2 - yl ] piperidine—1— carboxy1ate ( 1ntermediate A19 ; 100 mg , 0.255 mmo1 ) , ( 2E ) - 3 - ( 5 - bromo - 2 - thieny1 ) acry1ic acid ( 77.4 mg , 0.332 mmol ) , K2CO3 ( 88 mg , 0.64 mmol ) , PdCl2dppf - DCM ( 22 mg , 0.025 mmol ) in McCN / H2O ( 4 mL ; 2 : 1 ) was hcatcd at 160 0C for 20 min in a microanc rcactor. The mixture was ﬁltered through a pad of si1ica and concentrated to giVe the title. compound which was used direct1y in Example A137 and A138. INTERMEDIATE A23 1 - Methyl - 4 - { [ 5 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) pyridin - 2 - yl ] carbonyl } - . piperazine. A suspension of tert - buty1 4 - ( 6 - { 6 - [ ( 4 - methy1piperazin - 1 - y1 ) carbony1 ] pyridin - 3 - y1 } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ( Example A134 ; 122 mg , 0.234 mmo1 ) in 1 M HCl in MeOH ( 20 mL ) was stirred at r. t. for 80 min. The mixture was concentrated and the residue was partitioned between EtOAc and saturated aqueous Na2CO3. The organic phase was dried ( Na2SO4 ) and concentrated to giVe the title compound. Yie1d 64 mg ( 64% ) . Ana1ytica1 HPLC : purity 99% ( System A ) ; LRESIMS m / z = 423 ( M + H ) + . 10. l5. 20. WO 2009 / 150144 73 PCT / EP2009 / 057074. INTERMEDIATE A24 1 - Methyl - 4 - { [ 6 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benz0di0xin - 6 - yl ) pyridin - 3 - yl ] carb0nyl } - . piperazine. A suspension of tert - buty1 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - y1 ) carbony1 ] pyridin - 2 - y1 } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ( Example A132 ; 88 mg , 0.17 mmol ) in 1 M HC1 in MeOH ( 20 mL ) was stirred at r. t. for 80 min. The mixture was concentrated and the residue was partitioned between EtOAc and saturated aqueous Na2CO3. The organic phase was dried ( Na2SO4 ) and concentrated to giVe the title compound. Yield 71 mg ( 99% ) . Analytical HPLC : purity 99% ( System A ) ; LRESIMS m / z = 423 ( M + H ) + . EXAMPLE A1 Benzyl 4 - ( 6 - { 4 - [ ( dimethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0xylate. NNOmWo. o The title compound was prepared from benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - 1 - carboxy1ate ( Intermediate A1 ) and { 4 - [ ( dimethylamino ) carbony1 ] pheny1 } - boronic acid using the conditions described in general method A1. Yield 12.2 mg ( 53% ) . Ana1ytical HPLC : purity 94% ( System A and B ) ; HRESIMS ( ESE ) calcd for C30H32N2O5 500.2311 , found 500.2315. lO. l5. 20. WO 2009 / 150144 _ 74 _ PCT / EP2009 / 057074. EXAMPLE A2 Benzyl 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . \"SO 0 \.\.\ / \O O N o. T. O. carboxylate. The title compound was prepared from benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - 1 - carboxylate ( Intermediate A1 ) and [ 4 - ( methylsulfonyl ) phenyl ] boronic acid using the conditions described in genera1 method A1. Yie1d 10.5 mg ( 45% ) . Analytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH29NO6S 507.1716 , found 507.1731. EXAMPLE A3 Benzyl 4 - ( 6 - quin0lin - 5 - yl - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. 33 w. T. O The tit1e compound was prepared from benzy1 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) - piperidine - 1 - carboxylate ( Intermediate A1 ) and quinolin - 5 - ylboronic acid using the conditions described in general method A1. Yield 8.6 mg ( 39% ) . Analytica1 HPLC : purity 96% ( System A and B ) ; HRESIMS ( ESF ) ca1cd for C30H2gN204 480.2049 , found 480.2055. EXAMPLE A4 4 - { 2 - [ 1 - ( 3 , 4 - Dichl0r0benz0yl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } - N , N - dimethyl - . benzamide. 10. l5. 20. WO 2009 / 150144 75 PCT / EP2009 / 057074. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 , 4 - dichlorobenzoic acid using the conditions described in general method C1. Yie1d 8.0 mg ( 55% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C29H2gCl2N2O4 538.1426 , found 538.1427. EXAMPLE A5 4 - ( 2 - { 1 - [ ( 2 , 4 - Diﬂu0r0phenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - . dimethylbenzamide. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and ( 2 , 4 - diﬂuorophenyl ) acetic acid using the conditions described in general method C1. Yie1d 8.2 mg ( 58% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C3oH3oF2N2O4 520.2174 , found 520.2185. EXAMPLE A6 N , N - Dimethyl - 4 - [ 2 - ( 1 - { [ 3 - ( triﬂuoromethyl ) phenyl ] acetyl } piperidin - 4 - yl ) - 4H - 1 , 3 - . benz0dioxin - 6 - yl ] benzamide. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and [ 3 - ( triﬂuoromethyl ) pheny1 ] acetic acid using the conditions described in genera1 method C1. Yie1d 8.3 mg ( 56% ) . Ana1ytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C31H31F3N2O4 552.2236 , found 552.2251. 10. l5. 20. WO 2009 / 150144 76 PCT / EP2009 / 057074. EXAMPLE A7 4 - ( 2 - { 1 - [ ( 4 - Meth0xyphenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - . dimethylbenzamide. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - y1 ) benzamide ( Intermediate A3 ) and ( 4 - methoxyphenyl ) acetic acid using the conditions described in general method C1. Yie1d 8.4 mg ( 60% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C31H34N2O5 514.2468 , found 514.2484. EXAMPLE A8 4 - ( 2 - { 1 - [ ( 4 - Cyan0phenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - . dimethylbenzamide. o \N I ka O o o N. The tit1e compound was prepared from N , N - dimethy1 - 4 - ( 2 - piperidin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and ( 4 - cyanophenyl ) acetic acid using the conditions described in general method C1. Yie1d 8.4 mg ( 61% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESP ) calcd for C31H31N3O4 509.2315 , found 509.2327. EXAMPLE A9 4 - { 2 - [ 1 - ( 1H - Ind0l - 3 - ylacetyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } - N , N - dimethyl - . benzamide. 10. l5. 20. WO 2009 / 150144 77 PCT / EP2009 / 057074. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - y1 ) benzamide ( Intermediate A3 ) and 1H - indo1 - 3 - ylacetic acid using the conditions described in general method C1. Yie1d 8.9 mg ( 63% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C32H33N3O4 523.2471 , found 523.2479. EXAMPLE A10 N , N - Dimethyl - 4 - ( 2 - { 1 - [ ( 1 - methyl - 1H - indol - 3 - yl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - . I D O. The tit1e compound was prepared from N , N - dimethy1 - 4 - ( 2 - piperidin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and ( 1 - methyl - 1H - indol - 3 - yl ) acetic acid using thc conditions dcscribcd in gcncral mcthod C1. Yicld 8.8 mg ( 61% ) . Ana1ytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C33H35N3O4 537.2628 , found 537.2648. EXAMPLE A11 4 - { 2 - [ 1 - ( Cycl0hexylacetyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } - N , N - dimethyl - . benzamide. O. wﬂﬁ. m. 10. 15. 20. WO 2009 / 150144 78 PCT / EP2009 / 057074. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and cyclohexylacetic acid using the conditions described in general method C1. Yie1d 7.2 mg ( 54% ) . Ana1ytical HPLC : purity 100% ( System C ) ; HRESIMS ( ESF ) ca1cd for C30H38N204 490.2832 , found 490.2851. EXAMPLE A12 N , N - Dimethyl - 4 - { 2 - [ 1 - ( 3 - methyl - 3 - phenylbutan0yl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0 - . dioxin - 6 - yl } benzamide. \Nk‘.\m. The tit1e compound was prepared from N , N - dimethy1 - 4 - ( 2 - piperidin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 - methyl - 3 - phenylbutanoic acid using the conditions described in general method C1. Yie1d 8.5 mg ( 60% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESP ) calcd for C33H3gN2O4 526.2832 , found 526.2852. EXAMPLE A13 4 - ( 2 - { 1 - [ 3 - ( 4 - Meth0xyphenyl ) pr0pan0yl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - dimethylbenzamide. \N I C O O O. an“. O The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - y1 ) benzamide ( Intermediate A3 ) and 3 - ( 4 - methoxypheny1 ) propanoic acid using the conditions described in general method C1. Yield 7.9 mg ( 55% ) . Ana1ytical HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C32H36N2O5 528.2624 , found 528.2642. 10. l5. 20. WO 2009 / 150144 79 PCT / EP2009 / 057074. EXAMPLE A14 4 - ( 2 - { 1 - [ 3 - ( 3 - Chl0ro - 4 - meth0xyphenyl ) pr0pan0yl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0 - di0xin - 6 - yl ) - N , N - dimethylbenzamide. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 - ( 3 - chloro - 4 - methoxyphenyl ) propanoic acid using the conditions described in genera1 method C1. Yie1d 9.0 mg ( 59% ) . Ana1ytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C32H35C1N2O5 562.2234 , found 562.2244. EXAMPLE A15 4 - ( 2 - { 1 - [ 3 - ( 4 - Hydr0xyphenyl ) pr0pan0yl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - dimethylbenzamide. \N O O 0. www. o The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 - ( 4 - hydroxyphenyl ) propanoic acid using the conditions described in genera1 method C1. Yield 2.8 mg ( 20% ) . Ana1ytica1 HPLC : purity 98% ( System C ) ; HRESIMS ( ESI + ) calcd for C31H34N2O5 514.2468 , found 514.2472. 10. l5. 20. WO 2009 / 150144 80 PCT / EP2009 / 057074. EXAMPLE A16 4 - ( 2 - { 1 - [ 3 - ( 1H - Ind0l - 3 - yl ) pr0pan0yl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0di0xin - 6 - yl ) - N , N - . dimethylbenzamide. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 - ( 1H - indol - 3 - yl ) propanoic acid using the conditions described in genera1 method C1. Yie1d 9.4 mg ( 65% ) . Ana1ytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C33H35N3O4 537.2628 , found 537.2632. EXAMPLE A17 4 - { 2 - [ 1 - ( 3 - Cycl0hexylpr0panoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } - N , N - . dimethylbenzamide. O \N O O O. Thc titlc compound was prcparcd from N , N - dimcthyl - 4 - ( 2 - pipcridin - 4 - yl - 4H - 1 , 3 - bcnzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 3 - cyc1ohexylpropanoic acid using the conditions described in general method C1. Yie1d 7.9 mg ( 58% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C31H40N2O4 504.2988 , found 504.2991. EXAMPLE A18 4 - ( 2 - { 1 - [ 4 - ( 4 - Flu0r0phenyl ) butan0yl ] piperidin - 4 - yl } - 4H - 1 , 3 - benz0dioxin - 6 - yl ) - N , N - . dimethylbenzamide. O. . i‘.%. m. 10. 15. 20. WO 2009 / 150144 _ 8l _ PCT / EP2009 / 057074. The title compound was prepared from N , N - dimethyl - 4 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 4 - ( 4 - ﬂuorophenyl ) butanoic acid using the conditions described in general method C1. Yie1d 7.6 mg ( 53% ) . Analytica1 HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C32H35FN2O4 530.2581 , found 530.2593. EXAMPLE A19 N , N - Dimethyl - 4 - { 2 - [ 1 - ( 4 - 0x0pentan0yl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } - . benzamide. The tit1e compound was prepared from N , N - dimethy1 - 4 - ( 2 - piperidin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - yl ) benzamide ( Intermediate A3 ) and 4 - oxopentanoic acid using the conditions described in general method C1. Yie1d 7.6 mg ( 61% ) . Ana1ytical HPLC : purity 100% ( System C ) ; HRESIMS ( ESI‘ ) ca1cd for C27H32N2O5 464.2311 , found 464.2334. EXAMPLE A20 N , N - Dimethyl - 4 - { 2 - [ 1 - ( 4 - 0x0 - 4 - pyrr0lidin - 1 - ylbutan0yl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0 - . dioxin - 6 - yl } benzamide. O. \Nk.\ ( \ I O o O oxO o. N. rdo The title compound was prepared from N , N—dimethyl - 4 - ( 2—piperidin—4—yl—4H—1 , 3—benzodioxin - 6 - y1 ) benzamide ( 1ntermediate A3 ) and 4 - oxo - 4 - pyrro1idin - 1 - y1butanoic acid using the conditions described in general method C1. Yield 9.0 mg ( 64% ) . Ana1ytical HPLC : . purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C30H37N3O5 519.2733 , found 519.2750. 10. l5. 20. WO 2009 / 150144 _ 82 _ PCT / EP2009 / 057074. EXAMPLE A21 Benzyl 4 - ( 6 - { 4 - [ ( diethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benzodi0xin - 2 - yl ) piperidine - . 1 - carb0xylate. 3%. 05GW©. The title compound was prepared from benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - l - carboxylate ( Intermediate Al ) and { 4 - [ ( diethylamino ) carbony1 ] phenyl } - boronic acid using the conditions described in genera1 method A1. Yie1d 10.3 mg ( 42% ) . Ana1ytical HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) ca1cd for C32H35N2O5 528.2624 , found 528.2628. EXAMPLE A22 Benzyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperidin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0xylate. ﬂi“@©p3©. The title compound was prepared from benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - 1 - carboxylate ( Intermediate A1 ) and { 4 - [ ( 4 - methylpiperidin - 1 - yl ) carbonyl ] - pheny1 } boronic acid using the conditions described in genera1 method A1. Yield 13.3 mg ( 52% ) . Analytical HPLC : purity 100% ( System C ) ; HRESIMS ( ESI + ) calcd for C34H3gN205 554.278l , found 554.2800. 10. l5. 20. 25. WO 2009 / 150144 83 PCT / EP2009 / 057074. EXAMPLE A23 Benzyl 4 - ( 6 - { 4 - [ ( 4 - 0xopiperidin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0dioxin - 2 - yl ) - . piperidine - 1 - carb0xylate. .20 * 1.@©W©. The title compound was prepared from benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - l - carboxylate ( Intermediate Al ) and { 4 - [ ( 4 - oxopiperidin - l - yl ) carbonyl ] - pheny1 } boronic acid using the conditions described in genera1 method A1. Yie1d 2.9 mg ( 11% ) . Analytical HPLC : purity 90% ( System C ) ; HRESIMS ( ESI + ) calcd for C33H34N2O6 554.2417 , found 554.2395. EXAMPLE A24 Benzyl 4 - { 6 - [ 5 - ( methylsulf0nyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benz0dioxin - 2 - yl } piperidine - 1 - . carboxylate. A suspension of 2 - bromo - 5 - ( methy1sulfony1 ) pyridine ( 25 mg , 0.11 mmo1 ) , 5 , 5 , 5 ' , 5 ' - tetramethyl - 2 , 2 ' - bi - 1 , 3 , 2 - dioxaborinane ( 36 mg , 0.16 mmol ) , KOAc ( 31 mg , 0.32 mmol ) and PdCl2dppf - DCM ( 4 mg , 0.005 mmol ) in DME ( 2 mL ) was heated at 120 0C for 20 min in a microane reactor. To the mixture were added benzy1 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxylate ( Intermediate A1 ; 46 mg , 0.11 mmol ) , NaHCO3 ( 18 mg , 0.21 mmol ) , Pd ( PPh3 ) 4 ( 1 mg , 0.001 mmol ) and water ( 0.5 mL ) . The resulting mixture was heated at 120 0C for 800 sec in a microane reactor and then concentrated. The residue was puriﬁed by gradient ﬂash chromatography on silica ( DCM / heptane 3 : 1 —> DCM / EtOAc 9 : 1 ) . Yie1d 11 mg ( 20% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C27H2gN2O6S 508.1668 , found 508.1676. lO. l5. 20. WO 2009 / 150144 PCT / EP2009 / 057074. _ 84 _ EXAMPLE A25 1 - ( 2 - Fur0yl ) - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine / O 0 o 053 , g. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and 2 - furoic acid using the conditions described in general method C2. Yield 3.2 mg ( 17% ) . Analytical HPLC : purity 97% ( System C ) ; HRESIMS ( ESI + ) ca1cd for C25H25NO6S 467.1403 , found 467.1409. EXAMPLE A26 1 - [ ( 4 - Flu0r0phen0xy ) acetyl ] - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine. O. \ / / O O ‘ ( O O. ppd. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and ( 4 - ﬂuorophenoxy ) acetic acid using the conditions described in genera1 method C2. Yie1d 5.2 mg ( 25% ) . Ana1ytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESI + ) calcd for C2gH2gFNO6S 525.1621 , found 525.1622. EXAMPLE A27 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - 1 - ( 1H - pyrr0l - 2 - yl - . carb0nyl ) piperidine. 10. 15. 20. WO 2009 / 150144 85 PCT / EP2009 / 057074. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 1H - pyrrole - 2 - carboxylic acid using the conditions described in general method C2. Yie1d 2.9 mg ( 16% ) . Analytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESI + ) calcd for C25H26N2O5S 466.1562 , found 466.1567. EXAMPLE A28 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - 1 - ( 1H - tetraz0l - 1 - ylacetyl ) - piperidine. O. \ / / f O O \.\. : \O OO N WW. 0 N : N The tit1e compound was prepared from 4 - { 6 - [ 4 - ( methy1su1fony1 ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 1H - tetrazol - 1 - ylacetic acid using the conditions described in genera1 method C2. Yie1d 1.5 mg ( 8% ) . Ana1ytica1 HPLC : purity 96% ( System C ) ; HRESIMS ( ESI + ) calcd for C23H25N5O5S 483.1576 , found 483.1585. EXAMPLE A29 2 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - carh0nyl ] pyridine. O. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and pyridine - 2 - carboxylic acid using the conditions described in general method C2. Yie1d 4.7 mg ( 25% ) . Analytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESI + ) calcd for C26H26N2O5S 478.1562 , found 478.1564. 10. 15. 20. WO 2009 / 150144 8 6 PCT / EP2009 / 057074. EXAMPLE A30 4 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - carb0nyl ] pyridine \SUO O O okO / N N \ I. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and isonicotinic acid using the conditions described in general method C2. Yield 4.1 mg ( 21% ) . Analytical HPLC : purity 98% ( System C ) ; HRESIMS ( ESI + ) ca1cd for C26H26N2O5S 478.1562 , found 478.1568. EXAMPLE A31 2 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - . \SUO II o 0 \.\. : \O N O / 53p N o. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzo - . carb0nyl ] pyrazine. dioxin - 2 - yl } piperidine ( Intermediate A4 ) and pyrazine - 2 - carboxylic acid using the conditions described in general method C2. Yie1d 3.2 mg ( 17% ) . Analytica1 HPLC : purity 98% ( System C ) ; HRESIMS ( ESI + ) calcd for C25H25N3O5S 479.1515 , found 479.1516. EXAMPLE A32 6 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - . \SUO. / / . 0 0. ‘ ( \O OkOﬁ‘ ) : : [ / N N J N O. carb0ny1 ] quin0xa1ine. 10. 15. 20. WO 2009 / 150144 87 PCT / EP2009 / 057074. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and quinoxaline - 6 - carboxylic acid using the conditions described in genera1 method C2. Yie1d 4.5 mg ( 21% ) . Analytica1 HPLC : purity. 98% ( System C ) ; HRESIMS ( ESP ) calcd for C29H27N3O5S 529.1671 , found 529.1665. EXAMPLE A33 1 - ( 4 - Is0pr0p0xybenz0yl ) - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - . The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzo - . piperidine. dioxin - 2 - yl } piperidine ( Intermediate A4 ) and 4 - isopropoxybenzoic acid using the conditions described in genera1 method C2. Yie1d 4.9 mg ( 23% ) . Analytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) ca1cd for C30H33NO6S 535.2029 , found 535.2039. EXAMPLE A34 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - 1 - ( 2 - naphth0yl ) piperidine. The tit1e compound was prepared from 4 - { 6 - [ 4 - ( methy1su1fony1 ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 2 - naphthoic acid using the conditions described in general method C2. Yield 5.0 mg ( 24% ) . Ana1ytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) ca1cd for C31H29NO5S 527.1766 , found 527.1771. 10. 15. 20. WO 2009 / 150144 8 8 PCT / EP2009 / 057074. EXAMPLE A35 1 - Benz0yl - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine. The title compound was prepared from 4— { 6 - [ 4— ( methylsulfonyl ) phenyl ] —4H—1 , 3—benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and benzoic acid using the conditions described in general method C2. Yield 4.4 mg ( 23% ) . Analytical HPLC : purity 98% ( System C ) ; HRESIMS ( ESP ) ca1cd for C27H27NO5S 477.1610 , found 477.1615. EXAMPLE A36 5 - Methyl - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) carbonyl ] phen0l O \i O 0 O ‘ ( * OYg N. 0 OH The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 2 - hydroxy - 4 - methylbenzoic acid using the conditions described in genera1 method C2. Yie1d 0.7 mg ( 3% ) . Ana1ytica1 HPLC : purity 90% ( System C ) ; HRESIMS ( ESP ) calcd for C2gH29NO6S 507.1716 , found 507.1716. EXAMPLE A37. 5 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - carb0nyl ] - 2 - phen0xypyridine. o \ / / f 00. \.\.\ / \O. o / |O N \N o. 10. l5. 20. WO 2009 / 150144 89 PCT / EP2009 / 057074. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 6 - phenoxynicotinic acid using the conditions described in genera1 method C2. Yield 4.7 mg ( 21% ) . Ana1ytica1 HPLC : purity 90% ( System C ) ; HRESIMS ( ESP ) ca1cd for C32H3oN2O6S 570.1825 , found 570.1826. EXAMPLE A3 8 1 - ( Diphenylacetyl ) - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - . piperidine. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and diphenylacetic acid using the conditions described in general method C2. Yie1d 4.5 mg ( 20% ) . Ana1ytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) ca1cd for C34H33NO5S 567.2079 , found 567.2088. EXAMPLE A39 5 - Is0pr0p0xy - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) carbonyl ] pyridine. \ / O f o O ‘\ ( O OOYfTOY N \ I N o. The title compound was prepared from 4— { 6 - [ 4— ( methylsulfonyl ) phenyl ] —4H—1 , 3—benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and 5 - isopropoxypyridine - 2 - carboxy1ic acid using the conditions described in genera1 method C2. Yield 1.9 mg ( 9% ) . Analytical HPLC : purity 96% ( System C ) ; HRESIMS ( ESP ) calcd for C29H32N2O6S 536.1981 , found 536.1990. 10. 15. 20. WO 2009 / 150144 90 PCT / EP2009 / 057074. EXAMPLE A40 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - 1 - ( 3 , 3 , 3 - triﬂu0r0 - pr0pan0yl ) piperidine. \SUO / / O O ‘ ( \O O N. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzo - . F. F O F. dioxin - 2 - yl } piperidine ( Intermediate A4 ) and 3 , 3 , 3 - triﬂuoropropanoic acid using the conditions described in general method C2. Yie1d 3.6 mg ( 19% ) . Analytica1 HPLC : purity 94% ( System C ) ; HRESIMS ( ESP ) calcd for C23H24F3NO5S 483.1327 , found 483.1332. EXAMPLE A41 2 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - carb0nyl ] pyridin - 3 - 0l. f O O \.\. : \O o N / I N \ O OH. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 3 - hydroxypyridine - 2 - carboxylic acid using the conditions described in genera1 method C2. Yield 2.5 mg ( 13% ) . Ana1ytical HPLC : purity 97% ( system C ) , LRESIMS m / z = 495 ( M + H ) + . EXAMPLE A42 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - 1 - pr0pionylpiperidine. O. 10. 15. 20. WO 2009 / 150144 _ 91 _ PCT / EP2009 / 057074. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and propionic acid using the conditions described in genera1 method C2. Yie1d 5.1 mg ( 30% ) . Ana1ytical HPLC : purity 98% ( System C ) ; HRESIMS ( ESP ) ca1cd for C23H27NO5S 429.1610 , found 429.1614. EXAMPLE A43 1 - [ ( 7 - Meth0xy - 1 - benz0furan - 2 - yl ) carb0nyl ] - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - . benz0dioxin - 2 - yl } piperidine. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 7 - methoxy - 1 - benzofuran - 2 - carboxylic acid using the conditions described in genera1 method C2. Yield 5.1 mg ( 23% ) . Analytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) calcd for C30H29NO7S 547.1665 , found 547.1674. EXAMPLE A44 Dimethyl { 3 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) carbonyl ] phenyl } amine. O. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and 3 - ( dimethy1amino ) benzoic acid using the conditions described in genera1 method C2. Yie1d 4.9 mg ( 24% ) . Analytica1 HPLC : purity 98% ( System C ) ; HRESIMS ( ESP ) calcd for C29H32N2O5S 520.2032 , found 520.2047. 10. 15. 20. WO 2009 / 150144 _ 92 _ PCT / EP2009 / 057074. EXAMPLE A45 2 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - yl ) - carb0nyl ] phen0l. 0 OH The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ) and salicylic acid using the conditions described in genera1 method C2. Yie1d 3.6 mg ( 18% ) . Ana1ytical HPLC : purity 95% ( System C ) ; HRESIMS ( ESP ) ca1cd for C27H27NO6S 493.1559 , found 493.1560. EXAMPLE A46 2 - ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) - 2 - 0x0 - 1 - . phenylethan0ne. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and oxo ( phenyl ) acetic acid using the conditions described in general method C2. Yield 3.8 mg ( 19% ) . Ana1ytica1 HPLC : purity 98% ( System C ) ; HRESIMS ( ESP ) ca1cd for C2gH27NO6S 505.1559 , found 505.1564. EXAMPLE A47 1 - Methyl - 4 - [ 3 - ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) - 3 - 0x0pr0pyl ] piperazine. O. 10. 15. 20. 25. WO 2009 / 150144 93 PCT / EP2009 / 057074. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 3 - ( 4 - methy1piperazin - 1 - yl ) propanoic acid using the conditions described in genera1 method C2. Yie1d 3.7 mg ( 18% ) . Analytical HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) calcd for C2gH37N3O5S 527.2454 , found 527.2465. EXAMPLE A48 1 - Methyl - 4 - { 4 - [ ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0dioxin - 2 - yl } piperidin - 1 - yl ) carbonyl ] phenyl } piperazine. / O. \S / o” 0 / O N “96 , 69 N O The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 4 - ( 4 - methylpiperazin - 1 - yl ) benzoic acid using the conditions described in genera1 method C2. Yie1d 4.3 mg ( 19% ) . Ana1ytica1. HPLC : purity 97% ( System C ) ; HRESIMS ( ESP ) calcd for C32H37N3O5S 575.2454 , found 575.2470. EXAMPLE A49 1 - ( Meth0xyacetyl ) - 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - piperidine. O \ / , 0 O \.\. : \O 000 N\n / \O / O. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and methoxyacetic acid using the conditions described in general method C2. Yield 4.0 mg ( 22% ) . Ana1ytica1 HPLC : purity 98% ( System C ) ; HRESIMS ( ESP ) ca1cd for C23H27NO6S 445.1559 , found 445.1560. 10. 15. 20. WO 2009 / 150144 _ 94 _ PCT / EP2009 / 057074. EXAMPLE A50 3 , 5 - Diﬂu0r0 - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0dioxin - 2 - yl } piperidin - 1 - yl ) carbonyl ] pyridine. O \.\. : \O o N / |F N \ O F. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 3 , 5 - diﬂuoropyridine - 2 - carboxylic acid using the conditions described in genera1 method C2. Yield 4.7 mg ( 23% ) . Ana1ytica1 HPLC : purity 99% ( System C ) ; HRESIMS ( ESP ) calcd for C26H24F2N2O5S 514.1374 , found 514.1372. EXAMPLE A51 4 - { 4 - [ ( 4 - { 6 - [ 4 - ( Methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) - . carb0nyl ] benzyl } m0rph0line. 0 O * QY©FW. The title compound was prepared from 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ) and 4 - ( morpholin - 4 - ylmethyl ) benzoic acid using the conditions described in genera1 method C2. Yield 4.3 mg ( 28% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESP ) ca1cd for C32H36N2O6S 576.2294 , found 576.2296. 10. 15. 20. WO 2009 / 150144 95 PCT / EP2009 / 057074. EXAMPLE A52 6 - Br0m0 - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidin - 1 - yl ) carbonyl ] pyridin - 3 - 0l. To a Vial containing 6 - bromo - 3 - hydroxypyridine - 2 - carboxylic acid ( Intermediate A5 ; 61 mg , 0.28 mmol ) was added a so1ution of 4 - { 6 - [ 4 - ( methylsulfony1 ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine ( Intermediate A4 ; 95 mg , 0.25 mmol ) in THF ( 5 mL ) and triethylamine ( 140 uL , 1.0 mmol ) followed by HOBT ( 69 mg , 0.51 mmol ) and EDC ( 97 mg , 0.51 mmol ) . The resu1ting mixture was stirred oVernight. The solVent was remoVed under reduced pressure and the residue was puriﬁed by preparatiVe HPLC ( System D ) . Yield 20 mg ( 14% ) . Analytica1 HPLC : purity 91% ( System A and B ) ; HRESIMS ( ESP ) ca1cd for C26H25BrN2O6S 572.0618 , found 572.0613. EXAMPLE A53 Benzyl 4 - ( 6 - { 4 - [ ( methylsulf0nyl ) amin0 ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - . carboxylate. H. O\\ , N O O O N O Y. O A suspension of benzyl 4— ( 6—bromo—4H—1 , 3—benzodioxin—2—yl ) piperidine - 1 - carboxy1ate ( Intermediate A1 ; 10 mg , 0.023 mmol ) , 4 - ( methanesu1fonylamino ) phenylboronic acid ( 5.4 mg , 0.025 mmol ) , Pd ( OAc ) 2 ( 2 mg , 0.009 mmol ) , K2CO3 ( 8.0 mg , 0.058 mmol ) in MeCN ( 2 mL ) and water ( 0.5 mL ) was heated at 90 0C for 1.5 h. The mixture was ﬁ1tered and then puriﬁed by preparatiVe HPLC ( System D ) . Yie1d 3.0 mg ( 25% ) . Analytical GC : purity 99% ; HRESIMS ( ESP ) calcd for C28H30N206S 522.1825 , found 522.1824. 10. 15. 20. 25. WO 2009 / 150144 96 PCT / EP2009 / 057074. EXAMPLE A54 Benzyl 4 - [ 6 - ( 4 - { [ ( 2 - m0rph0lin - 4 - ylethyl ) amin0 ] sulf0nyl } phenyl ) - 4H - 1 , 3 - benz0dioxin - . 2 - yl ] piperidine - 1 - carb0xylate triﬂu0r0acetate. WVo napp. A suspension of benzy1 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A1 ; 100 mg , 0.23 mmol ) , 5 , 5 , 5 ' , 5 ' - tetramethyl - 2 , 2 ' - bi - 1 , 3 , 2 - dioxaborinane ( 78 mg , 0.35 mmol ) , KOAc ( 68 mg , 0.69 mmol ) and PdCl2dppf - DCM ( 10 mg , 0.012 mmo1 ) in DME ( 3 mL ) was heated at 90 0C for 1 h. To the mixture was then added 4 - iodo - . J. - CF3CO2H. N - ( 2 - morpholin - 4 - yl - ethyl ) benzene - sulfonamide ( 91 mg , 0.23 mmol ) followed by NaHCO3 ( 39 mg , 0.46 mmol ) , Pd ( PPh3 ) 4 ( 27 mg , 0.023 mmol ) and water ( 1 mL ) . The resu1ting mixture was heated at 90 OC oVemight and then concentrated. The residue was puriﬁed by preparatiVe HPLC ( System D ) . Yield 4.2 mg ( 2% ) . Analytical HPLC : purity 99% ( system A and B ) , LRESIMS ( ESP ) m / z = 622 ( M + H ) + . EXAMPLE A55 Benzyl 4 - { 6 - [ 4 - ( methylsulf0nyl ) - 2 - nitr0phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. O. 0 thWQ. 0 A suspension of benzyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A1 ; 2.0 g , 0.0046 mol ) , 5 , 5 , 5‘ , 5 ' - tetramethyl - 2 , 2 ' - bi - 1 , 3 , 2 - dioxaborinane ( 1.6 g , 0.0069 mo1 ) , potassium acetate ( 1.4 g , 0.014 mo1 ) and PdC12dppf - DCM ( 190 mg , 0.23 mmo1 ) in DME ( 20 mL ) was heated at 90 0C for 1 h. To the mixture were then added NaHCO3 ( 0.77 g , 0.0092 mol ) , Pd ( PPh3 ) 4 ( 53 mg , 0.046 mmol ) , 2—bromo—5— methy1sulfony1nitrobenzene ( 1.29 g , 0.0046 mo1 ) and water ( 5 mL ) . The mixture was heated at 90 0C for 15 h. The solVents were remoVed under reduced pressure and the. residue was partitioned between water ( 50 mL ) and ch1oroform ( 3 x 75 mL ) . The organic. 10. 15. 20. 25. WO 2009 / 150144 97 PCT / EP2009 / 057074. layers were combined and concentrated. The residue was puriﬁed by ﬂash chromatography on silica using heptane / EtOAc ( 1 : 1 ) . Yield 1.89 g ( 74% ) . Analytical HPLC : purity 98%. ( System A and B ) ; HRESIMS ( ESP ) calcd for C28H2gN2OgS 552.1566 , found 552.1579. EXAMPLE A56 Benzyl 4 - { 6 - [ 2 - amin0 - 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - . ‘€53 Q. A suspension of benzyl 4 - { 6 - [ 4 - ( methylsulfonyl ) - 2 - nitrophenyl ] - 4 - H 1 3 , - benzodioxin - 2 - . 1 - carb0xylate. y1 } p1per1d1ne1 - carboxy1ate ( Examp1e A55 ; 675 mg , 1.22 mmol ) and indium powder ( 560 mg , 4.89 mmol ) in saturated NH4Cl ( 8 mL ) and MeOH ( 10 mL ) was heated in a sealed tube at 85 °C for 15 h. The mixture was ﬁltered and concentrated. The residue was partitioned between water ( 75 mL ) and ch1oroform ( 2 x 100 mL ) and the organic 1ayers were combined and concentrated. Puriﬁcation by ﬂash chromatography on si1ica using EtOAc / DCM ( 1 : 3 ) gaVe an off - white solid. Yie1d 515 mg ( 81% ) . Ana1ytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESP ) ca1cd for C2gH30N2O6S 522.1825 , found 522.1825. EXAMPLE A57 Benzyl 4 - { 6 - [ 2 - { [ 2 - ( dimethylamin0 ) ethyl ] amin0 } - 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - . benz0di0xin - 2 - yl } piperidine - 1 - c - arb0xylate triﬂu0r0acetate. w.“. C - F3200H. A suspension of benzyl 4 - { 6 - [ 2 - iodo - 4 - ( methy1su1fonyl ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - 1 - carboxylate ( Intermediate A6 ; 50 mg , 0.079 mmol ) , N , N - dimethylethane - 1 , 2 - diamine ( 8 mg , 0.095 mmo1 ) , Pd2 ( dba ) 3 ( 2 mg , 0.002 mmo1 ) , Xantphos ( 5 mg , 0.008. mmol ) and potassium tert - butoxide ( 12 mg , 0.11 mmol ) in toluene ( 4 mL ) was heated at. 10. 15. 20. WO 2009 / 150144 98 PCT / EP2009 / 057074. 110 OC oVemight. The reaction mixture was concentrated and the residue was puriﬁed by preparatiVe HPLC ( System D ) . Yield 12 mg ( 21% ) . Analytical HPLC : purity 90% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C32H39N3O6S 593.2560 , found 593.2572. EXAMPLE A5 8 Benzyl 4 - { 6 - [ 2 - { [ 2 - ( is0pr0pylamin0 ) ethyl ] amin0 } - 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - . benz0di0Xin - 2 - yl } piperidine - 1 - carb0Xylate triﬂu0roacetate. \ / / . ooWo. . N. - CF3CO2H o. The title compound was prepared from benzyl 4 - { 6 - [ 2 - iodo - 4 - ( methylsulfony1 ) pheny1 ] - . 4H - l , 3 - benzodioxin - 2 - yl } piperidine - 1 - carboXylate ( Intermediate A6 ; 50 mg , 0.079 mmol ) . and N - isopropy1ethane - 1 , 2 - diamine ( 10 mg , 0.095 mmo1 ) using the conditions described. for EXamp1e A57. Yield 6 mg ( l1% ) . Analytical HPLC : purity 98% ( System A and B ) ; . HRESIMS ( ESI + ) calcd for C33H41N3O6S 607.2716 , found 607.2728. EXAMPLE A59 Benzyl 4 - ( 6 - { 4 - ( methylsulf0nyl ) - 2 - [ ( 2 - m0rpholin - 4 - ylethyl ) amin0 ] phenyl } - 4H - 1 , 3 - . benz0di0Xin - 2 - yl ) piperidine - 1 - carb0xylate triﬂu0roacetate. w FNN. 0 * oWo. - CF3CO2H. o The title compound was prepared from benzyl 4 - { 6 - [ 2 - iodo - 4 - ( methylsulfonyl ) phenyl ] - 4H - l , 3 - benzodioxin - 2 - yl } piperidine - 1 - carboXylate ( Intermediate A6 ; 50 mg , 0.079 mmol ) and ( 2 - morpho1in - 4 - y1ethyl ) amine ( 12 mg , 0.095 mmo1 ) using the conditions described for EXample A57. Yield 19 mg ( 32% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C34H41N3O7S 635.2665 , found 635.2679. 10. 15. 20. WO 2009 / 150144 99 PCT / EP2009 / 057074. EXAMPLE A60 Benzyl 4 - { 6 - [ 2 - [ 2 - ( dimethylamin0 ) eth0xy ] - 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - . benz0dioxin - 2 - yl } piperidine - 1 - carboxylate triﬂuoroacetate. \ , , 0 ff. , , S O. O O. ‘ ( \o. “3 Q. N O T O. - CF3CO2H. A suspension of benzy1 4 - { 6 - [ 2 - iodo - 4 - ( methylsu1fonyl ) pheny1 ] - 4H - 1 , 3 - benzodioxin - 2 - y1 } piperidine - 1 - carboxy1ate ( Intermediate A6 ; 50 mg , 0.079 mmo1 ) , CuI ( 3 mg , 0.016 mmol ) , l , 10 - phenanthroline monohydrate ( 6 mg , 0.032 mmol ) and Cs2CO3 ( 64 mg , 0.20 mmol ) in N , N - dimethylethanolamine ( 1 mL ) was heated at 110 0C for lS h. The reaction mixture was puriﬁed by preparatiVe HPLC ( System D ) . Yie1d 7 mg ( 13% ) . Analytica1 HPLC : purity 97% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C32H3gN2O7S 594.2400 , found 594.2411. EXAMPLE A61 N , N - Diethyl - 2 - ( 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidin - 1 - . yl ) acetamide triﬂu0r0acetate. \ 00 f O ‘ ( o O ) \ ( j O N\ ) J\N / \ K. - CF3CO2H. A suspension of 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ( Intermediate A4 ; 10 mg , 0.054 mmo1 ) , 2 - ch1oro - N , N - diethy1acetamide ( 9 mg , 0.059 mmo1 ) and K2CO3 ( 30 mg , 0.22 mmo1 ) in MeCN ( 2 mL ) was heated at 90 OC oVemight. The reaction mixture was ﬁltered and puriﬁed by preparatiVe HPLC ( System D ) . Yield 5.6 mg ( 17% ) . Ana1ytica1 HPLC : purity 96% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C26H34N2O5S 486.2188 , found 486.2204. 10. 15. 20. WO 2009 / 150144 _ 100 _ PCT / EP2009 / 057074. EXAMPLE A62 1 - Benz0yl - 4 - { ( 2R * ) - 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine. O. The racemic 1—benzoyl—4— { 6 - [ 4— ( methylsu1fonyl ) phenyl ] —4H— 1 , 3 —benzodioxin—2—y1 } — piperidine ( Examp1e A35 ; 60 mg , 0.13 mmo1 ) was separated by Chira1 Technologies Europe using the following conditions : Column : CHIRALPAK® IA 5 um , 250 x 21 mm ; Mobi1e phase : n - heptane / ethano1 / diethy1amine 40 / 60 / 0.1 ( v / v / v ) ; Flow rate : 15 mL / min ; Detection : UV 220 nm ; Temperature : 25 OC. The retention times of the ﬁrst eluting enantiomer ( the title compound ) and the second eluting enantiomer ( Example A63 ) were 26.8 min and 32.4 min , respectiVely. Yie1d 23 mg ( 38% ) . Analytica1 HPLC : purity 97% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H27NO5S 477.1610 , found 477.1613. EXAMPLE A63 1 - benz0yl - 4 - { ( 2S * ) - 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine O \ / / . f O ‘ ( o Oi - . The title compound was prepared from 1 - benzoyl - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - . w. 0. 1 , 3—benzodioxin—2—yl } piperidine ( Examp1e A35 ) in accordance with the method described for Example A62. Yield 29 mg ( 48% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H27NO5S 477.1610 , found 477.1634. EXAMPLE A64 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( methylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0 - dioxin - 2 - yl ) piperidine - 1 - carboxylate. 10. 15. 20. WO 2009 / 150144 _ 101 _ PCT / EP2009 / 057074. \NH. mﬂ 0 mon. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropyl ) methoxy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - y1 ] benzoic acid ( Intermediate A10 ) and methylamine using the conditions described in genera1 method D. Yie1d 1.3 mg ( 6% ) . Analytica1 HPLC : purity 95% ( System A ) ; HRESIMS ( ESP ) calcd for C27H32N2O5 464.231 l , found 464.2303. EXAMPLE A65 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( ethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0 - . dioxin - 2 - yl ) piperidine - 1 - carb0xylate. Aw‘. 0 m , &. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - y1 ] benzoic acid ( Intermediate A10 ) and ethylamine using the conditions described in general method D. Yield 4.4 mg ( 18% ) . Analytical HPLC : purity 94% ( System A ) ; HRESIMS ( ESP ) calcd for C2gH34N2O5 478.2468 , found 478.2458. EXAMPLE A66 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( ally ] amino ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0 - dioxin - 2 - yl ) piperidine - 1 - carb0xylate. 0. MM kin x N\ [ C ] ) / O. 10. 15. 20. 25. WO 2009 / 150144 _ 102 _ PCT / EP2009 / 057074. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } - piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzoic acid ( Intermediate Al0 ) and a1ly1amine using the conditions described in genera1 method D. Yie1d 0.6 mg ( 2% ) . Analytica1 HPLC : purity 98% ( System A ) ; HRESIMS ( ESI + ) calcd for C29H34N2O5 490.2468 , found 490.2469. EXAMPLE A67 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( cycl0propylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - . benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. A o 0 mM. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } piperidin—4—yl ) - 4H—1 , 3—benzodioxin - 6 - y1 ] benzoic acid ( Intermediate A10 ) and cyc1opropy1amine using the conditions described in genera1 method D. Yie1d 1.9 mg ( 8% ) . Analytica1 HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C29H34N2O5 490.2468 , found 490.2459. EXAMPLE A68 ( 1 - Methylcycl0pr0pyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydr0xyethyl ) amino ] carbonyl } phenyl ) - 4H - . 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate 0 WWW O 0 DO x N\ [ O1 / O. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - y1 ] benzoic acid ( Intermediate A10 ) and ethano1amine using the conditions described in genera1 method D. Yie1d 0.6 mg ( 2% ) . Analytical HPLC : purity 99% ( System A ) ; HRESIMS ( ESP ) calcd for C2gH34N2O6 494.2417 , found 494.2395. 10. 15. 20. WO 2009 / 150144 _ 103 _ PCT / EP2009 / 057074. EXAMPLE A69 ( 1 - Methylcycl0pr0pyl ) methyl 4 - [ 6 - ( 4 - { [ ( 3 - hydr0xypr0pyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carboxylate. O. W 0 AAA. 0 The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 3 - amino - 1 - propano1 using the conditions described in genera1 method D. Yie1d 1.2 mg ( 5% ) . Analytica1 HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C29H36N2O6 508.2573 , found 508.2561. EXAMPLE A70 ( 1 - Methylcycl0pr0pyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - meth0xyethyl ) amin0 ] carb0nyl } phenyl ) - 4H - . 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. / O\ / \N ‘ N\C [ ) ] / O. The title compound was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropy1 ) methoxy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 2 - methoxyethylamine using the conditions described in general method D. Yie1d 1.2 mg ( 5% ) . Analytical HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C29H36N2O6 508.2573 , found 508.2575. EXAMPLE A71 ( 1 - Methylcycl0pr0pyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydr0xy - 1 , 1 - dimethylethyl ) amin0 ] - carb0nyl } phenyl ) - 4H - l , 3 - benz0di0xin - 2 - yl ] piperidine - l - carboxylate. 10. 15. 20. WO 2009 / 150144 _ 104 _ PCT / EP2009 / 057074. mm 0 0 ma. The title compound Was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropyl ) methoXy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 2 - amino - 2 - methyl - 1 - propanol using the conditions described in general method D. Yield 2.0 mg ( 8% ) . Analytical HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C30H3gN206 522.273 , found 522.2736. EXAMPLE A72 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( 3 - hydr0xyazetidin - 1 - yl ) carb0nyl ] phenyl } - 4H - . 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. O. “““as. o. T. o The title compound Was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methy1cyc10propy1 ) methoXy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 3 - hydroXazctidinc hydrochloridc using thc conditions describcd in gcncral mcthod D. Yicld 0.8 mg ( 3% ) . Analytical HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C29H34N2O6 506.2417 , found 506.2398. EXAMPLE A73 ( 1 - Methylcycl0pr0pyl ) methyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] phenyl } - 4H - . 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. / o& ( %© x w. 10. 15. 20. 25. WO 2009 / 150144 _ 105 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropyl ) methoXy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 1 - methylpiperazine using the conditions described in genera1 method D. Yie1d 1.5 mg ( 6% ) . Analytical HPLC : purity 99% ( System A ) ; HRESIMS ( ESP ) ca1cd for C31H39N3O5 533.2890 , found 533.2896. EXAMPLE A74 ( 1 - Methylcycl0pr0pyl ) methyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amin0 } carbonyl ) phenyl ] - 4H - . 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - carb0xylate. / \ O ( ( MWO D . xO NTox. The title compound Was prepared from 4 - [ 2 - ( 1 - { [ ( 1 - methylcyclopropyl ) methoXy ] - carbonyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzoic acid ( Intermediate A10 ) and 2 - furan - 2 - yl - ethylamine using the conditions described in general method D. Yield 1.2 mg ( 4% ) . Analytical HPLC : purity 98% ( System A ) ; HRESIMS ( ESI + ) Calcd for C32H36N2O6 544.2573 , found 544.2568. EXAMPLE A75 tert - Butyl 4 - { 6 - [ 4 - ( methylsulf0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. \ 00 O O \.\.\ / \O N O T 7< O. The title compound Was prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioXin - 2 - yl ) - piperidine - 1 - carboxylate ( Intermediate A11 ; 20 mg , 0.05 mmol ) , and [ 4 - ( methylsulfonyl ) - phenyl ] boronic acid ( 11 mg , 0.055 mmo1 ) using the conditions described in genera1 method A2. Yield 7 mg ( 42% ) . Analytical HPLC : purity 90% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C25H31NO6S 473.1872 , found 473.1872. 10. 15. 20. WO 2009 / 150144 _ 106 _ PCT / EP2009 / 057074. EXAMPLE A76 tert - Butyl 4 - { 6 - [ 4 - ( amin0carb0ny ] ) phenyl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. O OkONlVOK. The title compound Was prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioXin - 2 - yl ) - piperidine - 1 - carboXylate ( Intermediate A11 ; 20 mg , 0.05 mmol ) , and [ 4 - ( aminocarbonyl ) - phenyl ] boronic acid ( 9 mg , 0.055 mmo1 ) using the conditions described in genera1 method A2. Yield 6.6 mg ( 30% ) . Analytical HPLC : purity 94% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C25H30N2O5 438.2155 , found 438.2152. EXAMPLE A77 tert - Butyl 4 - ( 6 - { 4 - [ ( dimethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0Xin - 2 - yl ) - . piperidine - 1 - carb0Xylate. T %% W. The title compound Was prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioXin - 2 - yl ) - piperidine - 1 - carboxylate ( Intermediate A11 ; 20 mg , 0.05 mmol ) and { 4 - [ ( dimethylamino ) - carbony1 ] pheny1 } boronic acid ( 11 mg , 0.055 mmo1 ) using the conditions described in general method A2. Yield 10.5 mg ( 46% ) . Analytical HPLC : purity 90% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C27H34N2O5 466.2468 , found 466.2469. 10. 15. 20. 25. WO 2009 / 150144 _ 107 _ PCT / EP2009 / 057074. EXAMPLE A78 tert - Butyl 4 - { 6 - [ 4 - ( m0rph0lin - 4 - y ] carb0nyl ) phenyl ] - 4H - 1 , 3 - benz0di0Xin - 2 - yl } - . piperidine - 1 - carb0Xylate. o& ( %© w. The title compound Was prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioXin - 2 - yl ) - piperidine - 1 - carboXylate ( Intermediate A11 ; 20 mg , 0.05 mmol ) and [ 4 - ( morpholin - 4 - ylcarbony1 ) pheny1 ] boronic acid ( 13 mg , 0.055 mmo1 ) using the conditions described in general method A2. Yield 8.5 mg ( 34% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H36N2O6 508.2573 , found 508.2573. EXAMPLE A79 2 - ( { 4 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0Xin - 6 - yl ] phenyl } sulf0nyl ) ethan0l. O I. HO\ / \ / S / D okO p N O. A mixture of 2 - [ ( 4 - bromophenyl ) sulfonyl ] ethanol ( prepared using similar conditions as described in Verhart , C. G. J et al. , Rec. TraV. Chim. Pays—Bas. 1988 , 107 ( 11 ) , 621—626 ) ( 66 mg , 0.25 mmol ) , 5 , 5 , 5 ' , 5 ' - tetramethy1 - 2 , 2 ' - bi - 1 , 3 , 2 - dioXaborinane ( 84 mg , 0.37 mmol ) , K2CO3 ( 73 mg , 0.75 mmol ) , PdC12dppf - DCM ( 10 mg , 0.01 mmo1 ) and DME ( 2 mL ) Was heated at 120 0C for 20 min in a microWaVe reactor. To the same tube Were then added NaHCO3 ( 42 mg , 0.5 mmol ) , Pd ( PPh3 ) 4 ( 9 mg , 0.01 mmol ) , 1 - benzoyl - 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine ( Intermediate A12 ; 100 mg , 0.25 mmol ) and Water ( 0.5 mL ) . The reaction mixture Was heated at 120 0C for 800 sec in a microWave reactor and then ﬁltered through Celite. The f11trate Was concentrated and the crude material Was purified by preparatiVe HPLC ( System E ) . Yield 30 mg ( 24% ) . Analytical HPLC : purity 95% ( System A and B ) ; HRESIMS ( ESP ) ca1cd for C28H29NO6S 507.1716 , found 507.1733. 10. 15. 20. 25. WO 2009 / 150144 _ 108 _ PCT / EP2009 / 057074. EXAMPLE A80 2 - ( { 4 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] phenyl } sulf0nyl ) - . ethanamine. O. H2N\ / \ / S” O ‘ ( O 0 o. A mixture of 1 - benzoyl - 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine ( Intermediate A12 ; 100 mg , 0.25 mmol ) , 5 , 5 , 5 ' , 5 ' - tetramethyl - 2 , 2 ' - bi - 1 , 3 , 2 - dioxaborinane ( 84 mg , 0.37 mmol ) , potassium acetate ( 73 mg , 0.75 mmol ) , PdCl2dpprCM ( 10 mg , 0.01 mmol ) and DME ( 2 mL ) Was heated at 120 0C for 20 min in a microane reactor. To the same tube Were added NaHCO3 ( 42 mg , 0.5 mmo1 ) , Pd ( PPh3 ) 4 ( 9.0 mg , 0.01 mmo1 ) , 2 - [ ( 4 - bromophenyl ) sulfonyl ] ethanamine hydrochloride ( Intermediate A13 ; 75 mg , 0.25 mmol ) and Water ( 0.5 mL ) . The reaction mixture Was heated at 120 °C for 800 sec in a microWaVe reactor and then f11tered through Celite. The f11trate Was concentrated and the residue Was purif1ed by preparatiVe HPLC ( System E ) . Yield 30 mg ( 24% ) . Analytical HPLC : purity 93% ( System A and B ) ; HRES1MS ( ESP ) calcd for C2gH30N2O5S 506.1875 , found 506.1882. EXAMPLE A81 tert - Butyl 4 - ( 6 - { 4 - [ ( methylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0xylate. 0 OxOleOK. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and methylamine using the conditions described in genera1 method D. Yie1d 2.1 mg ( 9% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C26H32N2O5 452.2311 , found 452.2305. 10. 15. 20. WO 2009 / 150144 _ 109 _ PCT / EP2009 / 057074. EXAMPLE A82 tert - Butyl 4 - ( 6 - { 4 - [ ( ethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - . 1 - carb0xylate. Amﬂ O OkONTOK. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and ethylamine using the conditions described in genera1 method D. Yie1d 2.5 mg ( 11% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H34N2O5 466.2468 , found 466.2471. EXAMPLE A83 tert - Butyl 4 - ( 6 - { 4 - [ ( allylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - . 1 - carb0xylate. o T K. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and allylamine using the conditions. described in general method D. Yield 0.7 mg ( 3% ) . Analytical HPLC : purity 100% ( SystemA and B ) ; HRESIMS ( ESI + ) calcd for C28H34N2O5 478.2468 , found 478.2466. EXAMPLE A84 tert - Butyl 4 - ( 6 - { 4 - [ ( cycl0pr0pylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0xylate. 10. 15. 20. 25. WO 2009 / 150144 _ 1 10 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and cyclopropylamine using the conditions described in general method D. Yield 3.6 mg ( 15% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH34N2O5 478.2468 , found 478.2469. EXAMPLE A85 tert - Butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydr0xyethyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. o HO\ / \N ) K.\.\ / \ O D fO N O. I K The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and ethanolamine using the conditions described in general method D. Yield 2.8 mg ( 12% ) . Ana1ytica1 HPLC : purity. 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H34N2O6 482.2417 , found 482.2418. EXAMPLE A86 tert - Butyl 4 - [ 6 - ( 4 - { [ ( 2 - methylpr0p - 2 - en - 1 - y ] ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0 - . dioxin - 2 - yl ] piperidine - 1 - carb0xylate. Wor. okONTOK. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and ( 2 - methylprop - 2 - en - 1 - yl ) amine using the conditions described in genera1 method D. Yie1d 0.3 mg ( 1% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H36N2O5 492.2624 , found 492.2617. 10. 15. 20. WO 2009 / 150144 _ 1 11 _ PCT / EP2009 / 057074. EXAMPLE A87 tert - Butyl 4 - ( 6 - { 4 - [ ( but - 3 - en - 1 - ylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0xylate. NN %% W. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - l , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and but - 3 - en - 1 - amine using the conditions described in genera1 method D. Yie1d 1.2 mg ( 5% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H36N2O5 492.2624 , found 492.2622. EXAMPLE A88 tert - Butyl 4 - [ 6 - ( 4 - { [ ( 3 - hydr0xypr0pyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. HO / \ / \N “ ( O50 W. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and 3 - amino - 1 - propanol using the conditions described in general method D. Yield 3.8 mg ( 15% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH36N2O6 496.2573 , found 496.2580. EXAMPLE A89 tert - Butyl 4 - [ 6 - ( 4 - { [ ( 2 - meth0xyethy ] ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. 10. 15. 20. WO 2009 / 150144 _ 1 12 _ PCT / EP2009 / 057074. / O\ / \N “o% W. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and 2 - methoxyethylamine using the conditions described in general method D. Yield 3.8 mg ( 15% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH36N2O6 496.2573 , found 496.2580. EXAMPLE A90 tert - Butyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydr0xycycl0pr0pyl ) methyl ] amin0 } carb0nyl ) phenyl ] - 4H - 1 , 3 - . benz0dioxin - 2 - yl } piperidine - 1 - carboxylate. O HOK” ) ‘\.\.\ / \ O 0 xO N O. T K The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoxycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and 1 - ( aminomethyl ) cyclopropanol using thc conditions dcscribcd in gcncra1 mcthod D. Yic1d 3.9 mg ( 16% ) . Ana1ytica1. HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H36N2O6 508.2573 , found 508.2581. EXAMPLE A91 tert - Butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydr0xy - 1 , 1 - dimethylethyl ) amin0 ] carbonyl } phenyl ) - 4H - 1 , 3 - . benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. 0. WW 0 ‘ * Q 0. ‘JK. 10. 15. 20. 25. WO 2009 / 150144 _ 1 13 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A14 ) and 2 - amino - 2 - methyl - 1 - propanol using the conditions described in genera1 method D. Yie1d 3.6 mg ( 14% ) . Ana1ytica1 HPLC : purity 97% ( System A and B ) ; HRESIMS ( ESI + ) calCd for C29H3gN2O6 510.2730 , found 510.2748. EXAMPLE A92 tert - Butyl 4 - ( 6 - { 4 - [ ( 3 - hydr0xyazetidin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0dioXin - 2 - yl ) piperidine - 1 - carb0Xylate. w OkOwr°7<. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3—benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and 3—hydroxazetidine hydrochloride using the conditions genera1 method D. Yie1d 3.8 mg ( 15% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH34N2O6 494.2417 , found 494.2345. EXAMPLE A93 tert - Butyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0Xylate. o. N m. N O. I K The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A14 ) and 1 - methylpiperazine using the conditions described in genera1 method D. Yie1d 4.0 mg ( 15% ) . Ana1ytica1 HPLC : purity. 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C30H39N3O5 521.289 , found 521.2906. 10. 15. 20. WO 2009 / 150144 _ 1 14 _ PCT / EP2009 / 057074. EXAMPLE A94 tert - Butyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethy ] ] amin0 } carb0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } piperidine - 1 - carb0xylate. / \ 0 QwWo 0 DO “W. The title compound Was prepared from 4 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3—benzodioxin - 6 - yl } benzoic acid ( Intermediate A14 ) and 2 - furan - 2 - yl—ethylamine using the conditions described in genera1 method D. Yie1d 3.9 mg ( 14% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C31H36N2O6 532.2573 , found 532.2567. EXAMPLE A95 4 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - methylbenzamide. O 00 O. The tit1e compound Was prepared from 4 - [ 2 - ( 1 - benzoy1piperidin - 4 - y1 ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and methylamine using the conditions described in genera1 method D. Yie1d 2.9 mg ( 13% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C28H2gN2O4 456.2049 , found 456.2058. EXAMPLE A96 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ethylbenzamide. O. “N. 10. 15. 20. WO 2009 / 150144 _ 1 15 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - y1 ] benzoic acid ( Intermediate A16 ) and ethy1amine using the conditions described in general method D. Yield 7.6 mg ( 32% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C29H3oN2O4 470.2206 , found 470.2202. EXAMPLE A97 N - Allyl - 4 - [ 2 - ( 1 - benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] benzamide. O. ka‘.\ / \ H D O 0 o / KO Q. N. o The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - y1 ] benzoic acid ( Intermediate A16 ) and a11y1amine using the conditions described. in general method D. Yield 5.5 mg ( 23% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C30H30N2O4 482.2206 , found 482.2200. EXAMPLE A98 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - cycl0pr0pylbenzamide. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and cyclopropylamine using the conditions described in genera1 method D. Yie1d 8.7 mg ( 36% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C30H30N2O4 482.2206 , found 482.2200. 10. 15. 20. WO 2009 / 150144 _ 1 l6 _ PCT / EP2009 / 057074. EXAMPLE A99 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ( 2 - hydr0Xyethyl ) - . benzamide. O. HO\ / \” ) K.\.\ / \ O O oops N O The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and ethano1amine using the conditions. described in genera1 method D. Yie1d 8.7 mg ( 36% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H30N2O5 486.2155 , found 486.2164. EXAMPLE A100 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ( 2 - methylpr0p - 2 - en - 1 - yl ) - . benzamide. O. Y”k.\. : \ o 0 Aop N o The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 2 - methylprop - 2 - en - 1 - amine using the conditions described in genera1 method D. Yie1d 6.0 mg ( 24% ) . Ana1ytica1 HPLC : purity. 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C31H32N2O4 496.2362 , found 496.2356. EXAMPLE A101 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - but - 3 - en - 1 - ylbenzamide. 0. MW. 10. 15. 20. WO 2009 / 150144 _ 1 17 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and but - 3 - en - 1 - amine using the conditions described in genera1 method D. Yie1d 9.2 mg ( 37% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C31H32N2O4 496.2362 , found 496.2352. EXAMPLE A102 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ( 3 - hydr0Xypr0py ] ) - . benzamide. The tit1e compound Was prepared from 4 - [ 2 - ( 1 - benzoy1piperidin - 4 - y1 ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 3 - amino - 1 - propanol using the conditions described in genera1 method D. Yie1d 9.2 mg ( 37% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI‘ ) ca1cd for C30H32N2O5 500.2311 , found 500.2310. EXAMPLE A103 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ( 2 - meth0xyethyl ) - . benzamide. 0. MW H o O oopo N o The tit1e compound Was prepared from 4 - [ 2 - ( 1 - benzoy1piperidin - 4 - y1 ) - 4H - 1 , 3 - benzodioXin - 6 - y1 ] benzoic acid ( Intermediate A16 ) and 2 - methoXyethy1amine using the conditions described in genera1 method D. Yie1d 6.0 mg ( 24% ) . Ana1ytica1 HPLC : purity. 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C30H32N2O5 500.2311 , found 500.2317. 10. 15. 20. WO 2009 / 150144 _ 1 l8 _ PCT / EP2009 / 057074. EXAMPLE A104 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - [ ( 1 - hydr0Xycycl0pr0pyl ) - . methyl ] benzamide O HOX\u O O 0 oopo N O. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 1 - ( aminomethy1 ) cyc1opropano1 using the conditions described in genera1 method D. Yie1d 7.9 mg ( 30% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C31H32N2O5 512.2311 , found 512.2311. EXAMPLE A105 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - ( 2 - hydr0Xy - 1 , 1 - dimethylethyl ) benzamide. O my ”0 00 O. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 2 - amino - 2 - methy1 - 1 - propano1 according to general method D. Yield 5.6 mg ( 22% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C31H34N2O5 514.2468 , found 514.2464. EXAMPLE A106 1 - { 4 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0Xin - 6 - yl ] benz0yl } azetidin - 3 - 0l. O. . L * %. 10. 15. 20. WO 2009 / 150144 _ 1 19 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 3 - hydroXazetidine hydrochloride using the conditions described in genera1 method D. Yie1d 11.7 mg ( 47% ) . Ana1ytica1 HPLC : . purity 100% ( System A and B ) ; LRESIMS m / z = 499 ( M + H ) + . EXAMPLE A107 1 - { 4 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0Xin - 6 - yl ] benz0yl } - 4 - methyl - . The tit1e compound Was prepared from 4 - [ 2 - ( 1 - benzoy1piperidin - 4 - y1 ) - 4H - 1 , 3 - benzo - . piperazine. dioXin - 6 - yl ] benzoic acid ( Intermediate A16 ) and 1 - methylpiperazine using the conditions described in genera1 method D. Yie1d 10 mg ( 38% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI‘ ) ca1cd for C32H35N3O4 525.2628 , found 525.2627. EXAMPLE A108 4 - [ 2 - ( 1 - Benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] - N - [ 2 - ( 2 - furyl ) ethyl ] - . benzamide. The title compound Was prepared from 4— [ 2 - ( 1—benzoylpiperidin—4—yl ) —4H—1 , 3—benzodioXin - 6 - y1 ] benzoic acid ( 1ntermediate A16 ) and 2 - furan - 2 - y1 - ethy1amine using the conditions described in genera1 method D. Yie1d 3.7 mg ( 14% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C33H32N2O5 536.2311 , found 536.2291. 10. 15. 20. WO 2009 / 150144 _ 120 _ PCT / EP2009 / 057074. EXAMPLE A109 Ethyl 4 - ( 6 - { 4 - [ ( methylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0Xin - 2 - yl ) piperidine - 1 - . carboxylate. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - y1 } benzoic acid ( Intermediate A18 ) and methy1amine using the conditions described in genera1 method D. Yie1d 3.0 mg ( 14% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C24H2gN2O5 424.1998 , found 424.1980. EXAMPLE A1 10 Ethyl 4 - ( 6 - { 4 - [ ( ethylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0Xin - 2 - yl ) piperidine - 1 - . carboxylate. O m 0 H D O O ﬁjl / OV. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and ethy1amine using the conditions described in genera1 method D. Yie1d 3.8 mg ( 17% ) . Ana1ytica1 HPLC : purity 100% ( SystemA and B ) ; HRESIMS ( ESI + ) calcd for C25H30N2O5 438.2155 , found 438.2142. EXAMPLE A1 11 Ethyl 4 - ( 6 - { 4 - [ ( allylamino ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0dioxin - 2 - yl ) piperidine - 1 - . carboxylate. 10. 15. 20. WO 2009 / 150144 _ 121 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and allylamine using the conditions described in genera1 method D. Yie1d 4.8 mg ( 22% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C26H3oN2O5 450.2155 , found 450.2142. EXAMPLE A112 Ethyl 4 - ( 6 - { 4 - [ ( cycl0pr0pylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0Xylate. The tit1e compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and cyclopropy1amine using the conditions described in genera1 method D. Yie1d 3.5 mg ( 16% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI‘ ) ca1cd for C26H30N2O5 450.2155 , found 450.2142. EXAMPLE A1 13 Ethyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxyethyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0Xin - 2 - yl ] - . piperidine - 1 - carb0xylate. O. HO\ / \N O H 0 O N O. \n / \ / . o The tit1e compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and ethanolamine using the conditions described in genera1 method D. Yie1d 8.6 mg ( 39% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C25H30N2O6 454.2104 , found 454.2107. 10. 15. 20. WO 2009 / 150144 _ 122 _ PCT / EP2009 / 057074. EXAMPLE A114 Ethyl 4 - [ 6 - ( 4 - { [ ( 2 - methylpr0p - 2 - en - 1 - yl ) amino ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. Yu %% WW. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - y1 } benzoic acid ( Intermediate A18 ) and 2 - methy1prop - 2 - en - 1 - amine according to genera1 method D. Yie1d 8.1 mg ( 35% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H32N2O5 464.2311 , found 464.2314. EXAMPLE A1 15 Ethyl 4 - ( 6 - { 4 - [ ( but - 3 - en - 1 - ylamin0 ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0Xylate. O o okO N\n / O\ / . The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and but - 3 - en - 1 - amine according to general method D. Yield 6.4 mg ( 28% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C27H32N2O5 464.2311 , found 464.2308. EXAMPLE A1 16 Ethyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroxypr0pyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] - . piperidine - 1 - carb0Xylate. O. HOMN O D o o / KO N\n / O\ / . O. 10. 15. 20. 25. WO 2009 / 150144 _ 123 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and 3 - amino - 1 - propanol using the conditions described in genera1 method D. Yie1d 6.8 mg ( 30% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C26H32N2O6 468.2260 , found 468.2248. EXAMPLE A1 17 Ethyl 4 - [ 6 - ( 4 - { [ ( 2 - meth0xyethyl ) amin0 ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] - . piperidine - 1 - carboXylate. O / O\ / \N O H D O O * O\|\n / O\ / . The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A18 ) and 2—methoxyethylamine using the conditions described in genera1 method D. Yie1d 8.3 mg ( 36% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C26H32N2O6 468.2260 , found 468.2255. EXAMPLE A1 18 Ethyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydr0Xycyclopr0pyl ) methyl ] amin0 } carb0nyl ) phenyl ] - 4H - 1 , 3 - . benz0dioXin - 2 - yl } piperidine - 1 - carboXylate O HOf” ) ‘\.\.\ / \ O D x© N O\ / 11. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and 1 - ( aminomethyl ) cyclopropanol using the conditions described in genera1 method D. Yie1d 8.4 mg ( 35% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H32N2O6 480.2260 , found 480.2242. 10. 15. 20. WO 2009 / 150144 _ 124 _ PCT / EP2009 / 057074. EXAMPLE A1 19 Ethyl 4 - [ 6 - ( 4 - { [ ( 2 - hydr0xy - 1 , 1 - dimethylethyl ) amino ] carb0nyl } phenyl ) - 4H - 1 , 3 - . benz0di0Xin - 2 - yl ] piperidine - 1 - carb0xylate. WW 0 0 m. - . The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - y1 } benzoic acid ( Intermediate A18 ) and 2 - amino - 2 - methy1 - 1 - propano1 according to genera1 method D. Yie1d 4.4 mg ( 18% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H34N2O6 482.2417 , found 482.2408. EXAMPLE A120 Ethyl 4 - ( 6 - { 4 - [ ( 3 - hydr0Xyazetidin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0Xylate. O. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and 3 - hydroxazetidine hydrochloride according to general method D. Yield 8.2 mg ( 36% ) . Analytical HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C26H30N2O5 466.2104 , found 466.2101. EXAMPLE A121 Ethyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] phenyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) - . piperidine - 1 - carb0Xylate. 10. 15. 20. 25. WO 2009 / 150144 _ 125 _ PCT / EP2009 / 057074. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and 1 - methylpiperazine using the conditions described in genera1 method D. Yie1d 8.6 mg ( 34% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C2gH35N3O5 493.2577 , found 493.2576. EXAMPLE A122 Ethyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amin0 } carb0nyl ) phenyl ] - 4H - 1 , 3 - benzodi0xin - 2 - yl } - . piperidine - 1 - carb0Xylate. / \ 0 Mi‘. 0 00© WW. The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } benzoic acid ( Intermediate A18 ) and 2 - furan - 2 - yl - ethylamine using the conditions described in genera1 method D. Yie1d 8.6 mg ( 34% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C29H32N2O6 504.2260 , found 504.2256. EXAMPLE A123 Ethyl 4 - [ 6 - ( 4 - { [ 2 - ( hydr0xymethyl ) m0rph0lin - 4 - yl ] carb0nyl } phenyl ) - 4H - 1 , 3 - benz0 - . dioXin - 2 - yl ] piperidine - 1 - carb0xylate. OH O. m. 0 The title compound Was prepared from 4 - { 2 - [ 1 - ( ethoXycarbony1 ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - yl } benzoic acid ( Intermediate A18 ) and 2 - morpholinemethanol using the conditions described in genera1 method D. Yie1d 9.9 mg ( 38% ) . Ana1ytica1 HPLC : purity 95% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C2gH34N2O7 510.2366 , found 510.2367. 10. 15. 20. WO 2009 / 150144 _ 126 _ PCT / EP2009 / 057074. EXAMPLE A124 3 - ( 3 - { 2 - [ 1 - ( tert - But0xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0Xin - 6 - yl } isoxaz0l - 5 - . yl ) pr0pan0ic acid. 0 11 K. The title compound Was prepared from tert - butyl 4 - [ 6 - ( dimethoXyboryl ) - 4H - 1 , 3 - benzodioXin - 2 - yl ] piperidine - 1 - carboXylate ( Intermediate A19 ) and 3 - ( 3 - bromoiszazol - 5 - yl ) - propanoic acid according to genera1 method B. Yie1d 3 mg ( 9% ) . Ana1ytica1 HPLC : purity 92% ( System A and B ) ; LRESIMS ( ESP ) m / z = 358 ( M + H - Boc ) + . EXAMPLE A125 [ ( 5 - { 2 - [ 1 - ( tert - But0Xycarb0nyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0Xin - 6 - yl } - 2 - fur0yl ) - . amino ] acetic acid. 4 Tth. The title compound Was prepared from tert - butyl 4 - [ 6 - ( dimethoXyboryl ) - 4H - 1 , 3 - benZodioXin - 2 - yl ] piperidine - 1 - carboxylate ( Intermediate A19 ) and N - ( 5 - bromo - 2 - ﬁ.1royl ) glycine using the conditions described in genera1 method B. Yie1d 4.4 mg ( 12% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calCd for C25H30N208 486.2002 , found 486.1992. EXAMPLE A126 tert - Butyl 4 - { 6 - [ 6 - ( methylsulf0nyl ) pyridin - 3 - yl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - . carboxylate. 10. 15. 20. 25. WO 2009 / 150144 _ 127 _ PCT / EP2009 / 057074. The tit1e compound Was prepared from tert - buty1 4 - [ 6 - ( dimethoXybory1 ) - 4H - 1 , 3 - benzodioXin - 2 - yl ] piperidine - 1 - carboxylate ( Intermediate A19 ) and 5 - bromo - 2 - ( methylsulfonyl ) - pyridine using the conditions described in genera1 method B. Yie1d 3.2 mg ( 9% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C24H3oN2O6S 474.1825 , found 474.1826. EXAMPLE A127 tert - Butyl 4 - { 6 - [ 5 - ( methylsulf0nyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } piperidine - 1 - carboxylate. \S / / 0. o" |\N. / o. OkONTIOK. The tit1e compound Was prepared from tert—buty1 4— [ 6— ( dimethoXybory1 ) —4H—1 , 3—benzodioXin - 2 - y1 ] piperidine - 1 - carboxylate ( lntermediate A19 ) and 2 - bromo - 5 - ( methy1su1fony1 ) - pyridine according to general method B. Yield 4.9 mg ( 13% ) . Analytical HPLC : purity 99% ( system A and B ) ; LRESIMS ( ESP ) m / Z : 419 ( M + H - tBu ) + . EXAMPLE A128 tert - Butyl 4 - { 6 - [ 4 - ( 1H - tetraz0l - 5 - yl ) phenyl ] - 4H - 1 , 3 - benz0di0Xin - 2 - yl } piperidine - 1 - carboxylate. N\ / N O k.\ ( \O N O ) r K O. The tit1e compound Was prepared from terz - buty1 4 - [ 6 - ( dimethoXybory1 ) - 4H - 1 , 3 - benzodioXin - 2 - y1 ] piperidine - 1 - carboxy1ate ( Intermediate A19 ) and 5 - ( 4 - bromopheny1 ) - 1H - tetrazo1e using the conditions described in genera1 method B. Yie1d 2.8 mg ( 8% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C25H29N5O4 463.2220 , found 463.2240. 10. 15. 20. WO 2009 / 150144 _ 128 _ PCT / EP2009 / 057074. EXAMPLE A129 tert - Butyl 4 - [ 6 - ( 2 - { [ amin0 ( imin0 ) methyl ] amin0 } - 4 - methyl - 1 , 3 - thiaz0l - 5 - yl ) - 4H - 1 , 3 - . benz0di0Xin - 2 - yl ] piperidine - 1 - carb0xylate w \ NH2 O / KO N O I K. The tit1e compound Was prepared from tert - buty1 4 - [ 6 - ( dimethoXyboryl ) - 4H - 1 , 3 - benzodioXin - 2 - y1 ] piperidine - 1 - carboxy1ate ( Intermediate A19 ) and N - ( 5 - bromo - 4 - methy1 - 1 , 3 - thiazol - 2 - yl ) guanidine according to general method B. Yie1d 1.5 mg ( 4% ) . Ana1ytical HPLC : purity 93% ( System A and B ) ; LRESIMS ( ESP ) m / z = 474 ( M + H ) + . EXAMPLE A130 tert - Butyl 4 - ( 6 - pyridin - 4 - yl - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. N \. | / o. AONTOK. A suspension of tert - buty1 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioxin - 2 - y1 ) piperidine - 1 - carboxy1ate ( Intermediate A11 ; 100 mg , 0.251 mmo1 ) , pyridin - 4 - y1boronic acid ( 37 mg , 0.301 mmo1 ) , K2CO3 ( 87 mg , 0.63 mmo1 ) , PdC12dppf - DCM ( 21 mg , 0.025 mmo1 ) in MeCN / H2O ( 3 mL ; 2 : 1 ) Was heated at 160 °C for 20 min in a microWaVe reactor. The miXture Was f11tered through a pad of silica , concentrated and the residue Was purified by preparatiVe HPLC ( System E ) . Yie1d 45 mg ( 45% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C23H2gN2O4 396.2049 , found 396.2068. EXAMPLE A131 tert - Butyl 4 - ( 6 - pyridin - 3 - yl - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. 10. 15. 20. 25. WO 2009 / 150144 _ 129 _ PCT / EP2009 / 057074. The title compound Was prepared from tert - butyl 4 - ( 6 - bromo - 4H - 1 , 3 - benzodioXin - 2 - yl ) - piperidine - 1 - carboxylate ( Intermediate A11 ; 70 mg , 0.18 mmo1 ) and pyridin - 3 - ylboronic acid ( 26 mg , 0.21 mmol ) using the conditions described for EXample A130. Yield 29 mg ( 42% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C23H2gN204 396.2049 , found 396.2061. EXAMPLE A132 tert - Butyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benz0 - dioXin - 2 - yl ) piperidine - 1 - carb0xylate. o oJ\O. N o. I K. To a suspension of 6 - { 2 - [ 1 - ( tert - butoxycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioxin - 6 - yl } nicotinic acid ( Intermediate A21 ; 50 mg , 0.11 mmol ) , HOBT ( 31 mg , 0.23 mmol ) , EDC ( 44 mg , 0.23 mmol ) and triethylamine ( 46 mg , 0.45 mmol ) in DMF ( 3 mL ) Was added 1 - methylpiperazine ( 17 mg , 0.17 mmol ) . The mixture Was stirred at r. t. for 12 h and then at 100 °C for 24 h. The so1Vent Was remoVed under reduced pressure and the residue Was purified by preparatiVe HPLC ( System E ) . Yield 10.3 mg ( 17% ) . Analytical HPLC : purity. 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H33N4O5 522.2842 , found 522.2853. EXAMPLE A133 tert - Butyl 4 - { 6 - [ 6 - ( m0rph0lin - 4 - ylcarb0nyl ) pyridin - 3 - yl ] - 4H - l , 3 - benz0di0xin - 2 - yl } - piperidine - 1 - carb0Xylate. OxONTOK. The title compound Was prepared from 5 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioXin - 6 - y1 } pyridine - 2 - carboxy1ic acid ( Intermediate A20 ; 50 mg , 0. l1 mmo1 ) and morpholine ( 15 mg , 0.17 mmol ) using the conditions described for Example A132. 10. 15. 20. WO 2009 / 150144 _ 130 _ PCT / EP2009 / 057074. Yield 1.4 mg ( 2% ) . Analytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C23H35N306 509.2526 , found 509.2540. EXAMPLE A134 tert - Butyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benz0 - dioXin - 2 - yl ) piperidine - 1 - carb0xylate. o N N \ / © %O w N O t ) < The title compound Was prepared from 5 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } pyridine - 2 - carboxylic acid ( Intermediate A20 ; 50 mg , 0.11 mmol ) and 1 - methylpiperazine ( 17 mg , 0.17 mmol ) using the conditions described for EXample. A132. Yield 1.7 mg ( 3% ) . Analytical HPLC : purity 96% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C29H3gN4O5 522.2842 , found 522.2854. EXAMPLE A135 tert - Butyl 4 - { 6 - [ 5 - ( m0rph0lin - 4 - ylcarb0nyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benz0di0xin - 2 - yl } - . piperidine - 1 - carb0Xylate. OkONTOK. The title compound Was prepared from 6 - { 2 - [ 1 - ( tert - butoXycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioXin - 6 - yl } nicotinic acid ( Intermediate A21 ; 50 mg , 0.11 mmol ) and morpholine ( 15 mg , 0.17 mmol ) using the conditions described for EXample A132. Yield 7.7 mg ( 17% ) . Analytical HPLC : purity 96% ( System B and C ) ; HRESIMS ( ESI + ) calcd for C2gH35N306 509.2526 , found 509.2529. 10. 15. 20. 25. WO 2009 / 150144 _ 131 _ PCT / EP2009 / 057074. EXAMPLE A136 tert - Butyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] - 2 - furyl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. N O O 9 oo . II 7<. A suspension of tert - buty1 4 - [ 6 - ( dimethoxybory1 ) - 4H - 1 , 3 - benzodioxin - 2 - y1 ] piperidine - 1 - carboxy1ate ( Intermediate A19 ; 100 mg , 0.254 mmo1 ) , 5 - bromo - 2 - furoic acid ( 58 mg , 0.31 mmo1 ) , K2CO3 ( 88 mg , 0.64 mmo1 ) , PdC12dppf - DCM ( 22 mg , 0.025 mmo1 ) in MeCN / H2O ( 4 mL ; 2 : 1 ) Was heated at 160 0C for 20 min in a microWaVe reactor. The mixture Was ﬁltered through a pad of silica and concentrated to giVe 5 - { 2 - [ 1 - ( terI - butoxycarbonyl ) - piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioxin - 6 - y1 } - 2 - furoic acid. Part ofthis material ( 50 mg , 0.116 mmol ) , HOBT ( 32 mg , 0.23 mmol ) , EDC ( 45 mg , 0.23 mmol ) , triethylamine ( 47 mg , 0.47 mmol ) and 1 - methylpiperazine ( 35 mg , 0.35 mmol ) Was disso1Ved in DMF ( 4 mL ) amd stirred at r. t. for 24 h. The mixture Was concentrated and the residue Was purif1ed by preparatiVe HPLC ( System E ) . Yie1d 17 mg ( 29% ) . Ana1ytica1. HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH37N3O6 511.2682 , found 511.2683. EXAMPLE A137 tert - Butyl 4 - ( 6 - { 5 - [ ( 1E ) - 3 - ( 4 - methylpiperazin - 1 - yl ) - 3 - 0x0pr0p - 1 - en - 1 - yl ] - 2 - thienyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate. A suspension of ( 2E ) - 3 - ( 5 - { 2 - [ 1 - ( tert - butoxycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - 2 - thieny1 ) acrylic acid ( Intermediate A22 ; 50 mg , 0.116 mmol ) HOBT ( 29 mg , 0.21 mmol ) , EDC ( 41 mg , 0.21 mmol ) , triethylamine ( 43 mg , 0.42 mmol ) and 1—methylpiperazine ( 32 mg , 0.32 mmo1 ) in DMF ( 3 mL ) Was stirred at r. t. for 24 h. The mixture Was concentrated and the residue Was puriﬁed by preparatiVe HPLC ( System E ) . Yie1d 12 mg. 10. 15. 20. WO 2009 / 150144 _ 132 _ PCT / EP2009 / 057074. ( 20% ) . Analytical HPLC : purity 90% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C30H39N3O5S 553.2610 , found 553.2623. EXAMPLE A138 tert - Butyl 4 - ( 6 - { 5 - [ ( 1E ) - 3 - m0rph0lin - 4 - yl - 3 - 0x0pr0p - 1 - en - 1 - yl ] - 2 - thienyl } - 4H - 1 , 3 - . benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. The title compound Was prepared from ( 2E ) - 3 - ( 5— { 2 - [ 1— ( tert - butoxycarbonyl ) piperidin—4— y1 ] - 4 [ - 1 - 1 , 3 - benzodioxin - 6 - y1 } - 2 - thieny1 ) acry1ic acid ( lntermediate A22 ; 50 mg , 0.12 mmol ) and morpholine ( 27 mg , 0.32 mmol ) using the conditions described for Example A137. Yicld 14 mg ( 25% ) . Analytical HPLC : purity 93% ( Systcm A and B ) ; HRESIMS ( ESI + ) calcd for C29H36N2O6S 540.2294 , found 540.2299. EXAMPLE A139 tert - Butyl 4 - ( 6 - { 5 - [ ( 4 - pyrimidin - 2 - ylpiperazin - 1 - yl ) carb0nyl ] pyridin - 2 - yl } - 4H - 1 , 3 - . benzodioxin - 2 - yl ) piperidine - 1 - carb0xylate. O J / 1 W \ O / OkO N o I K The tit1e compound Was prepared from 6 - { 2 - [ 1 - ( tert - butoxycarbony1 ) piperidin - 4 - y1 ] - 4H - 1 , 3 - benzodioxin - 6 - y1 } nicotinic acid ( Intermediate A21 ; 50 mg , 0.11 mmol ) and 2 - ( 1 - piperazinyl ) pyrimidine ( 28 mg , 0.17 mmol ) using the conditions described for Example. A137. Yie1d 9 mg ( 13% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESP ) ca1cd for C32H3gN6O5 586.2904 , found 586.2913. 10. 15. 20. WO 2009 / 150144 _ 133 _ PCT / EP2009 / 057074. EXAMPLE A140 tert - Butyl 4 - [ 6 - ( 5 - { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) amin0 ] carb0nyl } pyridin - 2 - yl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. O. ww. The title compound Was prepared from 6 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3—benzodioxin - 6 - yl } nicotinic acid ( Intermediate A21 ; 50 mg , 0.12 mmol ) and N , N , N ' — trimethy1ethane - 1 , 2 - diamine ( 17 mg , 0.17 mmo1 ) using the conditions described for Example A137. Yield 9 mg ( 15% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C29H40N4O5 524.2999 , found 524.3005. EXAMPLE A141 tert - Butyl 4 - [ 6 - ( 5 - { [ 4 - ( 2 - hydr0xyethyl ) piperazin - 1 - yl ] carb0nyl } pyridin - 2 - yl ) - 4H - 1 , 3 - . benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate. o MC * @C. HO / \ / N\ ) \ I o. okO N O. I K. The title compound Was prepared from 6 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - y1 ] - 4H - . 1 , 3 - benzodioxin - 6 - yl } nicotinic acid ( Intermediate A21 ; 50 mg , 0.11 mmol ) and N - ( 2 - . hydroxyethyl ) piperazine ( 22 mg , 0.17 mmol ) using the conditions described for Example. A137. Yield 17 mg ( 17% ) . Analytical HPLC : purity 99% ( System A and B ) ; MS ( ESI + ) ca1cd for C30H40N4O6 552.2948 , found 552.2958. 10. 15. 20. WO 2009 / 150144 _ 134 _ PCT / EP2009 / 057074. EXAMPLE A142 tert - Butyl 4 - [ 6 - ( 6 - { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) amin0 ] carb0nyl } pyridin - 3 - yl ) - 4H - 1 , 3 - benz0di0xin - 2 - yl ] piperidine - 1 - carb0xylate O ( \N / N | / N\ I \. 5Q?‘. The title compound Was prepared from 5 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - y1 ] - 4H - 1 , 3—benzodioxin - 6 - yl } pyridine—2—carboxylic acid ( Intermediate A20 ; 50 mg , 0.11 mmol ; ) and N , N , N ' - trimethy1ethane - 1 , 2 - diamine ( 17 mg , 0.17 mmo1 ) using the conditions described for Examp1e A137. Yie1d 1.5 mg ( 3% ) . Ana1ytica1HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C29H40N4O5 524.2999 , found 524.3010. EXAMPLE A143 Ethyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. O / KOKn / ‘K / . A suspension of 1 , 1 - carbonyldiimidazole ( 24 mg , 0.14 mmol ) , ethanol ( 7 mg , 0.14 mmol ) and DCM ( 0.5 mL ) under N2 ( g ) Was treated With a solution of 1 - methyl - 4 - { [ 5 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) pyridin - 2 - yl ] carbonyl } piperazine ( Intermediate A23 ; 30 mg , 0.07l mmol ; ) in DCM ( 0.5 mL ) and stirred at r. t. for 24 h. The solVent Was remoVed under reduced pressure and the residue Was puriﬁed by preparatiVe HPLC ( System E ) . Yield 5.2 mg ( 15% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C27H34N4O5 494.2529 , found 494.2543. 10. 15. 20. WO 2009 / 150144 _ 135 _ PCT / EP2009 / 057074. EXAMPLE A144 Is0pr0pyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benz0 - dioxin - 2 - yl ) piperidine - 1 - carb0xylate. o N N \ oo N O 11 Y The title compound Was prepared from 1 - methyl - 4 - { [ 5 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) pyridin—2—yl ] carbonyl } piperazine ( Intermediate A23 ; 30 mg , 0.071 mmo1 ) and 2 - propanol ( 9 mg , 0.14 mmo1 ) using the conditions described for Example A143. Yield 6.9. mg ( 19% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C2gH36N4O5 508.2686 , found 508.2700. EXAMPLE A145 Ethyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidine - 1 - carb0xylate. O / KOKWOv. The title compound Was prepared from 1 - methyl - 4 - { [ 6 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) pyridin - 3 - yl ] carbonyl } piperazine ( Intermediate A24 ; 22 mg , 0.052 mmo1 ) and ethanol ( 5 mg , 0.1 mmol ) using the conditions described for Examp1e A143. Yield 2.3 mg ( 9% ) . Analytical HPLC : purity 96% ( System A and B ) ; HRESIMS ( ESI + ) calcd for C27H34N4O5 494.2529 , found 494.2529. 10. 15. 20. WO 2009 / 150144 _ l36 _ PCT / EP2009 / 057074. EXAMPLE A146 1 - ( { 5 - [ 2 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 4H - 1 , 3 - benz0di0xin - 6 - yl ] pyridin - 2 - yl } carb0nyl ) - 4 - . methylpiperazine. A cooled ( 5 OC ) suspension of 1 - methy1 - 4 - { [ 5 - ( 2 - piperidin - 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - y1 ) - pyridin - 2 - y1 ] carbonyl } piperazine ( Intermediate A23 ; 30 mg , 0.071 mmo1 ) in dry pyridine ( 2 mL ) Was stirred under N2 for 10 min. To the mixture Was then added benzoy1 ch1oride ( 12 mg , 0.071 mmol ) and the resulting mixture Was stirred for 1 h. The solVent Was remoVed under reduced pressure and the residue Was puriﬁed by preparatiVe HPLC ( System E ) . Yie1d 6.3 mg ( 17% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C31H34N4O4 526.2580 , found 526.2601. EXAMPLE A147 1 - [ ( 5 - { 2 - [ 1 - ( 2 - Ethylbutan0yl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benz0di0xin - 6 - yl } pyridin - 2 - yl ) - . carb0nyl ] - 4 - methylpiperazine. O. N / O%\O oo m N o The title compound Was prepared from 1 - methyl - 4 - { [ 5 - ( 2 - piperidin - 4 - yl - 4H - 1 , 3 - benzodioxin - 6 - yl ) pyridin - 2 - yl ] carbony1 } piperazine ( Intermediate A23 ; 30 mg , 0.071 mmo1 ) and 2 - ethy1butanoy1 ch1oride ( 12 mg , 0.071 mmo1 ) using the conditions described for Example. A146. Yie1d 5.6 mg ( 15% ) . Ana1ytica1 HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C30H40N4O4 520.3050 , found 520.3068. 10. 15. 20. 25. WO 2009 / 150144 _ 137 _ PCT / EP2009 / 057074. EXAMPLE A148 2 - [ 4 - ( 6 - { 5 - [ ( 4 - Methylpiperazin - 1 - yl ) carb0nyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benz0di0xin - 2 - yl ) piperidin - 1 - yl ] pyrimidine. A suspension of 2—bromopyrimidine ( 6 mg , 0.037 mmo1 ) and 1—methy1—4— { [ 6— ( 2—piperidin— 4 - y1 - 4H - 1 , 3 - benzodioxin - 6 - y1 ) pyridin - 3 - y1 ] carbony1 } piperazine ( Intermediate A24 ; 14 mg , 0.033 mmo1 ) in dry DMSO ( 1 mL ) under N2 ( g ) Was stirred at 50 0C for 12 h. The so1Vent Was remoVed under reduced pressure and the residue Was puriﬁed by preparatiVe HPLC ( System E ) . Yield 2.1 mg ( 13% ) . Analytical HPLC : purity 99% ( System A and B ) ; HRESIMS ( ESI + ) ca1cd for C2gH32N6O3 500.2536 , found 500.2551. INTERMEDIATE B1 2 - Methyl - 1 , 3 - benz0xazol - 6 - amine. H2N O Ur. To a heated suspension ( 70 0C ) of 6 - nitro - 2 - methy1 - benzoxazo1e ( 4.00 g , 22.4 mmo1 ) in MeOH ( 60 mL ) Was added a so1ution of ammonium ch1oride ( 12.1 g , 0.227 mo1 ) in Water ( 40 mL ) fo11oWed by iron poWder ( 4.52 g , 80.1 mmo1 ) . The mixture Was stirred for 2 h at 70 OC and then ﬁltered through Celite and Washed With MeOH. The ﬁltrate Was concentrated and the residue Was partitioned betWeen Water and EtOAc. The organic 1ayers Were combined and the so1Vent Was remoVed under reduced pressure to giVe the tit1e compound. Yie1d 2.83 g ( 85% ) . Ana1ytical HPLC : purity 100% ( System A ) ; LRESIMS ( Esr ) m / z = 149 ( M + H ) + . INTERMEDIATE B2 N - ( 4 - Br0mo - 2 - hydr0xyphenyl ) acetamide. BrUOH K. O. 10. 15. 20. 25. 30. WO 2009 / 150144 _ l38 _ PCT / EP2009 / 057074. To a cooled ( 0 OC ) suspension of 2 - methy1 - 1 , 3 - benzoxazo1 - 6 - amine ( Intermediate B1 ; 1.96 g , 13.2 mmol ) in 1 M HBr ( 40 mL ) Was careﬁ111y added NaNO2 ( 1.38 g , 20 mmol ) . After stirring for 10 min , a solution of CuBr ( 2.92 g , 20 mmo1 ) in Water ( 14 mL ) Was added and the mixture Was stirred at 0 0C for 5 min. The ice - bath Was remoVed and the mixture Was stirred oVernight and then 25% aqueous ammonia ( 5 mL ) Was added. The miXture Was extracted With EtOAc ( 500 mL ) and the organic 1ayer Was concentrated. The residue Was puriﬁed by ﬂash chromatography on silica using MeOH / CHCl3 ( 0.05 : 1 ) as eluent. Yield 1.47 g ( 32% ) . Ana1ytica1 HPLC : purity 100% ( System A ) ; LRESIMS ( ESI + ) m / z = 230 / 232 ( M + H ) + . INTERMEDIATE B3 2 - Amin0 - 5 - bromophen0l. Br OH. UNW. A suspension of N - ( 4 - bromo - 2 - hydroxyphenyl ) acetamide ( Intermediate B2 ; 1.35 g , 5.87 mmo1 ) in EtOH ( 30 mL ) and 3 M HC1 ( 30 mL ) Was heated to 100 °C ( reﬂux ) for 3 h. To the mixture Was then added 1 M Na2CO3 ( 45 mL ) and the ethano1 Was remoVed under reduced pressure. The residue Was extracted With DCM ( 3 x 250 mL ) , dried and. concentrated. Yie1d 988 mg ( 89% ) . Ana1ytica1 HPLC : purity 100% ( System A ) ; LRESlMS ( ESI + ) m / z = 188 / 190 ( M + H ) + . INTERMEDIATE B4 tert - Butyl 4 - { [ methoxy ( methyl ) amin0 ] carb0nyl } piperidine - 1 - carb0xylate. A suspension of 1 - ( tert - butoxycarbony1 ) piperidine - 4 - carboxy1ic acid ( 5.0 g , 21.8 mmo1 ) , EDC ( 6.27 g , 32.7 mmol ) and HOBT ( 2.95 g , 21.8 mmol ) in DMF ( 10 mL ) Was stirred for 20 min. To the mixture Were then added 1 , 2 - dimethylhydroxylamine hydrochloride ( 3.19 g , 32.7 mmol ) and DIEA ( 13 mL , 76.3 mmol ) and the stirring continued oVemight. The reaction mixture Was poured into Water and extracted With EtOAc. The organic layer Was concentrated and the residue Was puriﬁed by ﬂash chromatography on si1ica using EtOAc as e1uent. Yie1d 5.22 g ( 88% ) . Ana1ytica1 HPLC : purity 100% ( System A and B ) ; LRESlMS ( ESI + ) m / z = 217 ( M + H - tBu ) + . 10. 15. 20. 25. WO 2009 / 150144 _ 139 _ PCT / EP2009 / 057074. INTERMEDIATE B5 tert - Butyl 4 - acetylpiperidine - 1 - carb0xylate. O O. H3“J€ , JV A 3 M solution of bromo ( methyl ) magnesium in diethylether ( 13.8 mL , 41.4 mmol ) Was coo1ed in an ice - bath and a so1ution of tert - buty1 4 - { [ methoxy ( methy1 ) amino ] carbony1 } - piperidine - 1 - carboxylate ( Intermediate B4 ; 5.2 g 19.2 mmol ) in Et2O ( 25 mL ) Was added dropWise. The ice—bath Was remoVed and the mixture Was stirred at r. t. for 2 h. The excess bromo ( methy1 ) magnesium Was quenched by dropWise addition of Water , and the Water. phase Was then extracted With ether. Yield 3.35 g ( 77% ) . Analytical HPLC : purity 95% ( System A ) ; LRESIMS ( ESI + ) m / z = 172 ( M + H - tBu ) + . INTERMEDIATE B6 tert - Butyl 4 - ( br0m0acetyl ) piperidine - 1 - carb0xylate. , . ) - C“‘ / <o + . To a coo1ed ( - 78 OC ) suspension of tert - buty1 4 - acety1piperidine - 1 - carboxy1ate ( Intermediate B5 ; 2.87 g , 12.6 mmol ) in THF ( 30 mL ) Was added 1 M lithium bis ( trimethy1si1yl ) amide in THF ( 13.3 mL ) oVer 20 min. The mixture Was stirred for 1 h before the addition of trimethylsilyl chloride ( 1.74 mL , 13.7 mmol ) . After stirring at 0 0C for 30 min , the so1ution Was cooled to - 78 OC and bromine ( 0.645 mL , 12.6 mmo1 ) Was added. The mixture Was alloWed to reach r. t. and then poured into a solution of 10% Na2S2O3 ( 20 mL ) and saturated NH4Cl ( 20 mL ) . Extraction With EtOAc ( 2 x 80 mL ) gaVe the tit1e compound. Yie1d 3.69 g ( 96% ) . INTERMEDIATE B7 tert - Butyl 4 - ( 7 - br0m0 - 2H - l , 4 - benz0xazin - 3 - yl ) piperidine - l - carb0xylate. Br 0 : N / j\O N O T 1< To a stirred so1ution of 2 - amino - 5 - bromopheno1 ( Intermediate B3 ; 898 mg , 4.78 mmo1 ) in. DMF ( 10 mL ) Was added K2CO3 ( 660 mg , 4.78 mmol ) . After 45 min , a solution of tert - . 10. 15. 20. 25. WO 2009 / 150144 _ 140 _ PCT / EP2009 / 057074. butyl 4 - ( bromoacetyl ) piperidine - 1 - carboxylate ( Intermediate B6 ; 1.53 g , ca 5 mmol ) in DMF ( 2 mL ) Was added and the mixture Was stirred at r. t. oVernight. Water Was added and the product Was extracted With toluene. The organic phase Was Washed With Water and brine , dried and eVaporated to giVe 952 mg of crude tit1e compound ( used in lntermediate B8 ) . The aqueous layer Was extracted With CHCl3 and the organic layer Was concentrated. The residue Was puriﬁed by ﬂash chromatography on silica using 1% MeOH / CHCl3 as eluent to giVe an additional 628 mg of the title compound. Total yield 1.58 g ( 84% ) . Ana1ytica1 HPLC : purity 83% ( System A ) ; LRESIMS ( ESI + ) m / z = 339 / 341 ( M + H - tBu ) + . INTERMEDIATE B8 tert - Butyl 4 - ( 7 - br0m0 - 3 , 4 - dihydr0 - 2H - 1 , 4 - benz0xazin - 3 - yl ) piperidine - 1 - carboxylate. Br 0 N O I 1<. A suspension of tert - buty1 4 - ( 7 - bromo - 2H - l , 4 - benzoxazin - 3 - y1 ) piperidine - 1 - carboxy1ate ( crude Intermediate B7 ; 952 mg , 2.4 mmo1 ) in ethanol ( 25 mL ) Was treated With NaBH4 ( 200 mg , 5.26 mmol ) and stirred for 6 h. To the reaction mixture Was then added HOAc ( 1.5 mL ) fo11oWed by 2 M NaOH ( 13 mL ) . The ethano1 Was remoVed under reduced pressure and the residue Was extracted With DCM. The organic 1ayer Was concentrated and the residue Was puriﬁed by ﬂash chromatography on silica using EtOAc / n - hexane ( 1 : 2 ) as eluent. Yield 306 mg. Ana1ytical HPLC : purity 100% ( System A ) ; LRESIMS ( ESI + ) m / z = 341 / 343 ( M + H - tBu ) + . EXAMPLE B1 tert - Butyl 4 - { 7 - [ 4 - ( methylsulf0nyl ) phenyl ] - 3 , 4 - dihydr0 - 2H - 1 , 4 - benz0xazin - 3 - yl } - . ‘ * 90 w. A suspension of tert - buty1 4 - ( 7 - bromo - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazin - 3 - y1 ) piperidine - 1 - . piperidine - 1 - carb0xylate. carboxy1ate ( Intermediate B8 ; 200 mg , 0.50 mmol ) , ( 4 - methy1sulfony1phenyl ) boronic acid. 10. 15. 20. 25. WO 2009 / 150144 _ 141 _ PCT / EP2009 / 057074. ( 120 mg , 0.6 mmol ) , NaHCO3 ( 126 mg , 1.5 mmol ) , PPh3 ( 20 mg , 0.075 mmol ) and Pd ( OAc ) 2 ( 6 mg , 0.025 mmol ) in 80% EtOH ( 4 mL ) Was heated at 80 OC oVernight. The reaction mixture Was ﬁltered through Celite and the ﬁltrate Was concentrated. The residue Was dissolVed in DCM and Washed With 5% NaHCO3 and brine. Flash chromatography using gradient elution ( 45 —> 60% EtOAc in n - hexane ) gaVe the title compound. Yield 30 mg ( 13% ) . Analytical HPLC : purity 98% ( System A ) ; HRESIMS ( ESI + ) calcd for C25H32N2O5S 472.2032 , found 472.2039. EXAMPLE B2 3 - [ 1 - ( Cyc ] 0hexylacetyl ) piperidin - 4 - yl ] - 7 - [ 4 - ( methylsulf0nyl ) phenyl ] - 3 , 4 - dihydr0 - 2H - . 1 , 4 - benz0xazine triﬂu0r0acetate. - CF3CO2H m. A suspension of tert - butyl 4 - { 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazin—3—yl } piperidine—1—carboxylate ( Example B1 ; 63 mg , 0.13 mmol ) in DCM ( 0.8 mL ) and TFA ( 0.2 mL ) Was stirred for 30 min and then concentrated. The residue Was partitioned betWeen CHCl3 ( 20 + 10 mL ) and 1 M Na2CO3 ( 2 mL ) and the combined organic layers Were concentrated to giVe 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 - piperidin - 4 - yl - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazine. The deprotected material Was then treated With DMF ( 0.8 mL ) , triethylamine ( 0.031 mL , 23 mg , 0.226 mmol ) and cyclohexylacetic acid ( 8l6 mg , 0.113 mmol ) followed by the addition of TBTU ( 43 mg , 0.135 mmol ) . The mixture Was stirred at r. t. oVemight. The solVent Was remoVed under reduced pressure and the residue Was puriﬁed by preparatiVe HPLC ( System D ) . Yield 16 mg ( 20% ) . Analytical HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C2gH35N2O4S 496.2396 , found 496.2407. 10. 15. 20. 25. 30. WO 2009 / 150144 _ 142 _ PCT / EP2009 / 057074. EXAMPLE B3 3 - ( 1 - Benz0ylpiperidin - 4 - yl ) - 7 - [ 4 - ( methylsulf0nyl ) phenyl ] - 3 , 4 - dihydr0 - 2H - 1 , 4 - . benz0xazine triﬂu0r0acetate. The title compound Was prepared from tert - butyl 4 - { 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazin - 3 - yl } piperidine - 1 - carboxylate ( Example B1 ; 42 mg , 0.089 mmol ) and benzoic acid ( 14 mg , 0.113 mmol ) using the conditions described for Example B2. Yield 15 mg ( 28% ) . Analytical HPLC : purity 100% ( System A ) ; HRESIMS ( ESI + ) calcd for C27H2gN204S 476.1770 , found 476.1763. BIOLOGICAL TESTS. Human GPRI I9 Actz ' vz ' zfy Assay. Agonists to the human GPR119 receptor Were characterized by measuring human GPR119 receptor - mediated stimulation of cyclic AMP ( cAMP ) in HEK 293 cells expressing the human GPR119 receptor. Brieﬂy , cAMP content Was determined using a cAMP kit based on HTRF technology ( Homogeneous Time - ResolVed Fluorescence , Cisbio Cat. no. 62AM2PEC ) . HEK293 cells stably expressing the human GPR119 receptor ( HEK293 - hGPR119 cells ) Were cultured in DMEM ( Gibco # 31966 - 021 ) supplemented With 10% BoVine Calf Serum ( Hyclone # SH30072.03 ) , and 500 ug / mL Hygromycin B ( Roche Diagnostics 843555 ) . At 80% conﬂuency , cells Were detached using Trypsine and aliquoted at a density of 5x106 cells / mL in freezing medium ( DMEM ( Gibco # 31966 - 021 ) , 20% BCS ( Hycl0ne # SH30072.03 ) , 10% DMSO ( Sigma #D2650 ) and stored at - 135 0C. On the experimental day , HEK293 - hGPR119 cells Were thaWn and diluted to 0.4x106 cells / mL in assay buffer ( 1x HBSS ( Gibco Cat. no. 14025 - 049 ) , 20 mM Hepes ( Gibco Cat. no.15630 - 056 ) , 0.1% BSA , pH 7.4 ) and incubated With test substances for 20 min at room temperature. Aﬂer addition of HTRF reagents diluted in lysis buffer , the 96 - or 384 - Well plates Were. incubated 1 hour , folloWed by measuring the ﬂuorescence ratio at 665 nm / 620 nm. Test. 10. 15. 20. 25. 30. WO 2009 / 150144 _ 143 _ PCT / EP2009 / 057074. substances Was diluted in compound buffer ( 1x HBSS ( Gibco Cat. no. 14025 - 049 ) , 20 mM Hepes ( Gibco Cat. no.15630 - 056 ) , 0.1% BSA , 2 mM IBMX ( Sigma - Aldrich Cat. No. I70l8 , pH 7.4 ) . The potency of the agonist Was quantiﬁed by determining the concentration that caused 50% actiVation of hGPR119 eVoked increase in cAMP , EC50. Compounds of the inVention shoWed a concentration - dependant increase in intracellular. cAMP leVel and generally had an EC50 Value of <10 uM. Hamster GPRI I 9 Activity Assay. Agonists to the GPR119 receptor are characterized by measuring receptor - mediated stimulation of cyclic AMP in HIT - T15 cells ( Hamster beta - cell line , American Type Culture Collection ) endogenously expressing the hamster GPR119. HIT - T15 cells are groWn in suitable media ( typically Fl2 Kaighn ' s Nutrient Mixture Kaighn ' s modiﬁcation supplemented With 10% Horse serum , 1.5 g / L sodium bicarbonate , 2.5% dialyzed and heat - inactiVated Fetal BoVine Serum ) as recommended by the proVider. Cells are trypsinated , resuspended in grthh media supplemented With 10 % DMSO , aliquoted and frozen as ready - to - use Vials. For potency analyses , frozen cells are thaWed , spun and resuspended in HTRF assay buffer at a suitable cell density. Cells are treated With Various concentrations of test compounds , a reference compound to deﬁne 100% response , forskolin or buffer containing the same DMSO concentration as the compound solutions to deﬁne base line. Typically , stimulation proceeds for 15 to 30 minutes and thereafter the cAMP leVels are determined using the HTRF® kit ( Homogenous Time - ResolVed FRET , CisBio ) . Eﬂects 0f GPRI I9 A g0nists 0n GIac0se—StimaIated Insalin Release. In vitr0 experiments. The effect of GPR119 agonists on glucose - stimulated insulin release is determined in isolated pancreatic islets from Wistar rats and diabetic rat models , e. g. GK rat. Brieﬂy , islets are isolated from the rats by digestion With collagenase according to standard protocol. The islets are cultured for 24 h in RPMI - 1640 medium supplemented With 11.1 mM glucose and lO % ( Vol / Vol ) fetal calf serum. On the experimental day , batches of three is1ets are preincubated in KRB ( Krebs - Ringer bicarbonate ) buffer and 3.3 mM glucose for 30 min , 37 °C. Thereafter the batches With islets are incubated in 16.7 mM glucose and. 10. 15. 20. 25. WO 2009 / 150144 _ 144 _ PCT / EP2009 / 057074. KRB buffer supplemented With Vehicle or test compounds for 60min at 37 OC. Aliquots of the medium Will be frozen for measurement of insulin using a radioimmunoassay With. rabbit ant - porcine insulin antibodies. In viv0 experiments. The effects of GPR119 agonists on glucose stimulated insulin release is determined in diabetic mice models ( eg. Lep°b / 0b or diet - induced obese ( DIO ) mice ) undergoing an oral glucose tolerance test. Brieﬂy , oVemight fasted mice is giVen either Vehicle or test compound at desired doses Via oral gaVage. Based on the pharmacokinetic of the test compounds , a glucose boluse dose is deliVered Via oral gaVage 30min - 2hrs folloWing the test compound. Plasma glucose and insulin leVels are determined at desired time points oVer a 2 hour period using blood collection from tail nick. Plasma glucose is determined using a Glucometer and plasma insulin is determined using an insulin ELISA folloWing blood collection in heparinated tubes and centriﬁJgation. For GLP - 1 and GIP pharmacodynamic studies , Vehicle or test compounds are administered orally prior to glucose bolus dose. Blood is collected in tubes containing EDTA and a DPPIV inhibitor at desired time points. After centrifugation , plasma is collected and. analysed for actiVe GLP - 1 and GIP ( using ELISA kit ) . Eﬂects 0f GPRI I 9 A g0nists 0n Incretin Secreti0n and Body Weight. In viv0 experiments. The effect of GPR119 agonists on body Weight is determined in diabetic and obese mice models , eg. Lep°b / 0b or diet—induced obese ( DIO ) mice. The food intake and body Weight gain is measured during subchronic treatment With Vehicle or test compound Via oral gaVage. At the end of the experiment , Vena caVa blood is collected and e. g. HbA1c , GLP - 1 , insulin , ALAT , ASAT arc mcasurcd. 10. 15. 20. 25. 30. WO 2009 / 150144. CLAIMS. 145 PCT / EP2009 / 057074. 1. A compound of Formula ( Ia ) . 1. Ar W\ U X Y / L\‘ [ : ; ; : ﬁ ] m N m \R1. ( 1a ) . or a pharmaceutically acceptable salt , solVate , hydrate , geometrical isomer , tautomer , . optical isomer or N - oxide thereof , Wherein : . W , X and Y are each independently CH2 , O , NH or N ( CH3 ) , proVided that at least one ofW and X is CH2 ; . m is each independently 0 or 1 ; . R1 is 4C ( O ) OR2 , 4C ( O ) R2 , 4C ( O ) NR2R3 , 4C ( O ) CH2NR2R3 , 4CH2C ( O ) NR2R3 , —S ( O ) 2R2 , —C ( O ) C ( O ) R9 or a 5 - or 6 - membered heteroary1 group linked Via a ring. carbon atom , Wherein said heteroaryl group is optionally substituted With C1 - 4 - alkyl ; . Ar1 is phenyl or heteroaryl , each of Which is optionally independently substituted in. one or more positions With a substituent selected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) . ( j ) ( k ) . CF3SO3 , . halogen selected from bromine , chlorine and ﬂuorine , C1 - 4 - alkylsulfo ximine , —S ( O ) R4 , . —S ( O ) 2R4 , —S ( O ) 2NR5R5 , —NR6S ( O ) 2R4 , —CH2 - NR6C ( O ) R4 , —NR6C ( O ) R4 , —C ( O ) NR5R5 , —CH2 - C ( O ) NR5R5 , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( 1 ) . ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) . ( s ) ( t ) ( u ) ( V ) ( W ) ( X ) ( y ) ( z ) ( aa ) ( bb ) ( cc ) ( dd ) ( ee ) ( ff ) ( gg ) ( hh ) ( ii ) ( ii ) ( kk ) ( 11 ) . PCT / EP2009 / 057074. —146—. —C ( O ) R4 , . H2N - C ( O ) O— , . CH3 - NH - C ( O ) O— , . ( CH3 ) 2NC ( O ) O— , . CH3OC ( O ) NH— , . C - heterocyclyl , optionally substituted With C1_4 - alkyl , N - heterocyclylcarbonylVinyl , Wherein N - heterocyclyl is substituted With C1 - 4 - alkyl , . —CN , . —OR8 , . —SCF3 , . —NO2 , . C—heterocyclylsulfonyl , optionally substituted With C1_4—alkyl , —NR5R5 , . —C ( OH ) CH3CF3 , . [ CF3CH3 ( OH ) C ] - C1_6 - alkyl , . cyano - C1_6 - alkyl , . guanidino , . amidino , . C1_6 - alkyl , . C1_6 - alkylthio , . C1_4 - alkoxy - C1_4 - alkyl , . ﬂuoro - C1_4 - alkyl , . C2_6—alkenyl , . ﬂuoro - C2_4 - a1keny1 , . hydroxy - C1_6 - alkyl , . C1_4 - alkylsulfonyl - C1_4 - alkyl , hydroxy - C2_4 - alkoxy - C1_4 - alkyl , . ( mm ) C2_3 - acyl - C1_3 - alkyl , . ( nn ) ( 00 ) ( pp ) ( qq ) ( rr ) . C2_6 - alkynyl , C3_6 - cycloalkyl , hydroxy - C3 - 6 - cycloalkyl , ﬂuoro - C3_6 - cyc1oa1ky1 , methyl - C3_6 - cycloalkyl , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( SS ) . —147—. PCT / EP2009 / 057074. C3_6 - cycloalkyl - C1_4 - alkyl , Wherein C3 - 6 - cycloalkyl is optionally. substituted With methyl , . ( tt ) C - heterocyclylcarbonyl , optionally substituted With C1_4 - alkyl , . ( uu ) C3_6 - cycloalkylthio , ( w ) R5R5N - C1_2 - alky1 , ( WW ) — ( CH2 ) nC ( O ) OR7 , Wherein n is 0 , 1 , 2 or 3 , . ( xx ) phenyl , and. ( yy ) heteroaryl , . Wherein phenyl or heteroaryl as substituent on Ar1 is optionally substituted in one or. more positions With a substituent independently selected from the group Z1. consisting of : . ( a ) ( b ) ( c ) ( d ) ( e ) ( f ) ( g ) ( h ) . ( j ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) ( s ) ( t ) ( 11 ) ( V ) ( W ) . halogen selected from bromine , chlorine and ﬂuorine , . C1_4—alkyl , . hydroxy , . C1 _4 - alkoxy , —OCF3 , . —SCF3 , . —CN , —C ( OH ) CH3CF3 , hydroxy - C1_4 - alkyl , —CF3 , . —S ( O ) 2CH3 , —S ( O ) 2NH2 , —S ( O ) 2NHCH3 , —S ( O ) 2N ( CH3 ) 2 , —N ( CH3 ) S ( O ) 2CH3 , —N ( CH3 ) C ( O ) CH3 , —C ( O ) NH2 , —C ( O ) NHCH3 , —C ( O ) N ( CH3 ) 2 , —C ( O ) CH3 , N - heterocyclylmethyl , . N - heterocyclyl , optional1y substituted With methy1 , . phenoxy , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( X ) ( V ) ( Z ) ( aa ) . — - 148 - —. —NH2 , —NHCH3 , —N ( CH3 ) 2 , and. methoxycarbonyl ; . R2 is selected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( ﬂ ( g ) ( h ) ( D G ) ( k ) ( D ( nD. ( 0 ) ( p ) ( q ) ( r ) ( s ) ( 0 ( u ) . ( V ) ( VV ) ( X ) ( V ) . ( aa ) . C 1 _6 - alkyl , C1_6 - alkoxy - C1_6 - alkyl , hydroxy - C2_6 - alkyl , ﬂuoro - C2_6 - alkyl , amino - C2_6 - alkyl , C1_3 - alkylamino - C2_6 - alkyl , di ( C1_3—alkyl ) amino - C2_6—alkyl , cyano - C1_6 - alkyl , . C1 _6 - alkylsulfonyl - C2_6 - alkyl , C2_3 - acylamino - C2_4 - alkyl , C1_4 - alkylthio - C2_4 - alkyl , C2_4 - acyl - C1_4 - alkyl , C3_6 - alkynyl , . C3_6 - alkenyl , . C3_7 - cycloalkyl , C5_g - cycloalkeny1 , . PCT / EP2009 / 057074. C - heterocyclyl , optionally substituted With C1_4 - alkyl , . C7_g—bicyclyl , optionally substituted With hydroxy , . C7_g - bicyc1y1methy1 , . azabicyclyl , optionally substituted With hydroxy , C3_7 - cycloalkyl - C1_4 - alkyl , Whercin cycloalkyl is optionally substituted. With methyl or hydroxy , C1_6 - alkylsulfonyl - C2_6 - alkyl , C2_3 - acyl - C1_4 - alkyl , diphenylmethyl , arylcarbonyl - C1 , 4 - alkyl , heteroarylcarbonyl - C1_4 - alkyl , [ CF3CH3 ( OH ) C ] - C1_6 - alkyl , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( bb ) . ( CC ) . ( dd ) ( ee ) ( fD ( gg ) ( hh ) ( ﬁ ) ( U ) ( kk ) ( H ) . 149 PCT / EP2009 / 057074. N - heterocyclylcarbonyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . C - heterocyclylcarbonyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . aminocarbonyl - C2_6 - alkyl , . C1_3 - alkylaminocarbonyl - C2_6 - alkyl , di ( C13 - alkyl ) aminocarbonyl - C2_6 - alkyl , . hydroxy - C2_4 - alkoxy - C2_4 - alkyl , . hydroxy - C4_6 - cycloalkyl , . oxo - C4_6 - cycloalkyl , . ﬂuoro - C4_6 - cyc1oa1ky1 , . C1_3 - alkoxy - C4_6 - cycloalkyl , . methyl - C3_6—cycloalkyl , . ( mm ) oxo - N - heterocyclyl - C2_4 - alkyl , . ( nn ) ( 00 ) ( pp ) ( qq ) . ( rr ) . ( SS ) ( tt ) . ( uu ) ( VV ) . ﬂuoro - N - heterocyclyl - C2_4 - alkyl , . amino - N - heterocyclyl - C2_4 - alkyl , . hydroxy - N - heterocyclyl - C2_4 - alkyl , . N - heterocyclyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . C - heterocyclyl - C1_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . aryl , . aryl - C1_4 - alkyl , . aryl—C3_6—alkenyl , . aryl - C3_6 - alkynyl , . ( WW ) aryloxymethyl , . ( XX ) ( y3 ) ( zz ) . hetcroaryl , hetero aryl - C 1 _4 - alkyl , heteroaryl - C3_6 - alkenyl , and. ( aaa ) heteroaryl - C3_6 - alkynyl , . Wherein any aryl or heteroaryl residue , alone or as part of another group , is. optionally independently substituted in one or more position With a substituent. selected from the group Z1 as deﬁned aboVe ; . 10. 15. 20. 25. 30. WO 2009 / 150144. —150—. R3 is selected from : . ( a ) ( b ) ( c ) ( d ) ( e ) ( D ( g ) ( h ) ( D G ) ( k ) ( D ( nD. hydrogen , . C 1 _6 - alkyl , . ﬂuoro - C2_6 - alkyl , hydroxy - C2_6 - alkyl , C1_6 - alkoxy - C2_6 - alkyl , amino - C2_6 - alkyl , C1_3 - alkylamino - C2_6 - alkyl , di ( C13 - alkyl ) amino - C2_6 - alkyl , cyano - C1_6 - alkyl , C1_6 - alkylsulfonyl - C2_6 - alkyl , C2_3 - acylamino - C2_4 - alkyl , C1_4—alkylthio - C2_4—alkyl , and C2_4 - acyl - C1_4 - alkyl ; . PCT / EP2009 / 057074. or R2 and R3 together With the nitrogen to Which they are attached form a. heterocyclic ring , Wherein said heterocyclic ring may be optionally substituted With : . i ) a substituent selected from : . ( aa ) ( bb ) ( CC ) ( dd ) ( CC ) ( fD. ( gg ) . hydroxy , . C 1 - 3 - alkyl , . amino , . methylamino , dimethylamino , hydroxy - C1 - 2 - alkyl , and. aminomethyl ; . ii ) one or tWo oxo groups ; or. iii ) one or tWo ﬂuorine atoms , . proVidcd that thn thc substitucnt is sclcctcd from ﬂuorinc , hydroxy , amino , . methylamino and dimethylamino , said substituent is attached to the heterocyclic ring. at a position other than alpha to a heteroatom ; . R4 is independently selected from : . ( a ) ( b ) ( C ) . C1 - 6 - alkyl , ﬂuoro - C1_6 - alky1 , hydroxy - C2_6 - alkyl , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( d ) ( e ) ( D ( g ) ( h ) ( D G ) ( k ) ( D. ( HD. ( 0 ) ( p ) ( q ) ( r ) ( S ) G ) ( u ) ( V ) ( VV ) . ( X ) . ( y ) ( Z ) ( aa ) ( bb ) ( CC ) . _ 151 PCT / EP2009 / 057074. C1_4 - alkoxy - C2_4 - alkyl , . C2_4 - acyl - C1_4 - alkyl , . carboxy - C1_3 - alkyl , . C3_6 - cycloalkyl , . oxo - C4_6 - cyclo alkyl , . hydroxy - C4_6 - cycloalkyl , . ﬂuoro - C4_6 - cycloalkyl , . methyl - C3_6 - cycloalkyl , . N - heterocyclylcarbonyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . N - heterocyclyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . oxo—N—heterocyclyl—C2_4—alkyl , . ﬂuoro - N - heterocyclyl - C2_4 - alkyl , . hydroxy - N - heterocyclyl - C2_4 - alkyl , . amino - N - heterocyclyl - C2_4 - alkyl , . aminocarbonyl - C2_4 - alkyl , . C1_3 - alkylaminocarbonyl - C2_4 - alkyl , di ( C1_3 - alkyl ) aminocarbonyl - C2_4 - alkyl , . C2_3 - acylamino - C2_4 - alkyl , . hydroxy - C2_4 - alkoxy - C2_4 - alkyl , . C - heterocyclylcarbonyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . C3_6—cycloalkyl—C1_2 - alkyl , Wherein cycloalkyl is optionally substituted With methyl , . amino - C2_4 - alkyl , . C 1 _2 - alkylamino - C2_4 - alkyl , . di ( C1_2 - alkyl ) amino - C2_4 - alkyl , . phenyl , and. heteroaryl , . Wherein any phenyl or heteroaryl residue is optionally substituted in one or more. positions With a substituent independently selected from the group Z2 consisting of : . ( a ) ( b ) . halogen selected from chlorine and ﬂuorine , . C1_4 - alkoxy , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( c ) ( d ) ( C ) ( D ( g ) ( h ) . —152—. hydroxymethyl , —CN , . - CF3 , . C 1 _4 - alkyl , —OCF3 , and —C ( O ) CH3 ; . R5 is each independently selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D. ( g ) . ( h ) . G ) ( k ) ( 1 ) ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) ( S ) ( t ) ( 11 ) . hydrogen , . C 1 _6 - alky1 , . C3 - 6 - alkenyl , C3_6 - cycloalkyl , methyl - C3_6—cycloalkyl , . C3_6 - cycloalkyl - C1 - 4 - alkyl , Wherein cycloalkyl is optionally substituted. With hydroxy or methyl , . N - heterocyclyl - C2 - 4 - alkyl , Wherein heterocyclyl is optionally substituted. With methyl , . heteroaryl - C1 - 4 - alkyl , Wherein heteroaryl is optionally substituted With. methyl , . carboxy - C1 - 3 - alkyl , ﬂuoro - C2_4 - alkyl , amino - C2_6 - alkyl , cyano - C1_6 - alkyl , hydroxy—C2_6—alkyl , dihydroxy - C2_6 - alkyl , C1_4 - alkoxy - C2_4 - alkyl , . C 1 _4 - alkylamino - C2_4 - alkyl , di ( C1_4 - alkyl ) amino - C2_4 - alkyl , aminocarbonyl - C1_4 - alkyl , C2_3 - acylamino - C2_4 - alkyl , C1_4 - alkylthio - C2_4 - alkyl , C2 , 4 - acyl - C1 , 4 - alkyl , and C1_4 - alkylsulfonyl - C1_4 - alkyl , . PCT / EP2009 / 057074. 10. 15. 20. 25. 30. WO 2009 / 150144. 15 3 PCT / EP2009 / 057074. or tWo R5 groups together With the nitrogen to Which they are attached form a. heterocyclic ring , Wherein said heterocyclic ring may be optionally substituted With : . i ) a substituent selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D ( g ) . hydroxy , . C 1 - 3 - alkyl , . amino , . methylamino , dimethylamino , hydroxy - C1 - 2 - alkyl , and. aminomethyl ; . ii ) one or tWo oxo groups ; or. iii ) one or tWo ﬂuorine atoms , . proVided that When the substituent is selected from ﬂuorine , hydroxy , amino , . methylamino and dimethylamino , said substituent is attached to the heterocyclic ring. at a position other than alpha to a heteroatom ; . or tWo R5 groups together With the nitrogen to Which they are attached form the. group 4 - ( pyrimidin - 2 - yl ) piperazin - 1 - yl ; . R6 is independently selected from : . ( a ) ( b ) ( C ) . hydrogen , C1_4 - alkyl , and hydroxy - C2_4 - alkyl ; . R7 is independently selected from : . ( a ) ( b ) . hydrogen , and C1_4 - alkyl ; . R8 is independently selected from : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D. hydrogen , C1_6 - alkyl , ﬂuoro - C1_6 - alkyl , hydroxy - C2.6 - alkyl , amino - C2_6 - alkyl , . C1_3 - alkylamino - C2_4 - alkyl , . 10. 15. 20. 25. WO 2009 / 150144 PCT / EP2009 / 057074. —154—. ( g ) di ( C13 - alkyl ) amino - C2_4 - alkyl , . ( h ) C1_4 - alkylsulfonyl - C2_4 - alkyl , . ( i ) N - heterocyclyl - C2_4 - alkyl , Wherein heterocyclyl is optionally substituted With methyl , . ( j ) C - heterocyclyl , optionally substituted With methyl , . ( k ) C2_3 - acylamino - C2_4 - alkyl , . ( l ) [ CF3CH3 ( OH ) C ] - C1_6 - alkyl , . ( m ) C3_6 - cycloalkyl , . ( n ) methyl - C3_6 - cycloalkyl , . ( o ) C3_6 - cycloalkyl - C1_2 - alkyl , Wherein cycloalkyl is optionally substituted With methyl , . ( p ) aryl , and. ( q ) heteroaryl , . Wherein any aryl or heteroaryl residue is optionally independently substituted in one. or tWo positions With a substituent selected from the group Z2 as deﬁned aboVe ; and. R9 is aryl or heteroaryl , each of Which is optionally substituted in one or more positions With a substituent independently selected from the group Z2 as deﬁned. aboVe. A compound according to claim 1 haVing Formula ( Ib ) : . ( 1b ) . Wherein W and X are each independently CH2 or O , proVided that at least one of W and X is CH2 ; . Y is CH2 , 0 or NH ; and. Ar1 , Z ] , Z2 , R1 to R9 are as deﬁned in claim l. 10. 15. 20. 25. 30. WO 2009 / 150144 _ 155 _ PCT / EP2009 / 057074 3. A compound according to claim 1 or 2 haVing Formula ( Ic ) : Ar1 mO N\ R1 ( Ic ) . Wherein Z1 , Z2 , R1 to R6 are as deﬁned in claim 1 ; . Ar1 is phenyl or heteroaryl , each of Which is optionally substituted in one or tWo. positions With a substituent independently selected from the group Z3 consisting of : . ( a ) ( b ) ( C ) ( d ) ( C ) ( D. ( g ) ( h ) ( D. G ) . ( k ) ( 1 ) . ( m ) ( n ) ( 0 ) ( p ) ( q ) ( r ) . ( S ) ( t ) ( 11 ) ( V ) . CF3SO3 , . halogen selected from bromine , chlorine and ﬂuorine , C1 - 4 - alkylsulfoximine , . —S ( O ) R4 , . —S ( O ) 2R4 , . —S ( O ) 2NR5R5 , . —NR6S ( O ) 2R4 , . —NR6C ( O ) R4 , . —CH2 - NR6C ( O ) R4 , . —C ( O ) NR5R5 , . —CH2 - C ( O ) NR5R5 , . —C ( O ) R4 , . H2N—C ( O ) O * , . CH3 - NH - C ( O ) O— , . ( CH3 ) 2NC ( O ) O— , . —NHC ( O ) OCH3 , . C - heterocyclyl , optionally substituted With methyl , N - heterocyclylcarbonylVinyl , Wherein N - heterocyclyl is optionally substituted With methyl , . —CN , . —OR8 , . —SCF3 , . nitro , . 10. 15. 20. 25. 30. WO 2009 / 150144. ( W ) ( X ) ( y ) ( z ) ( aa ) ( bb ) ( CC ) ( dd ) ( CC ) ( fD ( gg ) ( hh ) ( iD Gi ) ( kk ) ( 11 ) . ] 56 PCT / EP2009 / 057074. C - heterocyclylsulfonyl , optionally substituted With methyl , —NR5R5 , . —C ( OH ) CH3CF3 , cyano - C1_6 - alkyl , . guanidino , . C1_6 - alkyl , . C1_3 - alkylthio , C1_4 - alkoxy - C1_4 - alkyl , ﬂuoro - C1_4 - alkyl , . C2_6 - alkenyl , ﬂuoro - C2_4 - alkeny1 , hydroxy - C1_6 - alkyl , C1_4—alkylsulfonyl - C1_4—alkyl , hydroxy - C2_4 - alkoxy - C1_4 - alkyl , C2_3 - acyl - C1_3 - alkyl , C2_6 - alkynyl , . ( mm ) C3_6 - cycloalkyl , . ( nn ) ( 00 ) ( pp ) ( qq ) ( rr ) ( SS ) ( tt ) ( uu ) . hydroxy - C3_6 - cycloalkyl , . ﬂuoro - C3_6 - cycloalkyl , . methyl - C3_6 - cycloalkyl , . C - heterocyclylcarbonyl , optionally substituted With methyl , C3_6 - cycloalky1 - C1_4 - alky1 , . R5R5N - C1_2 - alkyl , . — ( CH2 ) nC ( O ) OH , Wherein n is 1 , 2 or 3 , and. heteroaryl , . Wherein any heteroaryl residue as substituent on Ar1 is optionally substituted in one. or morc positions With a substitucnt indcpendcntly sclcctcd from thc group Z2 as. deﬁned in claim 1 ; . R8 is independently selected from : . ( a ) ( b ) ( C ) ( d ) . hydrogen , C1 - 4 - alkyl , . CF3 , C3_5 - cycloalkyl , . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —157—. ( e ) methyl - C3_5 - cycloalkyl , ( f ) di ( C1_3 - alkyl ) amino - C2_3 - alkyl , and ( g ) C - heterocyclyl , optionally substituted With methyl ; . R9 is phenyl Which is optionally substituted in one or tWo positions With a substituent. independently selected from the group Z2 as deﬁned in claim 1. A compound according to claim 1 or 2 haVing Formula ( Id ) : . Wherein Z1 , Z2 , R1 to R6 are as deﬁned in claim l ; R8 and R9 are as deﬁned in claim 3 ; Ar1 is phenyl Which is optionally substituted in one or tWo positions With a. substituent independently selected from the group Z3 as deﬁned in c1aim 3. A compound according to any one of claims 1 to 4 , Which is selected from : . - benzyl 4 - ( 6 - { 4 - [ ( dimethylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - piperidine - 1 - carboxylate ; . - benzyl 4— { 6 - [ 4— ( methylsulfonyl ) phenyl ] —4H— 1 , 3—benzodioxin—2—yl } piperidine— 1— carboxylate ; . - benzyl 4 - ( 6 - quinolin - 5 - yl - 4I - I - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - 4 - { 2 - [ 1 - ( 3 , 4 - dichlorobenzoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - N , N - dimethylbenzamide ; . - 4 - ( 2 - { l - [ ( 2 , 4 - diﬂuorophenyl ) acetyl ] piperidin - 4 - yl } - 4I - I - l , 3 - benzodioxin - 6 - yl ) - N , N - dimethylbenzamide ; . - N , N - dimethyl - 4 - [ 2 - ( 1 - { [ 3 - ( triﬂuoromethyl ) phenyl ] acetyl } piperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] benzamide ; . - 4 - ( 2 - { 1 - [ ( 4 - methoxyphenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - yl ) - N , N - . dimethylbenzamide ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —158—. - 4 - ( 2 - { 1 - [ ( 4 - cyanophenyl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - yl ) - N , N - . dimethylbenzamide ; . - 4 - { 2 - [ 1 - ( 1H - indol - 3 - ylacetyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - N , N - . dimethylbenzamide ; . - N , N - dimethyl - 4 - ( 2 - { 1 - [ ( 1 - methyl - 1H - indol - 3 - yl ) acetyl ] piperidin - 4 - yl } - 4H - 1 , 3 - . benzodioxin - 6 - yl ) benzamide ; . - 4 - { 2 - [ 1 - ( cyclohexylacetyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - N , N - . dimethylbenzamide ; . - N , N - dimethyl - 4 - { 2 - [ 1 - ( 3 - methyl - 3 - phenylbutanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - . benzodioxin - 6 - yl } benzamide ; . - 4 - ( 2 - { 1 - [ 3 - ( 4 - methoxyphenyl ) propanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - . yl ) - N , N - dimethylbenzamide ; . - 4 - ( 2— { 1 - [ 3 — ( 3—chloro—4—methoxyphenyl ) propanoyl ] piperidin - 4 - yl } - 4H—1 , 3 —. benzodioxin - 6 - yl ) - N , N - dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ 3 - ( 4 - hydroxyphenyl ) propanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - . yl ) - N , N - dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ 3 - ( 1H - indo l - 3 - yl ) propanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - yl ) - . N , N - dimethylbenzamide ; . 0 4 - { 2 - [ 1 - ( 3 - cyclohexylpropanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - yl } - N , N - . dimethylbenzamide ; . - 4 - ( 2 - { 1 - [ 4 - ( 4 - ﬂuorophenyl ) butanoyl ] piperidin - 4 - yl } - 4H - 1 , 3 - benzodioxin - 6 - yl ) - . N , N - dimethylbenzamide ; . - N , N - dimethyl - 4 - { 2 - [ 1 - ( 4 - oxopentanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - benzodioxin - 6 - . yl } benzamide ; . - N , N - dimethyl - 4 - { 2 - [ 1 - ( 4 - oxo - 4 - pyrrolidin - 1 - ylbutanoyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - . benzodioxin - 6 - yl } benzamide ; . - bcnzyl 4 - ( 6 - { 4 - [ ( dicthylamino ) carbonyl ] phcnyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - benzyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperidin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine - l - carboxylate ; . - benzyl 4 - ( 6 - { 4 - [ ( 4 - oxopiperidin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine - l - carboxylate ; . - benzyl 4 - { 6 - [ 5 - ( methylsulfonyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —159—. - 1 - ( 2 - ﬁ1royl ) - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine ; . - 1 - [ ( 4 - ﬂuorophenoxy ) acetyl ] - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzo - . dioxin - 2 - yl } piperidine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - 1 - ( 1H - pyrrol - 2 - yl - . carbonyl ) piperidine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - 1 - ( 1H - tetrazol - 1 - yl - . acetyl ) piperidine ; . - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] pyridine ; . - 4 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] pyridine ; . - 2 - [ ( 4— { 6— [ 4— ( methylsulfonyl ) phenyl ] —4H—1 , 3 —benzodioxin - 2 - yl } piperidin - 1 - yl ) —. carbonyl ] pyrazine ; . - 6 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] quinoxaline ; . - 1 - ( 4 - isopropoxybenzoyl ) - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - . yl } piperidine ; . 0 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - 1 - ( 2 - naphthoyl ) - . piperidine ; . - 1 - benzoyl - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine ; - 5 - methyl - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) carbonyl ] pheno l ; . o 5 - [ ( 4— { 6— [ 4— ( methylsulfonyl ) phenyl ] —4H—1 , 3 —benzodioxin - 2 - yl } piperidin - 1 - yl ) —. carbonyl ] - 2 - phenoxypyridine ; . - 1 - ( diphenylacetyl ) - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . pipcridinc ; . - 5 - isopropoxy - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) carbonyl ] pyridine ; . - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - 1 - ( 3 , 3 , 3 - triﬂuoro - . propanoyl ) piperidine ; . - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4I - I - l , 3 - benzodioxin - 2 - yl } piperidin - l - yl ) - . carbonyl ] pyridin - 3 - ol ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —160—. o 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - 1 - propionyl - . piperidine ; . - 1 - [ ( 7 - methoxy - 1 - benzo furan - 2 - yl ) carbonyl ] - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - . 1 , 3 - benzodioxin - 2 - yl } piperidine ; . - dimethyl { 3 - [ ( 4 - { 6 - [ 4 - ( methylsulfo nyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) carbonyl ] phenyl } amine ; . - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] pheno l ; . - 2 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - 2 - . oxo - 1 - phenylethanone ; . - 1 - methyl - 4 - [ 3 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) - 3 - oxopropyl ] piperazine ; . - 1 - methyl—4— { 4— [ ( 4 - { 6— [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin—2—yl } - . piperidin - 1 - yl ) carbonyl ] phenyl } piperazine ; . - 1 - ( methoxyacetyl ) - 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine ; . - 3 , 5 - diﬂuoro - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) carbonyl ] pyridine ; . 0 4 - { 4 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidin - 1 - yl ) - . carbonyl ] benzyl } morpho line ; . 0 6 - bromo - 2 - [ ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) carbonyl ] pyridin - 3 - ol ; . - benzyl 4 - ( 6 - { 4 - [ ( methylsulfonyl ) amino ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine—1—carboxylate ; . - benzyl 4 - [ 6 - ( 4 - { [ ( 2 - morpholin - 4 - ylethyl ) amino ] sulfonyl } phenyl ) - 4H - 1 , 3 - . benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - bcnzyl 4 - { 6 - [ 4 - ( mcthylsulfonyl ) - 2 - nitrophenyl ] - 4H - 1 , 3 - bcnzodioxin - 2 - yl } - . piperidine - 1 - carboxylate ; . - benzyl 4 - { 6 - [ 2 - amino - 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine - 1 - carboxylate ; . - benzyl 4 - { 6 - [ 2 - { [ 2 - ( dimethylamino ) ethyl ] amino } - 4 - ( methylsulfo nyl ) phenyl ] - 4H - . 1 , 3 - benzodioxin - 2 - yl } piperi dine - l - carboxyl ate ; . - benzyl 4 - { 6 - [ 2 - { [ 2 - ( isopropylamino ) ethyl ] amino } - 4 - ( methylsulfonyl ) phenyl ] - 4H - . 1 , 3 - benzodioxin - 2 - yl } piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —161—. - benzyl 4 - ( 6 - { 4 - ( methylsulfonyl ) - 2 - [ ( 2 - morpho lin - 4 - ylethyl ) amino ] phenyl } - 4H - . 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - benzyl 4 - { 6 - [ 2 - [ 2 - ( dimethylamino ) ethoxy ] - 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - . benzodioxin - 2 - yl } piperidine - 1 - carboxylate ; . - N , N - diethyl - 2 - ( 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidin - 1 - yl ) acetamide ; . - 1 - benzoyl - 4 - { ( 2R * ) - 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine ; . - 1 - benzoyl - 4 - { ( 2S * ) - 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( methylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - . benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1—methylcyclopropyl ) methyl 4— ( 6— { 4— [ ( ethylamino ) carbonyl ] phenyl } —4H— 1 , 3 —. benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( allylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - . benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbonyl ] phenyl } - 4H - . 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . 0 ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxyethyl ) amino ] carbonyl } - . phenyl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroxypropyl ) amino ] carbonyl } - . phenyl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - methoxyethyl ) amino ] carbonyl } - . phenyl ) - 4H - 1 , 3 —benzodioxin - 2 - yl ] piperidine— l —carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxy - 1 , 1 - dimethylethyl ) amino ] - . carbonyl } phenyl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( 3 - hydroxyazetidin - 1 - yl ) carbonyl ] phcnyl } - . 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] phenyl } - . 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - l - carboxylate ; . - ( 1 - methylcyclopropyl ) methyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amino } carbonyl ) - . phenyl ] - 4H - l , 3 - benzodioxin - 2 - yl } piperidine - l - carboxylate ; . - tert - butyl 4 - { 6 - [ 4 - ( methylsulfonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - . 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —162—. - tert - butyl 4 - { 6 - [ 4 - ( aminocarbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - . 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( dimethylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - tert - butyl 4 - { 6 - [ 4 - ( morpholin - 4 - ylcarbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine - 1 - carboxylate ; . - 2 - ( { 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodio xin - 6 - yl ] phenyl } sulfonyl ) - . ethano l ; . - 2 - ( { 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4I - I - 1 , 3 - benzodio xin - 6 - yl ] phenyl } sulfonyl ) - . ethanamine ; . - tert - butyl 4 - ( 6 - { 4 - [ ( methylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - tert - butyl 4— ( 6 - { 4— [ ( ethylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin—2—yl ) - . piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( allylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine - 1 - carboxylate ; . 0 tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxyethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - methylprop - 2 - en - 1 - yl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - . benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( but - 3 - en - 1 - ylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine— l —carboxylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroxypropyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - mcthoxycthyl ) amino ] carbonyl } phcnyl ) - 4H - 1 , 3 - bcnzo - . dioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydroxycyclopropyl ) methyl ] amino } carbonyl ) phenyl ] - 4H - . 1 , 3 - benzodioxin - 2 - yl } piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxy - 1 , 1 - dimethylethyl ) amino ] carbonyl } phenyl ) - 4H - . l , 3 - benzodioxin - 2 - yl ] piperidine - l - carboxyl ate ; . - tert - butyl 4 - ( 6 - { 4 - [ ( 3 - hydroxyazetidin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —163—. - tert - butyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - furyl ) ethyl ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - benzo - . dioxin - 2 - yl } piperidine - 1 - carboxylate ; . - 4 - [ 2 - ( 1 - benzo ylp i p eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - methylb enzamide ; - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - ethylb enzamide ; . - N - allyl - 4 - [ 2 - ( 1 - b enzo ylpiperidin - 4 - yl ) - 4H - l , 3 - b enzo dioxin - 6 - yl ] benzamide ; . - 4 - [ 2 - ( 1 - benzoy1pip eridin - 4 - y1 ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - cyclopropyl - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - ( 2 - hydroxyethyl ) - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - ( 2 - methylprop - 2 - en - . 1 - yl ) benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] - N - but - 3 - en - 1 - yl - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - ( 3 - hydroxypropyl ) - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpip eridin - 4 - yl ) - 4H - 1 , 3 - b enzo dioxin - 6 - yl ] - N - ( 2 - methoxyethyl ) - . benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] - N - [ ( 1 - hydroxy - . cyclopropyl ) methyl ] benzamide ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] - N - ( 2 - hydroxy - 1 , 1 - . dimethylethyl ) benzamide ; . - 1 - { 4— [ 2 - ( 1—benzoylpiperidin—4—yl ) —4H— 1 , 3 —benzodioxin—6—yl ] benzoyl } azetidin—3 —. ol ; . 0 1 - { 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4I - I - 1 , 3 - benzodioxin - 6 - yl ] benzoyl } - 4 - methyl - . pipcrazinc ; . - 4 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4H - 1 , 3 - benzodioxin - 6 - yl ] - N - [ 2 - ( 2 - ﬁ1ryl ) ethyl ] - . benzamide ; . - ethyl 4 - ( 6 - { 4 - [ ( methylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 4 - [ ( ethylamino ) carbonyl ] phenyl } - 4I - I - l , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —164—. - ethyl 4 - ( 6 - { 4 - [ ( allylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - . 1 - carboxylate ; . - ethyl 4 - ( 6 - { 4 - [ ( cyclopropylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxyethyl ) amino ] carbonyl } phenyl ) - 4H - l , 3 - benzodioxin - 2 - . yl ] piperidine - 1 - carboxylate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 2 - methylprop - 2 - en - 1 - yl ) amino ] carbonyl } phenyl ) - 4H - l , 3 - benzo - . dioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 4 - [ ( but - 3 - en - 1 - ylamino ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) - . piperidine - 1 - carboxylate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 3 - hydroxypropyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - benzodioxin - . 2 - yl ] piperidine - 1 - carboxylate ; . - ethyl 4— [ 6 - ( 4— { [ ( 2—methoxyethyl ) amino ] carbonyl } phenyl ) - 4I - I - 1 , 3 —benzodioxin - 2 - . yl ] piperidine - 1 - carboxylate ; . - ethyl 4 - { 6 - [ 4 - ( { [ ( 1 - hydroxycyc lopropyl ) methyl ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - . benzodioxin - 2 - yl } piperidine - 1 - carboxylate ; . - ethyl 4 - [ 6 - ( 4 - { [ ( 2 - hydroxy - 1 , 1 - dimethylethyl ) amino ] carbonyl } phenyl ) - 4H - 1 , 3 - . benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . 0 ethyl 4 - ( 6 - { 4 - [ ( 3 - hydroxyazetidin - l - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 4 - [ ( 4 - methylpiperazin - l - yl ) carbonyl ] phenyl } - 4H - 1 , 3 - benzodioxin - 2 - . yl ) piperidine - 1 - carboxylate ; . - ethyl 4 - { 6 - [ 4 - ( { [ 2 - ( 2 - ﬁ1ryl ) ethyl ] amino } carbonyl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - . yl } piperidine—1—carboxylate ; . - ethyl 4 - [ 6 - ( 4 - { [ 2 - ( hydroxymethyl ) morpholin - 4 - yl ] carbonyl } phenyl ) - 4H - 1 , 3 - . benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . 0 3 - ( 3 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4H - 1 , 3 - bcnzodioxin - 6 - yl } - . isoxazol - 5 - yl ) propanoic acid ; . 0 [ ( 5 - { 2 - [ 1 - ( tert - butoxycarbonyl ) piperidin - 4 - yl ] - 4I - I - 1 , 3 - benzodioxin - 6 - yl } - 2 - . furoyl ) amino ] acetic acid ; . - tert - butyl 4 - { 6 - [ 6 - ( methylsulfonyl ) pyridin - 3 - yl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperi dine - l - carboxyl ate ; . - tert - butyl 4 - { 6 - [ 5 - ( methylsulfonyl ) pyridin - 2 - yl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } - . piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —165—. - tert - butyl 4 - { 6 - [ 4 - ( 1H - tetrazol - 5 - yl ) phenyl ] - 4H - 1 , 3 - benzodioxin - 2 - yl } piperidine - . 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 2 - { [ amino ( imino ) methyl ] amino } - 4 - methyl - 1 , 3 - thiazo l - 5 - yl ) - 4H - . 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - pyridin - 4 - yl - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; - tert - butyl 4 - ( 6 - pyridin - 3 - yl - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; - tert - butyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - { 6 - [ 6 - ( morpholin - 4 - ylcarbonyl ) pyridin - 3 - yl ] - 4H - 1 , 3 - benzodioxin - 2 - . yl } piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert—butyl 4— { 6— [ 5 — ( morpholin—4—ylcarbonyl ) pyridin - 2 - yl ] —4H— 1 , 3 —benzodioxin—2—. yl } piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] - 2 - furyl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - ( 6 - { 5 - [ ( 1E ) - 3 - ( 4 - methylpiperazin - 1 - yl ) - 3 - oxoprop - 1 - en - 1 - yl ] - 2 - . thienyl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . 0 tert - butyl 4 - ( 6 - { 5 - [ ( lE ) - 3 - moIpholin - 4 - yl - 3 - oxoprop - 1 - en - 1 - yl ] - 2 - thienyl } - 4H - . 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . 0 tert - butyl 4 - ( 6 - { 5 - [ ( 4 - pyrimidin - 2 - ylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - . 1 , 3 - benzodioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - tert - butyl 4 - [ 6 - ( 5 - { [ [ 2 - ( dimethylamino ) ethyl ] ( methyl ) amino ] carbonyl } pyridin - 2 - . yl ) —4H— l , 3 —benzodioxin—2—yl ] piperidine—1—carboxylate ; . - tert - butyl 4 - [ 6 - ( 5 - { [ 4 - ( 2 - hydroxyethyl ) piperazin - 1 - yl ] carbonyl } pyridin - 2 - yl ) - 4H - . 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . 0 tert - butyl 4 - [ 6 - ( 6 - { [ [ 2 - ( dimcthylamino ) cthyl ] ( methyl ) amino ] carbonyl } pyridin - 3 - . yl ) - 4H - 1 , 3 - benzodioxin - 2 - yl ] piperidine - 1 - carboxylate ; . - ethyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . - isopropyl 4 - ( 6 - { 6 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 3 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - l - carboxylate ; . - ethyl 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benzo - . dioxin - 2 - yl ) piperidine - 1 - carboxylate ; . 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. —166—. o 1 - ( { 5 - [ 2 - ( 1 - benzoylpiperidin - 4 - yl ) - 4I - I - 1 , 3 - benzodio xin - 6 - yl ] pyridin - 2 - yl } - carbonyl ) - 4 - methylpiperazine ; . - 1 - [ ( 5 - { 2 - [ 1 - ( 2 - ethylbutanoyl ) piperidin - 4 - yl ] - 4I - I - 1 , 3 - benzodioxin - 6 - yl } pyridin - 2 - yl ) carbonyl ] - 4 - methylpiperazine ; . - 2 - [ 4 - ( 6 - { 5 - [ ( 4 - methylpiperazin - 1 - yl ) carbonyl ] pyridin - 2 - yl } - 4H - 1 , 3 - benzodioxin - 2 - yl ) piperidin - 1 - yl ] pyrimidine ; . - tert - butyl 4 - { 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazin - 3 - yl } - piperidine - 1 - carboxylate ; . - 3 - [ 1 - ( cyclo hexylacetyl ) piperidin - 4 - yl ] - 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - benzoxazine ; and. o 3 - ( 1 - benzoylpiperidin - 4 - yl ) - 7 - [ 4 - ( methylsulfonyl ) phenyl ] - 3 , 4 - dihydro - 2H - 1 , 4 - . benzoxazine. A compound according to any one of claims 1 to 5 for use in therapy. A compound according to any one of claims 1 to 5 for use in the treatment or prophylaxis of disorders relating to GPR119 actiVity , Wherein said disorders are selected from the group consisting of Type 1 diabetes , Type 2 diabetes , inadequate glucose tolerance , insulin resistance , hyperglycemia , hyperlipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , . reduced ﬁbrinolysis , endothelial dysfunction and osteoporosis. Use of a compound according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment or prophylaxis of disorders relating to GPR119 actiVity , Wherein said disorders are selected from the group consisting of Type 1 diabctcs , Typc 2 diabctcs , inadcquatc glucosc tolcrancc , insulin rcsistancc , hyperglycemia , hyperlipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , reduced ﬁbrinolysis , endothelial dysfunction and. osteoporosis. A method for the treatment or prophylaxis of disorders relating to GPR119 actiVity. Which comprises administering to a mammal , including man , in need of such. 10. 15. 20. 25. 30. WO 2009 / 150144 PCT / EP2009 / 057074. 10. 11. 12. 13. —167—. treatment an effectiVe amount of a compound according to any one of claims 1 to 5 , Wherein said disorders relating to GPRl19 actiVity are selected from the group consisting of Type 1 diabetes , Type 2 diabetes , inadequate glucose tolerance , insulin resistance , hyperglycemia , hyperlipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , reduced ﬁbrinolysis , endothelial. dysfunction and osteoporosis. A pharmaceutical formulation containing a compound according to any one of claims 1 to 5 as actiVe ingredient in combination With a pharmaceutically acceptable diluent. or carrier. The pharmaceutical formulation according to claim lO for use in the treatment or prophylaxis of disorders relating to GPR119 actiVity , Wherein said disorders are selected from the group consisting of Type 1 diabetes , Type 2 diabetes , inadequate glucose tolerance , insulin resistance , hyperglycemia , hyperlipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , . reduced ﬁbrinolysis , endothelial dysﬁrnction and osteoporosis. Use of a compound according to any one of claims 1 to 5 , in combination With a DPP - IV inhibitor , in the manufacture of a medicament for the treatment or prophylaxis of disorders relating to GPR119 actiVity , Wherein said disorders are selected from the group consisting of Type 1 diabetes , Type 2 diabetes , inadequate g1ucose to1erance , insulin resistance , hyperg1ycemia , hyper1ipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systcmic inﬂammation , rctinopathy , neuropathy , ncphropathy , athcrosclerosis , . reduced ﬁbrinolysis , endothelial dysﬁJnction and osteoporosis. A method for the treatment or prophylaxis of disorders relating to GPR119 actiVity Which comprises administering to a mammal , including man , in need of such treatment an effectiVe amount of a compound according to any one of claims 1 to 5 in combination With a DPP - IV inhibitor , Wherein said disorders relating to GPR119. actiVity are selected from the group consisting of Type 1 diabetes , Type 2 diabetes , . WO 2009 / 150144 PCT / EP2009 / 057074. 14. —168—. inadequate glucose tolerance , insulin resistance , hyperglycemia , hyperlipidemia , hypercholesterolemia , dyslipidemia , syndrome X , obesity , hypertension , chronic systemic inﬂammation , retinopathy , neuropathy , nephropathy , atherosclerosis , . reduced ﬁbrinolysis , endothelial dysfunction and osteoporosis. The pharmaceutical formulation according to claim 10 Which in addition comprises a. DPP - IV inhibitor. . |NTERNAT|ONAL SEARCH REPORT. lntemational appllcallon No. PCT / EP2009 / 057074. . . i ' NiiLiSS ' R3iii‘3 ' i°4%U§JE°T”i\%Ti§31 / 454 - A61K31 / 4545 A61K31 / 496 A61K31 / 497. A6lK31 / 5377 A61K31 / 538 007D405 / 04 007D405 / 14 C07D413 / 04 A61P3 / 00. Aocording to IntemaiionaI Patent C|assiﬁcation ( IPC ) or to both na1iona| cIassiiication and iPC. . B. FIELDS SEARCHED. . Mtnimum documenIation searched ( classiﬁcation system ioliowed by classiiication symbols ) . C07D A61K A61P. . Documentation searched other than minimum documentatlon to lhe exlenl that such documents are included in the tieids searched. . Elecironic daIa base consuIted during the intemationaI search ( name 0l data base and , where practicaL search lerms used ) . EPO - Internai , NPI Data , BIOSIS , EMBASE , CHEM ABS Data. . C_ DOCUMENTS CONS|DERED TO BE RELEVANT. . Calegory ' Citation oi document , with indication , where appropriate , ol the reIevanl passages ReIevant to claim No. . A wo 2006 / 067532 A ( PROSIDION LTD [ GB ] ; FYFE 1—14 MATTHEw COLIN THOR [ GB ] ; THOMAS GERARD HUGH [ ) 29 June 2006 ( 2006—O6 - 29 ) cited 1n the appiication. the whole document. A w0 2008 / 008895 A ( SMITHKLINE BEECHAM CORP 1 - 14 [ US ] ; AMMALA CARINA [ US ] ; BRISCOE CELIA [ US ] ) 17 January 2008 ( 2008—01—17 ) . the whole document. . . . See patenl famiiy annex. D Further documents are listed in the continuation ot Box C. . ‘ SpeciaI categories ot ciled documents : . . . . . ' T ' Iater document puinshed atterthe intematronaI tiling date or priorily date and not in contIict with the application but cited to understand the principIe or theory underiying the invention document oi particular relevance ; the claimed invention cannoi be oonsidered noveI or cannot be considered to involve an inventive slep when the document is taken alone document oi particular relevance ; the cIaimed invention. cannol be considered lo involve an inventive step when the documenl is oombined wilh one or more olher such docu—. ' A ' document deiining the general stale oi the art which is not oonsidered to be ol panicular reievance. ' E ' earlier document but published on or allerlhe inlernational ' X ' iiiing date. ' L ' document which may throw doubts on priority claim ( s ) or which is ci1ed to eslablIsh the publication date of another . y. cilation or other specia| reason ( as speciiied ) . ' O ' document relerring to an ora| disclosure. use , exhibﬂion or . olher means ments_ such oombination being obvlous to a person ski|ied ' P ' document pub|ished prior to the international iiling date bul m "m “1 |aterthan lhe priorily dale claimed ' 81‘ document member oi the same patent tamily. . Date ot lhe actua| oompietion ol the inlemaiiona| search Dale oi mailing ol lhe intemationaI search report. 25 August 2009. oz / o9 / 2oo9. . Name and maiIing address oi the ISA / European Patent Office , PB 5818 Palent|aan 2 NL - 2280 HV Riiswiik Tel. ( + 31—70 ) 340—2040. Fax : ( + 3i - 70 ) 340—3016. . . Athorized oiticer. Lécaiiion , Jennifer. . Form PCT / |SA / 2i0 ( second sheel ) ( Apri| 2005 ) . . |NTERNATlONAL SEARCH REPORT. Informatlon on patent tamlIy members. . . lnternationaI appllcatlon No. . . . . . . PCT / EP2009 / 057074 Patent document Publication Patent iamiiy Pubtication cited in search report date member ( s ) date. wo 2006067532 A 29—06—2006 EP 1838706 A1 03 - 10—2007 JP 2008525417 T 17—07 - 2008 US 2009099227 A1 16 - 04—2009 wo 2008008895 A 17 - 01 - 2008 EP 2043744 A2 08 - 04 - 2009 N0 2008008887 A2 17—O1 - 2008. . . . Form PCT / |SA / 210 ( patent lamily annex ) ( Apri| 2005 )